<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="t">
		<monograph id="1" status="active">
			<mono_name>tacrolimus (Rx) (<emphasis style="smallcaps">po</emphasis>, <emphasis style="smallcaps">iv</emphasis>)</mono_name>
			<info>
				<pronunciation>(tak-row′lim-us)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x271">Astagraf XL</tradename>
					<tradename id="tnidelem4x270">Prograf</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="2" status="active">
			<mono_name>tacrolimus (topical) (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x320">Protopic</tradename>
				</tradenames>
				<class type="func"> Immunosuppressant</class>
				<class type="chem"> Macrolide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x42">
				<sec_title>Action:</sec_title>
				<para>Produces immunosuppression by inhibiting T-lymphocytes</para>
			</section>
			<section type="uses" id="sidelem4x47">
				<sec_title>Uses:</sec_title>
				<para>Organ transplants to prevent rejection; <emphasis style="bold">topical:</emphasis> atopic dermatitis</para>
				<section type="none" id="sidelem4x55">
					<section type="none" id="sidelem4x56">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Severe recalcitrant psoriasis, contact dermatitis, GVHD prophylaxis/disease, pancreas/heart/kidney/liver/lung/small-bowel transplant rejection, uveitis, ulcerative colitis, nephrotic syndrome, lichen sclerosus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x61">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;2 yr (topical); hypersensitivity to this product or to some kinds of castor oil (IV); long-term use (topical)</para>
				<section type="none" id="sidelem4x66">
					<section type="none" id="sidelem4x67">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, severe renal/hepatic disease; diabetes mellitus, hyperkalemia, hyperuricemia, hypertension, acute bronchospasm, African American patients, heart failure, seizures, QT prolongation</para>
						<para>
							<bbw>Children &lt;12, lymphomas, infection, neoplastic disease, neonates, infants, requires a specialized setting, requires an experienced clinician; liver transplant (ext rel)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x82">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x85">
					<section type="none" id="sidelem4x86">
						<sec_title>Kidney transplant rejection prophylaxis</sec_title>
						<section type="none" id="sidelem4x94">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x94">
									<item>
										<label>•</label>
										<para> 0.03-0.05 mg/kg/day as  give no sooner than 6 hr after transplantation;  0.1 mg/kg daily preoperatively on empty stomach, 1st dose 12 hr before reperfusion and 0.2 mg/kg once daily postoperatively, 1st dose within 12 hr of reperfusion but ≥4 hr after preoperative dose in combination with mycophenolate and corticosteroids</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x104">
						<sec_title>Liver transplant rejection prophylaxis</sec_title>
						<section type="none" id="sidelem4x112">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x112">
									<item>
										<label>•</label>
										<para> 0.1-0.15 mg/kg/day in 2 divided doses q12hr; give no sooner than 6 hr after transplantation;  0.03-0.05 mg/kg/day as  give no sooner than 6 hr after transplantation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x122">
						<sec_title>Heart transplant rejection prophylaxis</sec_title>
						<section type="none" id="sidelem4x130">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x130">
									<item>
										<label>•</label>
										<para> 0.075 mg/kg/day in 2 divided doses q12hr; give no sooner than 6 hr after transplantation;  0.01 mg/kg/day as  give no sooner than 6 hr after transplantation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x140">
						<sec_title>Atopic dermatitis</sec_title>
						<section type="none" id="sidelem4x148">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x148">
									<item>
										<label>•</label>
										<para> use 0.03% or 0.1% ointment; apply bid × 7 days after clearing of signs</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x155">
							<label>•</label>
							<sec_title>Child ≥ 2-15 yr<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x155">
									<item>
										<label>•</label>
										<para> 0.03% ointment; apply bid × 7 days after clearing of signs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x159">
						<sec_title>Graft-versus-host disease (Orphan drug)</sec_title>
						<section type="none" id="sidelem4x167">
							<label>•</label>
							<sec_title>Adult and adolescent<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x167">
									<item>
										<label>•</label>
										<para> 0.1 mg/kg/day in 2 divided doses given with other immunosuppressants or  0.3 mg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x177">
							<label>•</label>
							<sec_title>
								<route>Child CONT IV INFUSION</route>
							</sec_title>
							<para>
								<list id="lidelem4x177">
									<item>
										<label>•</label>
										<para> 0.1 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x181">
						<sec_title>Graft-versus-host prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x189">
							<label>•</label>
							<sec_title>Adult<route> CONT IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x189">
									<item>
										<label>•</label>
										<para> 0.03 mg/kg/day starting 1-2 days before bone marrow transplant;  0.12 mg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x199">
							<label>•</label>
							<sec_title>Adolescent and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x199">
									<item>
										<label>•</label>
										<para> 0.12 mg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x203">
						<sec_title>Heart transplant rejection (unlabeled)</sec_title>
						<section type="none" id="sidelem4x211">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x211">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg/day or  0.2-0.3 mg/kg/day in 2 divided doses; adjust to maintain whole blood concentration 7-15 ng/ml</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x218">
						<sec_title>Lung transplant rejection (unlabeled)</sec_title>
						<section type="none" id="sidelem4x226">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x226">
									<item>
										<label>•</label>
										<para> 0.15 mg/kg/day, maintain 12-hr trough, whole blood concentration 1-1.5 ng/ml</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x231">
						<sec_title>Small-bowel transplant rejection (unlabeled)</sec_title>
						<section type="none" id="sidelem4x239">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x239">
									<item>
										<label>•</label>
										<para> 0.1-0.15 mg/kg/day, then  0.3 mg/kg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x246">
						<sec_title>Contact dermatitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x254">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x254">
									<item>
										<label>•</label>
										<para> 0.1% ointment, apply bid × 8 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x258">
						<sec_title>Available forms:</sec_title>
						<para> Inj 5 mg/ml; caps 0.5, 1, 5 mg; ext rel cap 0.5, 1, 5 mg; ointment 0.03%, 0.1%</para>
					</section>
					<section type="none" id="sidelem4x263">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x266">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x270">
									<item>
										<label>•</label>
										<para>Give on empty stomach; food decreases absorption</para>
									</item>
									<item>
										<label>•</label>
										<para>For several days before transplant surgery, patients should be placed in protective isolation</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x281">
							<sec_title>Extended release</sec_title>
							<para>
								<list id="lidelem4x285">
									<item>
										<label>•</label>
										<para>Take in morning on empty stomach, 1 hr before or 2 hr after a meal</para>
									</item>
									<item>
										<label>•</label>
										<para>Swallow whole, do not chew, divide, crush</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use with alcohol</para>
									</item>
									<item>
										<label>•</label>
										<para>If dose is missed, up to 14 hr from scheduled dose, take dose, if &gt;14 hr, skip</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x306">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x311">
									<item>
										<label>•</label>
										<para>Apply thin layers to affected skin only; rub in gently</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x316">
									<item>
										<label>•</label>
										<para>Do not use occlusive dressings</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x321">
									<item>
										<label>•</label>
										<para>Use on small area of skin</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x329">
								<label>•</label>
								<sec_title>
									<route>Topical ointment has risk of developing cancer; use only when other options have failed</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x332">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x336">
									<item>
										<label>•</label>
										<para>After diluting in 0.9% NaCl or D<emphasis style="inf">5</emphasis>W to 0.004 to 0.02 mg/ml as continuous infusion over 24 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amifostine, amikacin, aminophylline, amiodarone, amphotericin B colloidal, amphotericin B liposome, anidulafungin, argatroban, atracurium, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium acetate/chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, DOXOrubicin hydrochloride, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, foscarnet, fosphenytoin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, inamrinone, insulin, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, meropenem, mesna, metaraminol, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, mitoMYcin, mitoXANtrone, mivacurium, morphine, multivitamins, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pancuronium, PEMEtrexed, penicillin G, pentamidine, pentazocine, perphenazine, phentolamine, phenylephrine, piperacillin/tazobactam, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quinapristin/dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, teniposide, theophylline, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x350">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x353">
					<section type="none" id="sidelem4x354">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, headache,</emphasis> insomnia, paresthesia, chills, fever, <emphasis style="bold">seizures,</emphasis> posterior reversible encephalopathy syndrome, BK-virus–associated nephropathy, <emphasis style="bold">coma</emphasis></para>
					</section>
					<section type="none" id="sidelem4x367">
						<sec_title>CV:</sec_title>
						<para> Hypertension, myocardial hypertrophy, <emphasis style="bold">prolonged QTc,</emphasis> cardiomyopathy</para>
					</section>
					<section type="none" id="sidelem4x375">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, photophobia</para>
					</section>
					<section type="none" id="sidelem4x380">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, constipation, <emphasis style="bold">GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x387">
						<sec_title>GU:</sec_title>
						<para> UTIs, <emphasis style="bold">albuminuria, hematuria, proteinuria, renal failure, hemolytic uremic syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x394">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukocytosis, thrombocytopenia, purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x401">
						<sec_title>INTEG:</sec_title>
						<para> Rash, flushing, itching, alopecia</para>
					</section>
					<section type="none" id="sidelem4x406">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia, hyperuricemia, hypokalemia, <emphasis style="bold">hypomagnesemia, hyperkalemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x413">
						<sec_title>MS:</sec_title>
						<para> Back pain, muscle spasms</para>
					</section>
					<section type="none" id="sidelem4x418">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pleural effusion, atelectasis,</emphasis> dyspnea, <emphasis style="bold">interstitial lung disease</emphasis></para>
					</section>
					<section type="none" id="sidelem4x428">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> infection, malignancy</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x436">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x439">
					<section type="none" id="sidelem4x440">
						<sec_title>PO:</sec_title>
						<para> Extensively metabolized, half-life 10 hr, 75% protein binding</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x445">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone); do not use together</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity—aminoglycosides, CISplatin, cycloSPORINE</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> blood levels—antifungals, calcium channel blockers, cimetidine, danazol, mycophenolate, mofetil</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> blood levels—carBAMazepine, PHENobarbital, phenytoin, rifamycin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of live-virus vaccines</para>
				<section type="none" id="sidelem4x470">
					<section type="none" id="sidelem4x471">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Decrease: immunosuppression—astragalus, echinacea, melatonin, ginseng, St. John’s wort</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x477">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—grapefruit juice</para>
						<para>
							<emphasis style="bold">Decreased absorption:</emphasis> food</para>
					</section>
					<section type="none" id="sidelem4x488">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, BUN, creatinine</para>
						<para>
							<emphasis style="bold">Increase or decrease:</emphasis> LFTs, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> magnesium, Hgb, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x503">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x506">
					<section type="none" id="sidelem4x507">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x515">
							<label>•</label>
							<sec_title>Blood studies<route> Hgb, WBC, platelets during treatment monthly; if leukocytes &lt;3000/mm3 or platelets &lt;100,000/mm3, product should be discontinued or reduced; decreased hemoglobulin level may indicate bone marrow suppression</route></sec_title>
						</section>
						<section type="none" id="sidelem4x527">
							<label>•</label>
							<sec_title>Hepatic studies<route> alk phos, AST, ALT, amylase, bilirubin; for hepatotoxicity</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x530">
								<item>
									<label>•</label>
									<para>Serum creatinine/BUN, serum electrolytes, lipid profile, serum tacrolimus concentration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x536">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, pruritus, wheezing, laryngeal edema; stop infusion, initiate emergency procedures</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x544">
							<label>•</label>
							<sec_title>QT prolongation<route> ECG, ejection fraction; assess for chest pain, palpitations, dyspnea</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x574">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x578">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of graft rejection; immunosuppression in patients with autoimmune disorders</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x585">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x588">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x596">
								<label>•</label>
								<sec_title>
									<route>To report fever, rash, severe diarrhea, chills, sore throat, fatigue; that serious infections may occur; to report clay-colored stools, cramping (hepatotoxicity), nephrotoxicity, signs of diabetes mellitus</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x599">
									<item>
										<label>•</label>
										<para>To avoid crowds, persons with known infections to reduce risk for infection; to avoid eating raw shellfish</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x604">
									<item>
										<label>•</label>
										<para>To avoid exposure to natural or artificial sunlight</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x612">
								<label>•</label>
								<sec_title>
									<route>Not to breastfeed while taking product</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x615">
									<item>
										<label>•</label>
										<para>That repeated lab tests will be needed during treatment</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x620">
									<item>
										<label>•</label>
										<para>To avoid vaccines</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x625">
									<item>
										<label>•</label>
										<para>Not to use with alcohol, grapefruit</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x633">
								<label>•</label>
								<sec_title>
									<route>To report if pregnancy is planned or suspected</route>
								</sec_title>
							</section>
							<para>
								<bbw>To report symptoms of lymphoma</bbw>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>tadalafil (Rx)</mono_name>
			<info>
				<pronunciation>(tah-dal′a-fil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x6511">Adcirca</tradename>
					<tradename id="tnidelem4x6510">Cialis</tradename>
				</tradenames>
				<class type="func"> Impotence agent</class>
				<class type="chem"> Phosphodiesterase type 5 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x661">
				<sec_title>Action:</sec_title>
				<para>Inhibits phosphodiesterase type 5 (PDE5); enhances erectile function by increasing the amount of cGMP, which causes smooth muscle relaxation and increased blood flow into the corpus cavernosum; improves erectile function for up to 36 hr</para>
			</section>
			<section type="uses" id="sidelem4x666">
				<sec_title>Uses:</sec_title>
				<para>Treatment of erectile dysfunction, benign prostatic hyperplasia (BPH) with or without erectile dysfunction pulmonary arterial hypertension (PAH) (Adcirca only)</para>
				<section type="none" id="sidelem4x671">
					<section type="none" id="sidelem4x672">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Sexual dysfunction in males receiving antidepressants</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x677">
				<sec_title>Contraindications:</sec_title>
				<para>Newborns, children, women, hypersensitivity, patients taking organic nitrates either regularly and/or intermittently, patients taking any α-adrenergic antagonist other than 0.4 mg once-daily tamsulosin</para>
				<section type="none" id="sidelem4x682">
					<section type="none" id="sidelem4x683">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) although not indicated for females, anatomic penile deformities, sickle cell anemia, leukemia, multiple myeloma, CV/renal/hepatic disease, bleeding disorders, active peptic ulcer, prolonged erection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x688">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x691">
					<section type="none" id="sidelem4x692">
						<sec_title>Erectile dysfunction</sec_title>
						<section type="none" id="sidelem4x700">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x700">
									<item>
										<label>•</label>
										<para> (Cialis) 10 mg taken before sexual activity; dose may be reduced to 5 mg or increased to max 20 mg; usual max dosing frequency is 1×/day; once-daily dosing 2.5 mg/day at same time each day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x704">
						<sec_title>BPH</sec_title>
						<section type="none" id="sidelem4x712">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x712">
									<item>
										<label>•</label>
										<para> 5 mg daily at the same time every day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x716">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x724">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 51-80 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x727">
						<sec_title>
							<emphasis style="bold">Hepatic dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x736">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh A, B) max 10 mg/day or 20 mg/day, (pulmonary hypertension) max 40 mg/day; (Child-Pugh C) not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x739">
						<sec_title>Concomitant medications</sec_title>
						<para>
							<list id="lidelem4x743">
								<item>
									<label>•</label>
									<para>Ketoconazole, itraconazole, ritonavir, max 10 mg q72hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x749">
						<sec_title>Pulmonary hypertension</sec_title>
						<section type="none" id="sidelem4x757">
							<label>•</label>
							<sec_title>Adult<route> PO (Adcirca only)</route></sec_title>
							<para>
								<list id="lidelem4x757">
									<item>
										<label>•</label>
										<para> 40 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x764">
							<label>•</label>
							<sec_title>Adult taking ritonavir<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x764">
									<item>
										<label>•</label>
										<para> 20 mg daily initially, then increase to 40 mg daily as tolerated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x768">
						<sec_title>Male sexual dysfunction (from antidepressants) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x776">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x776">
									<item>
										<label>•</label>
										<para> (Cialis) 10-20 mg before sexual activity</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x780">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10, 20 mg; PO tab (Adcirca) 20 mg</para>
					</section>
					<section type="none" id="sidelem4x786">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x794">
							<label>•</label>
							<sec_title>
								<route>Product should not be used with nitrates in any form</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x800">
							<label>•</label>
							<sec_title>Sexual dysfunction</sec_title>
							<para>
								<list id="lidelem4x800">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Sexual dysfunction:</emphasis> give before sexual activity; do not use more than 1×/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x807">
							<label>•</label>
							<sec_title>Pulmonary hypertension</sec_title>
							<para>
								<list id="lidelem4x807">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pulmonary hypertension:</emphasis> give Adcirca with/without meals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x811">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x814">
					<section type="none" id="sidelem4x815">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, flushing, dizziness,</emphasis><emphasis style="bold">seizures,</emphasis> transient global amnesia</para>
					</section>
					<section type="none" id="sidelem4x825">
						<sec_title>CV:</sec_title>
						<para>  Hypotension, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x832">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, exfoliative dermatitis,</emphasis> urticaria</para>
					</section>
					<section type="none" id="sidelem4x840">
						<sec_title>MISC:</sec_title>
						<para> Back pain/myalgia, <emphasis style="italic">dyspepsia, nasal congestion, UTI,</emphasis> blurred vision, changes in color vision, <emphasis style="italic">diarrhea,</emphasis> pruritus, priapism, <emphasis style="bold">nonarteritic ischemic optic neuropathy (NAION),</emphasis> hearing loss</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x854">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; metabolized by liver by CYP3A4; terminal half-life 17.5 hr; peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-6 hr; excreted primarily as metabolites in feces, urine; excreted 61% in feces, 36% in urine; 94% protein bound; rate and extent of absorption not influenced by food</para>
			</section>
			<section type="interactions" id="sidelem4x865">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with nitrates because of unsafe drop in B/P, which could result in MI or stroke</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tadalafil levels—itraconazole, ketoconazole, ritonavir (although not studied, may also include other HIV protease inhibitors)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> B/P—alcohol, α-blockers, amLODIPine, angiotensin II receptor blockers, enalapril</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of tadalafil—bosentan, antacids</para>
				<section type="none" id="sidelem4x885">
					<section type="none" id="sidelem4x886">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> tadalafil effect—grapefruit</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x893">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x896">
					<section type="none" id="sidelem4x897">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x905">
							<label>•</label>
							<sec_title>Cialis</sec_title>
							<para>
								<list id="lidelem4x905">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cialis:</emphasis> underlying cause of erectile dysfunction before treatment; use of organic nitrates that should not be used with this product; any severe loss of vision while taking this or any similar products</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x912">
							<label>•</label>
							<sec_title>Adcirca</sec_title>
							<para>
								<list id="lidelem4x912">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adcirca:</emphasis> hemodynamic parameters at baseline and periodically</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x916">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x920">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to engage in sexual intercourse, improvement in exercise ability in pulmonary hypertension</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x926">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x931">
								<item>
									<label>•</label>
									<para>To take 1 hr before sexual activity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x936">
								<item>
									<label>•</label>
									<para>Not to drink large amounts of alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x941">
								<item>
									<label>•</label>
									<para>That product does not protect against sexually transmitted diseases, including HIV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x946">
								<item>
									<label>•</label>
									<para>That product has no effect in the absence of sexual stimulation; to seek medical help if erection lasts &gt;4 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x951">
								<item>
									<label>•</label>
									<para>To notify physician about all medicines, vitamins, herbs being taken, especially ritonavir, indinavir, ketoconozole, itraconazole, erythromycin, nitrates, α-blockers; that tadalafil is contraindicated for use with α-blockers except 0.4 mg/day tamsulosin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x957">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber immediately and to stop taking product if vision, hearing loss occur or if erection lasts &gt;4 hr or if chest pain occurs</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active" ha="yes">
			<mono_name> tamoxifen (Rx)</mono_name>
			<info>
				<pronunciation>(ta-mox′i-fen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x9694">
						<country code="CAN">Apo-Tamox </country>
					</tradename>
					<tradename id="tnidelem4x9693">Soltamox</tradename>
					<tradename id="tnidelem4x9692">
						<country code="CAN">Tamofen </country>
					</tradename>
					<tradename id="tnidelem4x9691">
						<country code="CAN">Tamone</country>
					</tradename>
					<tradename id="tnidelem4x9690">
						<country code="CAN">Tamoplex</country>
					</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Antiestrogen hormone</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x990">
				<sec_title>Action:</sec_title>
				<para>Inhibits cell division by binding to cytoplasmic estrogen receptors; resembles normal cell complex but inhibits DNA synthesis and estrogen response of target tissue</para>
			</section>
			<section type="uses" id="sidelem4x995">
				<sec_title>Uses:</sec_title>
				<para>Advanced breast carcinoma not responsive to other therapy in estrogen-receptor–positive patients (usually postmenopausal), prevention of breast cancer, after breast surgery/radiation for ductal carcinoma in situ</para>
				<section type="none" id="sidelem4x1000">
					<section type="none" id="sidelem4x1001">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Mastalgia, to reduce pain/size of gynecomastia, ovulation stimulation, malignant carcinoid tumor, carcinoid syndrome, metastatic melanoma, desmoid tumors, McCune-Albright syndrome (female pediatric patients), osteoporosis, bipolar I disorder, infertility, precocious puberty, gynecomastia, mastalgia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1006">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<para>
					<bbw>Thromboembolic disease</bbw>
				</para>
				<section type="none" id="sidelem4x1021">
					<section type="none" id="sidelem4x1022">
						<sec_title>Precautions:</sec_title>
						<para> Women of childbearing age, leukopenia, thrombocytopenia, cataracts</para>
						<para>
							<bbw>Endometrial cancer, stroke</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1037">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1040">
					<section type="none" id="sidelem4x1041">
						<sec_title>Breast cancer</sec_title>
						<section type="none" id="sidelem4x1049">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1049">
									<item>
										<label>•</label>
										<para> 20-40 mg/day for 5 yr; doses &gt;20 mg/day, divide <emphasis style="smallcaps">am</emphasis>/<emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1058">
						<sec_title>High risk for breast cancer</sec_title>
						<section type="none" id="sidelem4x1066">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1066">
									<item>
										<label>•</label>
										<para> 20 mg/day × 5 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1070">
						<sec_title>Ductal carcinoma in situ (DCIS)</sec_title>
						<section type="none" id="sidelem4x1078">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1078">
									<item>
										<label>•</label>
										<para> 20 mg/day × 5 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1082">
						<sec_title>McCune-Albright syndrome/precocious puberty (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1090">
							<label>•</label>
							<sec_title>Child 2-10 yr (girls)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1090">
									<item>
										<label>•</label>
										<para> 20 mg/day for ≤1 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1094">
						<sec_title>Bipolar I disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1102">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1102">
									<item>
										<label>•</label>
										<para> 40 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1106">
						<sec_title>Stimulation of ovulation with infertility (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1114">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1114">
									<item>
										<label>•</label>
										<para> 20-80 mg/day × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1118">
						<sec_title>Mastalgia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1126">
							<label>•</label>
							<sec_title>Adult (female)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1126">
									<item>
										<label>•</label>
										<para> 10-20 mg/day × 3-6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1130">
						<sec_title>Mastalgia/gynecomastia in men with prostate cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1138">
							<label>•</label>
							<sec_title>Adult (male)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1138">
									<item>
										<label>•</label>
										<para> 20 mg/day for ≤1 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1142">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20 mg; oral solution 10 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x1147">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1151">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>Antacid before oral agent; give product after evening meal, before bedtime; give with food or fluids for GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product to prevent vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1172">
						<sec_title>Oral solution:</sec_title>
						<para> Use calibrated container, dose &gt;20 mg/day should be divided morning and evening, may be used with food for gastric irritation</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1177">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1180">
					<section type="none" id="sidelem4x1181">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Hot flashes, headache, lightheadedness,</emphasis> depression, mood changes</para>
					</section>
					<section type="none" id="sidelem4x1189">
						<sec_title>CV:</sec_title>
						<para> Chest pain, <emphasis style="bold">stroke,</emphasis> fluid retention, flushing</para>
					</section>
					<section type="none" id="sidelem4x1197">
						<sec_title>EENT:</sec_title>
						<para> Ocular lesions, retinopathy, cataracts, corneal opacity, blurred vision (high doses)</para>
					</section>
					<section type="none" id="sidelem4x1202">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> altered taste (anorexia)</para>
					</section>
					<section type="none" id="sidelem4x1210">
						<sec_title>GU:</sec_title>
						<para> Vaginal bleeding, pruritus vulvae, <emphasis style="bold">uterine malignancies,</emphasis><emphasis style="italic">altered menses, amenorrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1219">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia,</emphasis> DVT</para>
					</section>
					<section type="none" id="sidelem4x1227">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> alopecia</para>
					</section>
					<section type="none" id="sidelem4x1235">
						<sec_title>META:</sec_title>
						<para> Hypercalcemia</para>
					</section>
					<section type="none" id="sidelem4x1240">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pulmonary embolism</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1247">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1250">
					<section type="none" id="sidelem4x1251">
						<sec_title>PO:</sec_title>
						<para> Peak 4-7 hr, half-life 7 days (1 wk terminal), metabolized in liver, excreted primarily in feces</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1256">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: risk for death from breast cancer—PARoxetine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tamoxifen levels—bromocriptine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> thromboembolic events—cytotoxics</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity—CYP3A4 inhibitors (aprepitant, antiretroviral protease inhibitors, clarithromycin, danazol, delavirdine, diltiazem, erythromycin, fluconazole, FLUoxetine, fluvoxaMINE, imatinib, ketoconazole, mibefradil, nefazodone, telithromycin, voriconazole)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> tamoxifen levels—aminoglutethimide, rifamycin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> letrozole levels—letrozole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> tamoxifen effect—CYP3A4 inducers (barbiturates, bosentan, carBAMazepine, efavirenz, phenytoins, nevirapine, rifabutin, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> tamoxifen effects—CYP2D6 inhibitors (antidepressants)</para>
				<section type="none" id="sidelem4x1298">
					<section type="none" id="sidelem4x1299">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x1303">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort, dong qui, black cohosh</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1309">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum calcium, T<emphasis style="inf">4</emphasis>, AST, ALT, cholesterol, triglycerides</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1319">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1322">
					<section type="none" id="sidelem4x1323">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1331">
							<label>•</label>
							<sec_title>
								<route>CBC, differential, platelet count weekly; withhold product if WBC count is &lt;3500 or platelet count is &lt;100,000; notify prescriber; breast exam, mammogram, pregnancy test, bone mineral density, LFTs, serum calcium, serum lipid profile, periodic eye exams (cataracts, retinopathy)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1345">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1351">
								<item>
									<para>
										<emphasis alert="nurse">Uterine malignancies, symptoms of stroke, pulmonary embolism that may occur in women with ductal carcinoma in situ (DCIS) and women at high risk for breast cancer</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1357">
								<item>
									<para>
										<emphasis alert="nurse">Severe allergic reactions: rash, pruritus, urticaria, purpuric skin lesions, itching, flushing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1362">
								<item>
									<label>•</label>
									<para>Bone pain; may give analgesics; pain usually transient</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1367">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1371">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1377">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x1385">
							<label>•</label>
							<sec_title>
								<route>To use nonhormonal contraception during and for 2 mo after discontinuing treatment, pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1388">
								<item>
									<label>•</label>
									<para>To notify prescriber of stroke: blurred vision, headache, weakness on one side of the body; PE: chest pain, fainting, sweating, difficulty breathing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1393">
								<item>
									<label>•</label>
									<para>To report any complaints, side effects to prescriber; that use may be 5 yr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1398">
								<item>
									<label>•</label>
									<para>To increase fluids to 2 L/day unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1403">
								<item>
									<label>•</label>
									<para>To wear sunscreen, protective clothing, sunglasses</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1408">
								<item>
									<label>•</label>
									<para>That vaginal bleeding, pruritus, hot flashes are reversible after discontinuing treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1416">
							<label>•</label>
							<sec_title>
								<route>To immediately report decreased visual acuity, which may be irreversible; about need for routine eye exams; that care providers should be told about tamoxifen therapy</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1419">
								<item>
									<label>•</label>
									<para>To report vaginal bleeding immediately</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1427">
							<label>•</label>
							<sec_title>
								<route>Tumor flare—increase in size of tumor, increased bone pain—may occur and will subside rapidly; may take analgesics for pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1430">
								<item>
									<label>•</label>
									<para>That premenopausal women must use mechanical birth control because ovulation may be induced</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1435">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>tamsulosin (Rx)</mono_name>
			<info>
				<pronunciation>(tam-sue-lo′sen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x14450">Flomax</tradename>
				</tradenames>
				<class type="func"> Selective α-peripheral adrenergic blocker, BPH agent</class>
				<class type="chem"> Sulfamoylphenethylamine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1458">
				<para>
					<confusion>
						<tradename id="tnidelem4x14580">Flomax</tradename>
						<drug type="generic" refid="idelem4x14580">Fosamax/Volmax</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1462">
				<sec_title>Action:</sec_title>
				<para>Binds preferentially to α<emphasis style="inf">1A</emphasis>- adrenoceptor subtype, which is located mainly in the prostate</para>
			</section>
			<section type="uses" id="sidelem4x1470">
				<sec_title>Uses:</sec_title>
				<para>Symptoms of benign prostatic hyperplasia (BPH)</para>
			</section>
			<section type="contra" id="sidelem4x1476">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1481">
					<section type="none" id="sidelem4x1482">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, hepatic disease, CAD, severe renal disease, prostate cancer; cataract surgery (floppy iris syndrome)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1487">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1495">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1495">
							<item>
								<label>•</label>
								<para> 0.4 mg/day increasing to 0.8 mg/day if required after 2-4 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1499">
					<section type="none" id="sidelem4x1500">
						<sec_title>Available forms:</sec_title>
						<para> Caps 0.4 mg</para>
					</section>
					<section type="none" id="sidelem4x1505">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1509">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Swallow caps whole; do not break, crush, or chew</para>
								</item>
								<item>
									<label>•</label>
									<para>Give <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr after same meal each day</para>
								</item>
								<item>
									<label>•</label>
									<para>If treatment is interrupted for several days, restart at lowest dose (0.4 mg/day)</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container in cool environment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1541">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1544">
					<section type="none" id="sidelem4x1545">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> asthenia, insomnia</para>
					</section>
					<section type="none" id="sidelem4x1553">
						<sec_title>CV:</sec_title>
						<para> Chest pain, orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x1558">
						<sec_title>EENT:</sec_title>
						<para> Amblyopia, floppy iris syndrome</para>
					</section>
					<section type="none" id="sidelem4x1563">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, dysgeusia</para>
					</section>
					<section type="none" id="sidelem4x1568">
						<sec_title>GU:</sec_title>
						<para> Decreased libido, abnormal ejaculation, <emphasis style="bold">priapism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1575">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria</para>
					</section>
					<section type="none" id="sidelem4x1580">
						<sec_title>MS:</sec_title>
						<para> Back pain</para>
					</section>
					<section type="none" id="sidelem4x1585">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, pharyngitis, cough</para>
					</section>
					<section type="none" id="sidelem4x1590">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1597">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 4-5 hr, duration 9-15 hr, half-life 9-13 hr, metabolized in liver, excreted via urine, extensively protein bound (98%)</para>
			</section>
			<section type="interactions" id="sidelem4x1602">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P—prazosin, terazosin, doxazosin, α-blockers, vardenafil</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—cimetidine</para>
			</section>
			<section type="considerations" id="sidelem4x1613">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1616">
					<section type="none" id="sidelem4x1617">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1625">
							<label>•</label>
							<sec_title>Prostatic hyperplasia</sec_title>
							<para>
								<list id="lidelem4x1625">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Prostatic hyperplasia:</emphasis> change in urinary patterns at baseline and throughout treatment; I&amp;O ratios, weight daily; edema; report weight gain or edema</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1632">
							<label>•</label>
							<sec_title>Orthostatic hypotension</sec_title>
							<para>
								<list id="lidelem4x1632">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orthostatic hypotension:</emphasis> monitor B/P, standing, sitting</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1636">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1640">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of benign prostatic hyperplasia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1646">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1650">
								<item>
									<label>•</label>
									<para>Not to drive or operate machinery for 4 hr after 1st dose or after dosage increase</para>
								</item>
								<item>
									<label>•</label>
									<para>To continue to take even if feeling better</para>
								</item>
								<item>
									<label>•</label>
									<para>To advise providers of all products, herbs taken</para>
								</item>
								<item>
									<label>•</label>
									<para>To make position changes slowly because orthostatic hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To take <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr before same meal each day</para>
								</item>
								<item>
									<label>•</label>
									<para>To teach about priapism (rare)</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to crush, break, chew</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active" ha="yes">
			<mono_name> tapentadol (Rx)</mono_name>
			<info>
				<pronunciation>(ta-pen′ta-dol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x16991">Nucynta</tradename>
					<tradename id="tnidelem4x16990">Nucynta ER</tradename>
				</tradenames>
				<class type="func"> Analgesic, misc.</class>
				<class type="chem"> μ-Opioid receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="actions" id="sidelem4x1711">
				<sec_title>Action:</sec_title>
				<para>Centrally acting synthetic analgesic; μ-opioid agonist activity is thought to result in analgesia; inhibits norepinephrine uptake</para>
			</section>
			<section type="uses" id="sidelem4x1716">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain, diabetic peripheral neuropathy</para>
			</section>
			<section type="contra" id="sidelem4x1721">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, asthma, ileus, respiratory depression</para>
				<para>
					<bbw>Respiratory depression</bbw>
				</para>
				<section type="none" id="sidelem4x1736">
					<section type="none" id="sidelem4x1737">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, increased intracranial pressure, MI (acute), severe heart disease, respiratory depression, renal/hepatic disease, GI obstruction, ulcerative colitis, sleep apnea, seizure disorder</para>
						<para>
							<bbw>Accidental exposure, avoid ethanol, substance abuse, neonatal opioid withdrawal syndrome, potential for overdose, poisoning</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1754">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1762">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1762">
							<item>
								<label>•</label>
								<para> 50-100 mg q4-6hr, may give 2nd dose ≥1 hr after 1st dose, max 700 mg on day 1, max 600 mg/day thereafter; ext rel 50 mg q12hr (opioid-naive), titrate to 100-250 mg q12hr, max 250 mg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1766">
					<section type="none" id="sidelem4x1767">
						<sec_title>Hepatic Disease</sec_title>
						<para>
							<emphasis alert="lifethreat">Adult: PO Immediate rel/oral sol 50 mg q8hr, may titrate to response; ext rel 50 mg daily max 100 mg/day</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x1773">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 75, 100 mg; tabs ext rel 50, 100, 150, 200, 250 mg</para>
					</section>
					<section type="none" id="sidelem4x1778">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1782">
								<item>
									<label>•</label>
									<para>With antiemetic if nausea, vomiting occur</para>
								</item>
								<item>
									<label>•</label>
									<para>When pain is beginning to return; determine dosage interval by response</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not crush, chew, break, or use with alcohol, ext rel product</para>
								</item>
								<item>
									<label>•</label>
									<para>Preferred analgesic in those with altered cytochrome P450 or mild hepatic, mild to moderate renal disease</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant area at room temperature
<bbw>These products have high potential for overdose, poisoning, may be fatal because of respiratory depression</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1817">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1820">
					<section type="none" id="sidelem4x1821">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, euphoria,</emphasis> hallucinations, restlessness, syncope, anxiety, flushing, psychological dependence, insomnia, lethargy, tremors, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1831">
						<sec_title>CV:</sec_title>
						<para> Palpitations, bradycardia, hypo/hypertension, orthostatic hypotension, sinus tachycardia</para>
					</section>
					<section type="none" id="sidelem4x1836">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, constipation, cramps,</emphasis> gastritis, dyspepsia, biliary spasms</para>
					</section>
					<section type="none" id="sidelem4x1844">
						<sec_title>GU:</sec_title>
						<para> Urinary retention/frequency</para>
					</section>
					<section type="none" id="sidelem4x1849">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x1857">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression,</emphasis> cough</para>
					</section>
					<section type="none" id="sidelem4x1865">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> infection, serotonin syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1873">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 32%, extensively metabolized by liver, excreted in urine 99%, terminal half-life 4 hr, protein binding 20%</para>
			</section>
			<section type="interactions" id="sidelem4x1878">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects with other CNS depressants—alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—MAOIs</emphasis>
				</para>
				<para><emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin-receptor agonists, tricyclics</emphasis></para>
				<para>
					<bbw>Do not use with alcohol, fatal overdose may occur</bbw>
				</para>
				<section type="none" id="sidelem4x1900">
					<section type="none" id="sidelem4x1901">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> sedative effect—kava, St. John’s wort, valerian</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1908">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1911">
					<section type="none" id="sidelem4x1912">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1920">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x1920">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> intensity, location, type, characteristics; need for pain medication by pain/sedation scoring; physical dependence</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1924">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1929">
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1936">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome: increased heart rate, shivering, sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1944">
							<para>
								<list id="lidelem4x1944">
									<item>
										<label>•</label>
										<para>Allergic reactions: rash, urticaria, anaphylaxis
<bbw>Addiction risk, previous substance abuse: assess before using ext rel product</bbw>

<bbw>Identify if alcohol has been used before giving this product, may be fatal if used with tapentadol</bbw>

<bbw>
												<emphasis alert="lifethreat">Respiratory dysfunction:</emphasis> respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;10/min; B/P, pulse</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1975">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1979">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1985">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1990">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions, seizures, serotonin syndrome</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1995">
								<item>
									<label>•</label>
									<para>That physical dependency may result from extended use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2000">
								<item>
									<label>•</label>
									<para>That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2005">
								<item>
									<label>•</label>
									<para>To avoid CNS depressants, alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2010">
								<item>
									<label>•</label>
									<para>To avoid driving, operating machinery if drowsiness, dizziness occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2015">
								<item>
									<label>•</label>
									<para>To change positions slowly to decrease orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2023">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy planned, suspected or if breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active" ru="yes">
			<mono_name> tasimelteon</mono_name>
			<info>
				<pronunciation>(tas′i-mel′tee-on)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x20420">Hetlioz</tradename>
				</tradenames>
				<class type="func"> Anxiolytic/sedative/hypnotics</class>
			</info>
			<section type="uses" id="sidelem4x2048">
				<sec_title>Uses:</sec_title>
				<para> Sleep-wake disorder in the blind</para>
			</section>
			<section type="contra" id="sidelem4x2053">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x2058">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2067">
					<label>•</label>
					<sec_title>Adults<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2067">
							<item>
								<label>
									<emphasis alert="lifethreat">•</emphasis>
								</label>
								<para> 20 mg before bedtime at the same time every night; take without food</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>tavaborole topical</mono_name>
			<section type="none" id="sidelem4x2074">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="9" status="active" ru="yes">
			<mono_name> tbo-filgrastim</mono_name>
			<info>
				<pronunciation>(fil-gras′tim)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x20850">Neutrophil</tradename>
				</tradenames>
				<class type="func"> Biologic modifier</class>
				<class type="chem"> Short-acting granulocyte colony-stimulating factor (G-CSF)</class>
			</info>
			<section type="uses" id="sidelem4x2095">
				<sec_title>Uses:</sec_title>
				<para>Chemotherapy-induced neutropenia prophylaxis to reduce the duration of severe neutropenia in nonmyeloid malignancies</para>
			</section>
			<section type="contra" id="sidelem4x2100">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x2105">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2113">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x2113">
							<item>
								<label>•</label>
								<para> 5 mcg/kg/day</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>teduglutide</mono_name>
			<info>
				<pronunciation>(te′due-gloo′tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x21220">Gattex</tradename>
				</tradenames>
				<class type="func"> Functional GI disorder agent</class>
				<class type="chem"> Recombinant glucagon-like peptide-2 analog</class>
			</info>
			<section type="actions" id="sidelem4x2132">
				<sec_title>Action:</sec_title>
				<para>Increases intestinal, portal blood flow, inhibits gastric acid secretion, decreases gastric motility</para>
			</section>
			<section type="uses" id="sidelem4x2137">
				<sec_title>Uses:</sec_title>
				<para>Short bowel syndrome, dependent on parenteral support</para>
				<section type="none" id="sidelem4x2142">
					<section type="none" id="sidelem4x2143">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, diarrhea, pancreatitis, renal disease, electrolyte imbalances, GI obstruction, heart failure, neoplastic disease, biliary tract disease, cardiac disease, gastric cancer, GI disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2148">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2156">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x2156">
							<item>
								<label>•</label>
								<para> 0.05 mg/kg daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2160">
					<section type="none" id="sidelem4x2161">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 5 mg</para>
					</section>
					<section type="none" id="sidelem4x2166">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2169">
							<sec_title>Subcut route</sec_title>
							<section type="none" id="sidelem4x2177">
								<label>•</label>
								<sec_title>Reconstitution</sec_title>
								<para>
									<list id="lidelem4x2177">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Reconstitution:</emphasis>
												</emphasis> Slowly inject the 0.5 ml of preservative-free sterile water for injection provided in the prefilled syringe into the vial; allow to stand for 30 sec and gently roll the vial between your palms for 15 sec; do not shake, allow to stand 2 min; if undissolved powder is present, roll the vial again until all material is dissolved; if the product remains undissolved after the second attempt, do not use; discard unused portion; use within 3 hr after reconstitution</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x2185">
								<label>•</label>
								<sec_title>Subcut injection</sec_title>
								<para>
									<list id="lidelem4x2185">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Subcut injection:</emphasis>
												</emphasis> Calculate dose, withdraw into a syringe, and give; do not use IV, IM; if a dose is missed, it should be given as soon as possible on the same day; two doses should not be given on the same day; alternate sites</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2190">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2193">
					<section type="none" id="sidelem4x2194">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue</para>
					</section>
					<section type="none" id="sidelem4x2199">
						<sec_title>GI:</sec_title>
						<para> Nausea, abdominal pain, cholecystitis, cholestasis, GI obstruction, pancreatitis, vomiting</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2204">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 2 hr; 1.3 hr (short bowel syndrome)</para>
			</section>
			<section type="interactions" id="sidelem4x2209">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> absorption of—benzodiazepine, carBAMazepine, cycloSPORINE, digoxin, disopyramide, ethosuximide, flecainide, levothyroxine, lithium, phenytoin, procainamide, quiNIDine, sirolimus, tacrolimus, theophylline, valproic acid, warfarin</para>
			</section>
			<section type="considerations" id="sidelem4x2216">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2219">
					<section type="none" id="sidelem4x2220">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2224">
								<item>
									<label>•</label>
									<para>GI symptoms: nausea, abdominal pain</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor alk phos, amylase, bilirubin, serum electrolytes, lipase baseline, q6mo</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2235">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2239">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased absorption of nutrients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2245">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2249">
								<item>
									<label>•</label>
									<para>To notify prescriber of GI symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>telaprevir</mono_name>
			<info>
				<pronunciation>(tel-a’pre-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x22600">Incivek</tradename>
				</tradenames>
				<class type="func"> Antivirals, antihepatitis agent</class>
				<class type="chem"> NS3/4A protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x2270">
				<sec_title>Action:</sec_title>
				<para>Prevents hepatitis C viral (HCV) replication by blocking the proteolytic activity of HCV NS3/4A serine protease; hepatitis C virus NS3/4A serine protease is an enzyme responsible for the conversion of HCV-encoded polyproteins to mature/functioning viral proteins; these proteins (NS4A, NS4B, NS5A, NS5B) are needed for viral replication</para>
			</section>
			<section type="uses" id="sidelem4x2275">
				<sec_title>Uses:</sec_title>
				<para>Chronic hepatitis C</para>
			</section>
			<section type="contra" id="sidelem4x2280">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>) in combination, male partners of women who are pregnant</para>
				<section type="none" id="sidelem4x2285">
					<section type="none" id="sidelem4x2286">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, neonates, infants, children, adolescents &lt;18 yr of age, anemia, neutropenia, thrombocytopenia, HIV, hepatitis B, decompensated hepatic disease, liver or other organ transplants</para>
						<para>
							<bbw>Serious rash</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2302">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2305">
					<section type="none" id="sidelem4x2306">
						<section type="none" id="sidelem4x2307">
							<sec_title>Chronic hepatitis C infection (genotype 1) in compensated liver disease without cirrhosis who are previously untreated or have relapsed after treatment with interferon and ribavirin therapy</sec_title>
							<section type="none" id="sidelem4x2315">
								<label>•</label>
								<sec_title>Adults<route> PO</route></sec_title>
								<para>
									<list id="lidelem4x2315">
										<item>
											<label>•</label>
											<para> 1125 mg bid with peginterferon alfa and ribavirin; duration is determined by patient’s HCV RNA level at treatment wk 4, 12; if the HCV RNA is undetectable at wk 4, 12, give three-drug regimen for 12 wk, then give an additional 12 wk of only peginterferon alfa and ribavirin (24 wk total); if the HCV RNA is detectable but ≤1000 international units/ml at wk 4 or 12, give three-drug regimen × 12 wk, then an additional 36 wk of only peginterferon alfa and ribavirin (48 wk total)</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x2319">
							<sec_title>Without cirrhosis who are previously partial or null responders to interferon and ribavirin therapy/or those with cirrhosis:</sec_title>
							<section type="none" id="sidelem4x2327">
								<label>•</label>
								<sec_title>Adults<route> PO</route></sec_title>
								<para>
									<list id="lidelem4x2327">
										<item>
											<label>•</label>
											<para> 1125 mg bid with peginterferon alfa and ribavirin; give three-drug regimen × 12 wk, then another 36 wk (48 wk total) of only peginterferon alfa and ribavirin</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x2331">
							<sec_title>Available forms:</sec_title>
							<para> Tab 375 mg</para>
						</section>
						<section type="none" id="sidelem4x2336">
							<sec_title>Administer:</sec_title>
							<section type="none" id="sidelem4x2344">
								<label>•</label>
								<sec_title>
									<route>Only use in combination with peginterferon alfa and ribavirin; never give as monotherapy</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x2348">
									<item>
										<para>
											<emphasis alert="nurse">Discontinue in all patients with hepatitis C virus RNA concentrations ≥1000 IU/ml at wk 4 or 12 or a confirmed detectable HCV RNA concentration at wk 24</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2354">
									<item>
										<para>
											<emphasis alert="nurse">Any contraindication to peginterferon alfa or ribavirin also applies to this product; see ribavirin or peginterferon alfa monographs for additional information regarding contraindications and warning associated with these products</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2359">
									<item>
										<label>•</label>
										<para>For relief of mild to moderate rashes, give oral antihistamines and/or topical corticosteroids; treatment with systemic steroids is not recommended</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2364">
									<item>
										<label>•</label>
										<para>Give with food, not low-fat</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2369">
									<item>
										<label>•</label>
										<para>Store tabs at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2374">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2377">
					<section type="none" id="sidelem4x2378">
						<sec_title>CNS:</sec_title>
						<para> Fatigue</para>
					</section>
					<section type="none" id="sidelem4x2383">
						<sec_title>GI:</sec_title>
						<para> Hemorrhoids, anorectal discomfort, pruritus ani, rectal burning, nausea, diarrhea, vomiting, dysgeusia, hyperbilirubinemia</para>
					</section>
					<section type="none" id="sidelem4x2388">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, decreased Hgb, lymphopenia, leukopenia, neutropenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2395">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS),</emphasis> rash, pruritus, severe rashes (bullous rash, vesicular rash, and skin ulcerations)</para>
					</section>
					<section type="none" id="sidelem4x2403">
						<sec_title>META:</sec_title>
						<para> Increased uric acid</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2408">
				<sec_title>Pharmacokinetics</sec_title>
				<para>59%-76% plasma protein binding, primarily to α 1-acid glycoprotein and albumin; metabolized extensively in liver by hydrolysis, oxidation, reduction by CYP3A4; excreted in feces (82%), exhaled (9%), excreted in urine (1%); elimination half life 4-4.7 hr; steady-state half life 9-11 hr, peak 4-5 hr; food increases effect; steady-state is reduced by 15% in mild hepatic disease, 46% in moderate hepatic disease (Child-Pugh class B)</para>
			</section>
			<section type="interactions" id="sidelem4x2413">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: life-threatening reactions of each product—alfuzosin, ergots (dihydroergotamine, ergotamine, ergonovine, methylergonovine), cisapride, pimozide, lovastatin, simvastatin, ezetimibe, niacin with simvastatin and boceprevir; triazolam, oral midazolam; sildenafil, tadalafil (pulmonary arterial hypertension); do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect and adverse reactions of each product—phosphodiesterase type 5 (PDE5) inhibitors (for erectile dysfunction), atorvastin, lidocaine, atorvastatin, amiodarone, bepridil, flecainide, propafenone, quiNIDine, digoxin, ketoconazole, itraconazole, posaconazole, voriconazole, desipramine, traZODone, erythromycin, clarithromycin, telithromycin, rifabutin, dexamethasone, felodipine, niCARdipine, NIFEdipine, budesonide, bosentan, warfarin, astemizole, boceprevir, bupivacaine, busPIRone, cevimeline, chloroquine, cilostazol, cinacalcet, clomiPRAMINE, clonazePAM, clopidogrel, cloZAPine, cyclobenzaprine, dapsone, dextromethorphan, diazepam, diclofenac, disopyramide, disulfiram, dolasetron, donepezil, colchicine, cycloSPORINE, tacrolimus, sirolimus, buprenorphine, salmeterol, vardenafil, ALPRAZolam, citalopram, amLODIPine, diltiazem, nisoldipine, verapamil, systemic corticosteroids, acetaminophen, alfentanil, aliskiren, almotriptan, alosetron, ARIPiprazole, dutasteride, ebastine, eplerenone, erlotinib, omeprazole, estazolam, eszopiclone, ethosuximide, exemestane, finasteride, flunitrazepam, flurazepam, galantamine, gefitinib, granisetron, halofantrine, haloperidol, HYDROcodone, ifosfamide, imipramine, indiplon, isradipine, ivermectin, ixabepilone, losartan, meloxicam, mirtazapine, montelukast, nateglinide, oxybutynin, oxyCODONE, palonosetron, paricalcitol, prasugrel, praziquantel, quazepam, QUEtiapine, quinacrine, ramelteon, repaglinide, ropivacaine, selegiline, sibutramine, sitaxsentan, solifenacin, SUFentanil, SUNItinib, theophylline, aminophylline, tiaGABine, tinidazole, tolterodine, traMADol, venlafaxine, amitriptyline, carvedilol, DAUNOrubicin, loratadine, desloratadine, lansoprazole, dexlansoprazole, DOCEtaxel, DOXOrubicin, droperidol, eletriptan, etoposide, fentaNYL, fexofenadine, glyburide, irinotecan, loperamide, maraviroc, mefloquine, mitoMYcin, morphine, nortriptyline, ondansetron, PACLitaxel, plicamycin, risperiDONE, sertraline, silodosin, teniposide, terfenadine, testosterone, tolvaptan, vinBLAStine, vinCRIStine and others; use cautiously, may need to reduce dose</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—drospirenone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> estrogen levels—ethinyl estradiol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> telaprevir effect—CYP3A4 inhibitors (phenytoin, carBAMazepine, PHENobarbital, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—methadone</para>
				<para>Possible treatment failure: efavirenz, ritonavir, atazanavir, lopinavir with ritonavir</para>
				<section type="none" id="sidelem4x2445">
					<section type="none" id="sidelem4x2446">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="nurse">Do not use with St. John’s wort</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2454">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2457">
					<section type="none" id="sidelem4x2458">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2464">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy: pregnancy (X) combination therapy; obtain a pregnancy test before, monthly during, and for 6 mo after treatment is completed; those who are not willing to practice strict contraception should not receive treatment with these products; report any cases of prenatal ribavirin exposure to the Ribavirin Pregnancy registry at (800) 593-2214</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2470">
								<item>
									<para>
										<emphasis alert="nurse">Anemia: monitor hemoglobin before, at treatment wk 4, 8, 12, and as needed; if Hgb is &lt;10 g/dL, decrease ribavirin dosage; if Hgb is &lt;8.5 g/dL, discontinuation of therapy is recommended; telaprevir dosage should not be altered based on adverse reactions; anemia may be managed through ribavirin dose modifications; never alter the dose of telaprevir; if anemia persists despite a reduction in ribavirin dose, consider discontinuing telaprevir; if management of anemia requires permanent discontinuation of ribavirin, treatment with telaprevir must also be permanently discontinued; once telaprevir has been discontinued, it must not be restarted; monitor CBC with differential at treatment wk 4, 8, 12, and at other treatment points</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2476"/>
						<section type="none" id="sidelem4x2492">
							<label>•</label>
							<sec_title>Hepatitis C</sec_title>
							<para>
								<list id="lidelem4x2492">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatitis C:</emphasis> Hepatitis C RNA baseline, wk 4, and wk 12; thyroid function tests, LFTs, serum bilirubin/creatinine, BUN, bilirubin, serum electrolytes, serum uric acid, baseline and periodically during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2497">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2501">
								<item>
									<label>•</label>
									<para>Decreasing hepatitis C viral infection, HCV-RNA level ≥1000 IU/ml at wk 4 and 12, confirm wk 24</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2507">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2512">
								<item>
									<label>•</label>
									<para>That 3-drug regimen must be used, not to discontinue unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2517">
								<item>
									<label>•</label>
									<para>To take with food with fat for increased absorption</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2522">
								<item>
									<label>•</label>
									<para>Transmission of infection may still occur; use precautions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2527">
								<item>
									<label>•</label>
									<para>If dose is missed, take if within 6 hr of when dose should have been used, provide “Medication Guide”</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2532">
								<item>
									<label>•</label>
									<para>Drink plenty of fluids to prevent dehydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2537">
								<item>
									<label>•</label>
									<para>Not to use other products (OTC, Rx, herbs, supplements) unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2543">
								<item>
									<para>
										<emphasis alert="nurse">To use two forms of effective contraception (intrauterine devices and barrier methods) during treatment and for 6 mo after treatment; pregnancy (X), not to breastfeed</emphasis>
<bbw>That if a serious skin reaction occurs, to seek urgent medical care; all components of the triple-drug regimen must be discontinued immediately</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>telavancin (Rx)</mono_name>
			<info>
				<pronunciation>(tel-a-van′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x25630">Vibativ</tradename>
				</tradenames>
				<class type="func"> Antiinfective, miscellaneous</class>
				<class type="chem"> Lipoglycopeptide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2573">
				<sec_title>Action:</sec_title>
				<para>Inhibits bacterial cell-wall synthesis, disrupts cell membrane integrity, blocks glycopeptides</para>
			</section>
			<section type="uses" id="sidelem4x2578">
				<sec_title>Uses:</sec_title>
				<para>Skin/skin-structure infections caused by <emphasis style="italic">Enterococcus faecalis, E. faecium, Staphylococcus aureus</emphasis> (MSRA), <emphasis style="italic">S. aureus</emphasis> (MSSA), <emphasis style="italic">S. epidermidis, S. haemolyticus, Streptococcus agalactiae</emphasis> (group B), <emphasis style="italic">S. dysgalactiae, S. pyogenes</emphasis> (group A β-tremolytic), <emphasis style="italic">S. anginosus, S. intermedius, S. constellates,</emphasis> nosocomial pneumonia caused by susceptible gram-positive bacteria</para>
				<section type="none" id="sidelem4x2598">
					<section type="none" id="sidelem4x2599">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bacteremia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2604">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2609">
					<section type="none" id="sidelem4x2610">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, renal disease, antimicrobial resistance, diabetes mellitus, diarrhea, GI disease, heart failure, hypertension, pseudomembranous colitis, QT prolongation, vancomycin hypersensitivity</para>
						<para>
							<bbw>Pregnancy (C)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2625">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2628">
					<section type="none" id="sidelem4x2629">
						<sec_title>Complicated skin/skin-structure infections</sec_title>
						<section type="none" id="sidelem4x2637">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2637">
									<item>
										<label>•</label>
										<para> 10 mg/kg over 60 min q24hr × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2641">
						<sec_title>Nosocomial pneumonia</sec_title>
						<section type="none" id="sidelem4x2649">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2649">
									<item>
										<label>•</label>
										<para> 10 mg/kg q24hr × 7-21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2653">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2661">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 30-50 ml/min 7.5 mg/kg q24hr; CCr 10-29 ml/min 10 mg/kg q48hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2664">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder for inj 250, 750 mg</para>
					</section>
					<section type="none" id="sidelem4x2669">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2673">
								<item>
									<label>•</label>
									<para>Use only for susceptible organisms to prevent drug-resistant bacteria</para>
								</item>
								<item>
									<label>•</label>
									<para>Antihistamine if red man syndrome occurs: decreased B/P; flushing of neck, face</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid IM, subcut use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2689">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x2697">
								<label>•</label>
								<sec_title>
									<route>avoid rapid IV; may cause red man syndrome</route>
								</sec_title>
								<para>
									<list id="lidelem4x2697">
										<item>
											<label>•</label>
											<para>After reconstitution with 15 ml D<emphasis style="inf">5</emphasis>W sterile water for inj; 0.9% NaCl (15 mg/ml) 250-mg vial; add 45 ml to 750-mg vial (15 mg/ml) for dose of 150-800 mg; further dilute with 100-250 ml of compatible sol; for dose &lt;150 mg or &gt;800 mg, further dilute to concentration of 0.6-8 mg/ml with compatible sol; give over 60 min; reconstituted or diluted sol is stable for 4 hr room temperature, 7 hr refrigerated; </para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x2706">
						<sec_title>Y-site compatibility:</sec_title>
						<para> Amphotericin B lipid complex (Abelcet), ampicillin-sulbactam, azithromycin, calcium gluconate, caspofungin, cefepime, cefTAZidime, cefTRIAXone, ciprofloxacin, dexamethasone, diltiazem, DOBUTamine, DOPamine, doripenem, doxycycline, ertapenem, famotidine, fluconazole, gentamicin, hydrocortisone, labetalol, magnesium sulfate, mannitol, meropenem, metoclopramide, milrinone, norepinephrine, ondansetron, pantoprazole, phenylephrine, piperacillin-tazobactam, potassium chloride/phosphates, ranitidine, sodium bicarbonate, sodium phosphates, tigecycline, tobramycin, vasopressin</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2711">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2714">
					<section type="none" id="sidelem4x2715">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, chills, flushing, headache, insomnia, dizziness</para>
					</section>
					<section type="none" id="sidelem4x2720">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT prolongation,</emphasis> irregular heartbeat</para>
					</section>
					<section type="none" id="sidelem4x2728">
						<sec_title>EENT:</sec_title>
						<para> Hearing loss</para>
					</section>
					<section type="none" id="sidelem4x2733">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Nausea,</emphasis> vomiting, <emphasis style="bold">pseudomembranous colitis,</emphasis> abdominal pain, constipation, diarrhea, metallic/soapy taste</para>
					</section>
					<section type="none" id="sidelem4x2744">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity,</emphasis><emphasis style="italic">increased BUN, creatinine,</emphasis><emphasis style="bold">renal failure,</emphasis> foamy urine</para>
					</section>
					<section type="none" id="sidelem4x2756">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, eosinophilia, anemia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2763">
						<sec_title>INTEG:</sec_title>
						<para> Chills, fever, rash, thrombophlebitis at inj site; urticaria, pruritus, necrosis (red man syndrome)</para>
					</section>
					<section type="none" id="sidelem4x2768">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, superinfection</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2775">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset rapid, half-life 8-9 hr, excreted in urine (76%), protein binding 90%, hepatic metabolism</para>
			</section>
			<section type="interactions" id="sidelem4x2780">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: otoxicity or nephrotoxicity—aminoglycosides, cephalosporins, colistin, polymyxin, bacitracin, CISplatin, amphotericin B, nondepolarizing muscle relaxants, cidofovir, tacrolimus, IV pentamine acyclovir, adefovir, cycloSPORINE, foscarnet, ganciclovir, pamidronate, streptozocin, zoledronic acid, NSAIDs, salicylates, ACE inhibitors</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA, III antidysrhythmics; some phenothiazines; chloroquine, clarithromycin, droperidol, dronedarone, erythromycin, haloperidol, levomethadye, methadone, pimozide, ziprasidone</emphasis>
				</para>
				<section type="none" id="sidelem4x2793">
					<section type="none" id="sidelem4x2794">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False increase:</emphasis> INR, PT, PTT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2801">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2804">
					<section type="none" id="sidelem4x2805">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2813">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x2813">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> WBC, urine, stools, sputum, characteristics of wound throughout treatment C&amp;S</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2820">
							<label>•</label>
							<sec_title>
								<route>I&amp;O ratio; report hematuria, oliguria; nephrotoxicity may occur</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2826">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> Monitor for diarrhea, fever, blood in stools, abdominal pain, may be several wk after therapy ends, report to prescriber immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2832">
							<label>•</label>
							<sec_title>Anaphylaxis<route> Monitor for rash, itching, wheezing, laryngeal edema, discontinue and notify prescriber immediately, emergency equipment and epinephrine should be nearby</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2844">
								<item>
									<label>•</label>
									<para>Auditory function during, after treatment; hearing loss; ringing, roaring in ears; product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2849">
								<item>
									<label>•</label>
									<para>B/P during administration; sudden drop may indicate red man syndrome; also flushing, pruritus, rash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2854">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, tightness in chest</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2859">
								<item>
									<label>•</label>
									<para>Adequate intake of fluids (2 L/day) to prevent nephrotoxicity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2864">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2868">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative culture</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2874">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2879">
								<item>
									<label>•</label>
									<para>About all aspects of product therapy; that culture may be taken after completed course of medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2884">
								<item>
									<label>•</label>
									<para>To notify prescriber if infection continues</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2889">
								<item>
									<label>•</label>
									<para>That bitter taste, nausea, vomiting, headache may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2897">
							<label>•</label>
							<sec_title>
								<route>To report sore throat, fever, fatigue; could indicate superinfection; diarrhea (pseudomembranous colitis); hearing loss; rash, wheezing, tightness of chest, itching, tightening of throat (anaphylaxis)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2903">
							<label>•</label>
							<sec_title>
								<route>To use contraception while taking this product; not to breastfeed; to notify prescriber if pregnancy is planned or suspected</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>telbivudine (Rx)</mono_name>
			<info>
				<pronunciation>(tel-bi′vyoo-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x29111">
						<country code="CAN">Sebivo </country>
					</tradename>
					<tradename id="tnidelem4x29110">Tyzeka</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nucleoside reverse transcriptase inhibitor (NRTI)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x2924">
				<sec_title>Action:</sec_title>
				<para>Inhibits replication of HBV DNA polymerase, which inhibits HBV replication</para>
			</section>
			<section type="uses" id="sidelem4x2929">
				<sec_title>Uses:</sec_title>
				<para>Treatment of chronic hepatitis B</para>
			</section>
			<section type="contra" id="sidelem4x2934">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding</para>
				<section type="none" id="sidelem4x2939">
					<section type="none" id="sidelem4x2940">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), children, severe renal disease, anemia, organ transplant, dialysis, HIV, obesity, alcoholism; Hispanic or African descendents (safety not established)</para>
						<para>
							<bbw>Impaired hepatic function, lactic acidosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2955">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2963">
					<label>•</label>
					<sec_title>Adult and adolescent &gt;16 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2963">
							<item>
								<label>•</label>
								<para> 600 mg/day; max 600 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2967">
					<section type="none" id="sidelem4x2968">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2976">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-49 ml/min, 600 mg tab q48hr or 400 mg oral sol daily; CCr &lt;30 ml/min (not requiring dialysis), 600 mg tab q72hr or 200 mg oral sol daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2979">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 600 mg</para>
					</section>
					<section type="none" id="sidelem4x2984">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2988">
								<item>
									<label>•</label>
									<para>With/without food with a full glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2999">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3002">
					<section type="none" id="sidelem4x3003">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever, headache, malaise,</emphasis> weakness, <emphasis style="italic">dizziness, insomnia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3013">
						<sec_title>EENT:</sec_title>
						<para> Taste change, hearing loss, photophobia</para>
					</section>
					<section type="none" id="sidelem4x3018">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, anorexia,</emphasis> abdominal pain, hepatomegaly</para>
					</section>
					<section type="none" id="sidelem4x3026">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3033">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3040">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia, muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x3045">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3050">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted by kidneys (unchanged), steady-state 5-7 days, protein binding 3.3%, terminal half-life 40-49 hr, peak 1-4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3055">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x3060">
						<item>
							<label>•</label>
							<para>Altered telbivudine levels: any agent altering renal function</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x3068">
					<label>•</label>
					<sec_title>
						<route>Do not use with pegylated interferon α-2a</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> myopathy risk possible—HMG-CoA reductase inhibitors, fibric acid derivatives, penicillamine, zidovudine, ZDV, cycloSPORINE, erythromycin, niacin, azole antifungals, corticosteroids, hydrochloroquine</para>
			</section>
			<section type="considerations" id="sidelem4x3075">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3078">
					<section type="none" id="sidelem4x3079">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>LFTs, hepatitis B serology, creatine kinase, periodically, monitor HBV DNA after 24 wk; if viral suppression incomplete (≥300 copies/ml), start alternate therapy; monitor HBV DNA q6mo</bbw>
						</para>
						<para>
							<bbw>Lactic acidosis: obtain baseline liver function tests; if elevated, discontinue treatment; discontinue even if liver function tests normal but lactic acidosis, hepatomegaly present; may be fatal</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x3102">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3106">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing hepatitis B serology</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3112">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3117">
								<item>
									<label>•</label>
									<para>That GI complaints and insomnia may resolve after 3-4 wk of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3123">
								<item>
									<label>•</label>
									<para>That product does not cure hepatitis B and does not stop its spread to others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3128">
								<item>
									<label>•</label>
									<para>That follow-up visits must be continued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3136">
							<label>•</label>
							<sec_title>
								<route>That serious product interactions may occur if OTC products are ingested; to check with prescriber before taking</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3139">
								<item>
									<label>•</label>
									<para>That product may cause dizziness; to avoid hazardous activities until response is known</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3147">
							<label>•</label>
							<sec_title>
								<route>To report symptoms of cough, difficulty sleeping, excessive headache, muscle pain/weakness</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x3153">
							<label>•</label>
							<sec_title>To report progressive liver dysfunction<route> light-colored stools, dark urine, poor appetite, nausea, yellowing of skin, eyes</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3159">
							<label>•</label>
							<sec_title>
								<route>That product will not cure HBV, and precautions should be taken to protect others</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>telmisartan (Rx)</mono_name>
			<info>
				<pronunciation>(tel-mih-sar′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x31670">Micardis</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II receptor (Type AT) antagonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3180">
				<sec_title>Action:</sec_title>
				<para>Blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II; selectively blocks the binding of angiotensin II to the AT<emphasis style="inf">1</emphasis> receptor found in tissues</para>
			</section>
			<section type="uses" id="sidelem4x3188">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination; stroke, MI prophylaxis (&gt;55 yr) in patients unable to take ACE inhibitors</para>
				<section type="none" id="sidelem4x3193">
					<section type="none" id="sidelem4x3194">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Heart failure, proteinuria in diabetic nephropathy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3199">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Pregnancy (D) 2nd/3rd trimesters</bbw>
				</para>
				<section type="none" id="sidelem4x3214">
					<section type="none" id="sidelem4x3215">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) 1st trimester, breastfeeding, children, geriatric patients; hypersensitivity to ACE inhibitors; renal/hepatic disease, renal artery stenosis, dialysis, CHF, hyperkalemia, hypotension, hypovolemia, African descent</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3220">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3228">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3228">
							<item>
								<label>•</label>
								<para> 40 mg/day; range 20-80 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3232">
					<section type="none" id="sidelem4x3233">
						<sec_title>Stroke, MI prophylaxis</sec_title>
						<section type="none" id="sidelem4x3241">
							<label>•</label>
							<sec_title>Adult &gt;55 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3241">
									<item>
										<label>•</label>
										<para> 80 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3245">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20, 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x3250">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3254">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Increased dose to African American patients or consider alternative agent; B/P response may be reduced</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not remove from blister pack until ready to use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3270">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3273">
					<section type="none" id="sidelem4x3274">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, insomnia, <emphasis style="italic">anxiety,</emphasis> headache, fatigue, syncope</para>
					</section>
					<section type="none" id="sidelem4x3282">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, dyspepsia, <emphasis style="italic">anorexia, vomiting</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3289">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x3294">
						<sec_title>MS:</sec_title>
						<para> Myalgia, pain</para>
					</section>
					<section type="none" id="sidelem4x3299">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, upper respiratory infection,</emphasis> sinusitis, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x3307">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3314">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset of antihypertensive activity 3 hr, peak 0.5-1 hr, extensively metabolized, terminal half-life 24 hr, protein binding 99.5%, excreted in feces &gt;97%, B/P response is less in African American patients</para>
			</section>
			<section type="interactions" id="sidelem4x3319">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin peak/trough concentrations—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive action—diuretics, other antihypertensives, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics, potassium salt substitutes, ACE inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x3338">
					<section type="none" id="sidelem4x3339">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3348">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3351">
					<section type="none" id="sidelem4x3352">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Pregnancy test, if positive stop treatment</bbw>
						</para>
						<para>
							<list id="lidelem4x3366">
								<item>
									<label>•</label>
									<para>B/P, pulse standing, lying; note rate, rhythm, quality; if severe hypotension occurs, place in supine position, usually occurs during first few weeks of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3371">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic, electrolytes studies before therapy begins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3379">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x3379">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema in feet, legs daily; jugular venous distention; dyspnea, crackles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3383">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3387">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3393">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3398">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better; to take at same time of day; that therapeutic effect may take 2-4 wk</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3406">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, fever, swelling of hands or feet, irregular heartbeat, chest pain, decreased urine output</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3409">
								<item>
									<label>•</label>
									<para>Not to stop abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3414">
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in blood pressure; to consult prescriber if these occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3419">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, lightheadedness; to avoid hazardous activities until response is known
<bbw>To notify prescriber if pregnancy is planned or suspected, pregnancy (D) 2nd/3rd trimester</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3433">
								<item>
									<label>•</label>
									<para>To notify prescriber of all prescriptions, OTC products, and supplements taken; to rise slowly from sitting to prevent drop in B/P</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3441">
							<label>•</label>
							<sec_title>Overdose<route> dizziness, bradycardia, or tachycardia</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active" ha="yes">
			<mono_name> temazepam (Rx)</mono_name>
			<info>
				<pronunciation>(te-maz′e-pam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x34510">Restoril</tradename>
				</tradenames>
				<class type="func"> Sedative/hypnotic</class>
				<class type="chem"> Benzodiazepine, short to intermediate acting</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule> (USA), Schedule F (Canada)</class>
			</info>
			<section type="confusion" id="sidelem4x3464">
				<para>
					<confusion>
						<tradename id="tnidelem4x34640">Restoril</tradename>
						<drug type="generic" refid="idelem4x34640">Risperdal</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3468">
				<sec_title>Action:</sec_title>
				<para>Produces CNS depression at limbic, thalamic, hypothalamic levels of the CNS; may be mediated by neurotransmitter γ-aminobutyric acid (GABA); results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, anxiolytic action</para>
			</section>
			<section type="uses" id="sidelem4x3473">
				<sec_title>Uses:</sec_title>
				<para>Insomnia, short-term treatment (generally 7-10 days)</para>
			</section>
			<section type="contra" id="sidelem4x3478">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity to benzodiazepines</para>
				<section type="none" id="sidelem4x3483">
					<section type="none" id="sidelem4x3484">
						<sec_title>Precautions:</sec_title>
						<para> Children &lt;15 yr, geriatric patients, anemia, renal/hepatic disease, suicidal individuals, drug abuse, psychosis, acute closed-angle glaucoma, seizure disorders, angioedema, sleep-related behaviors (sleepwalking), intermittent porphyria, COPD, dementia, myasthenia gravis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3489">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3497">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3497">
							<item>
								<label>•</label>
								<para> 7.5 to 30 mg at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3504">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3504">
							<item>
								<label>•</label>
								<para> 7.5 mg at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3508">
					<section type="none" id="sidelem4x3509">
						<sec_title>Available forms:</sec_title>
						<para> Caps 7.5, 15, 22.5, 30 mg</para>
					</section>
					<section type="none" id="sidelem4x3514">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3518">
								<item>
									<label>•</label>
									<para>15-30 min before bedtime for sleeplessness</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use with CNS depressants; serious CNS depression may result</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container in cool environment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3540">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3543">
					<section type="none" id="sidelem4x3544">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Lethargy, drowsiness, daytime sedation,</emphasis> dizziness, confusion, light-headedness, headache, anxiety, irritability, complex sleep-related reactions (sleep driving, sleep eating), fatigue</para>
					</section>
					<section type="none" id="sidelem4x3552">
						<sec_title>CV:</sec_title>
						<para> Chest pain, pulse changes, hypotension</para>
					</section>
					<section type="none" id="sidelem4x3557">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x3562">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, heartburn, abdominal pain, constipation, anorexia</para>
					</section>
					<section type="none" id="sidelem4x3567">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Severe allergic reactions</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3574">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 30 min, peak 1-2 hr, duration 6-8 hr, half-life 10-20 hr, metabolized by liver, excreted by kidneys, crosses placenta, excreted in breast milk, 98% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x3579">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of cimetidine, disulfiram, oral contraceptives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of both products—alcohol, CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of temazepam—probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of antacids, theophylline, rifampin</para>
				<section type="none" id="sidelem4x3598">
					<section type="none" id="sidelem4x3599">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—hops, kava, valerian, chamomile, skullcap</para>
					</section>
					<section type="none" id="sidelem4x3606">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> temazepam effect—caffeine</para>
					</section>
					<section type="none" id="sidelem4x3613">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3620">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3623">
					<section type="none" id="sidelem4x3624">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3629">
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, memory (long, short), orientation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3634">
								<item>
									<label>•</label>
									<para>Type of sleep problem: falling asleep, staying asleep, baseline, periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3642">
							<label>•</label>
							<sec_title>Dependency</sec_title>
							<para>
								<list id="lidelem4x3642">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Dependency:</emphasis> restrict amount given to patient, assess for physical/psychological dependency; high-level risk for abuse</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3646">
								<item>
									<label>•</label>
									<para>Assistance with ambulation after receiving dose</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3651">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3655">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to sleep at night, decreased early morning awakening if taking product for insomnia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3661">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3666">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities requiring alertness until stabilized</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3671">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3676">
								<item>
									<label>•</label>
									<para>That effects may take 2 nights for benefits to be noticed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3681">
								<item>
									<label>•</label>
									<para>To limit to 7-10 days of continuous use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3686">
								<item>
									<label>•</label>
									<para>About alternative measures to improve sleep: reading, exercise several hours before bedtime, warm bath, warm milk, TV, self-hypnosis, deep breathing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3691">
								<item>
									<label>•</label>
									<para>Not to discontinue abruptly, withdraw gradually</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3696">
								<item>
									<label>•</label>
									<para>That complex sleep-related behaviors may occur: sleep driving/eating</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3701">
								<item>
									<label>•</label>
									<para>That hangover, memory impairment are common in geriatric patients but less common than with barbiturates</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3707">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber if pregnancy is planned or suspected, pregnancy (X); to use contraception while taking this product</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x3712">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, activated charcoal; monitor electrolytes, VS</para>
			</section>
		</monograph>
<monograph id="16" status="active" ha="yes">
			<mono_name> temozolomide (Rx)</mono_name>
			<info>
				<pronunciation>(tem-oh-zole′oh-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x37240">Temodar</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-alkylating agent</class>
				<class type="chem"> Imidazotetrazine derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x3734">
				<sec_title>Action:</sec_title>
				<para>Prodrug that undergoes conversion to MTIC; MTIC action prevents DNA transcription</para>
			</section>
			<section type="uses" id="sidelem4x3739">
				<sec_title>Uses:</sec_title>
				<para>Anaplastic astrocytoma with relapse, glioblastoma multiforme, malignant glioma</para>
				<section type="none" id="sidelem4x3744">
					<section type="none" id="sidelem4x3745">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Metastatic melanoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3751">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding; hypersensitivity to this product, carbazine, or gelatin</para>
				<section type="none" id="sidelem4x3756">
					<section type="none" id="sidelem4x3757">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, radiation therapy, renal/hepatic disease, bone marrow suppression, infection, myelosuppression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3762">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3765">
					<section type="none" id="sidelem4x3766">
						<sec_title>Anaplastic astrocytoma</sec_title>
						<section type="none" id="sidelem4x3774">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3774">
									<item>
										<label>•</label>
										<para> adjust dose based on nadir neutrophil and platelet counts 150 mg/m<emphasis style="sup">2</emphasis>/day × 5 days during a 28-day cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3781">
						<sec_title>Glioblastoma multiforme</sec_title>
						<section type="none" id="sidelem4x3789">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x3789">
									<item>
										<label>•</label>
										<para> 75 mg/m<emphasis style="sup">2</emphasis>/day × 42 days with focal radiotherapy, then maintenance of 6 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3796">
						<sec_title>Refractory anaplastic astrocytoma</sec_title>
						<section type="none" id="sidelem4x3804">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3804">
									<item>
										<label>•</label>
										<para> 150 mg/m<emphasis style="sup">2</emphasis>/day over 90 min on days 1-5 q28days, may increase to 200 mg/m<emphasis style="sup">2</emphasis>/day on days 1-5 q28days if hematologic parameters permit</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3814">
						<sec_title>Available forms:</sec_title>
						<para> Caps 5, 20, 100, 140, 180, 250 mg; powder for inj 100 mg</para>
					</section>
					<section type="none" id="sidelem4x3819">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3822">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3826">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew, open caps</para>
									</item>
									<item>
										<label>•</label>
										<para>Antiemetic 30-60 min before product to prevent vomiting</para>
									</item>
									<item>
										<label>•</label>
										<para>Caps 1 at a time with 8 oz of water at same time of day</para>
									</item>
									<item>
										<label>•</label>
										<para>Fluids IV or PO before chemotherapy to hydrate patient</para>
									</item>
									<item>
										<label>•</label>
										<para>If caps accidentally damaged, do not allow contact with skin or inhale</para>
									</item>
									<item>
										<label>•</label>
										<para>Use proper procedures for handling/disposing of chemotherapy products</para>
									</item>
									<item>
										<label>•</label>
										<para>Give on empty stomach at bedtime to prevent nausea/vomiting</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in light-resistant container in a dry area</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3867">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x3871">
									<item>
										<label>•</label>
										<para>Bring vial to room temperature; discard if cloudy</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject 41 ml sterile water for inj into vial (2.5 mg/ml)</para>
									</item>
									<item>
										<label>•</label>
										<para>Gently swirl; do not shake</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3887">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3891">
									<item>
										<label>•</label>
										<para>Withdraw up to 40 ml from each vial to make total dose; transfer to empty 250-ml PVC infusion bag; flush before and after infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Run over 90 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Use reconstituted sol within 14 hr, including infusion time</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3912">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3915">
					<section type="none" id="sidelem4x3916">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis><emphasis style="italic">hemiparesis, dizziness, poor coordination, amnesia, insomnia, paresthesia, somnolence, paresis, ataxia, anxiety, dysphagia, depression, confusion</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3925">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia, vomiting,</emphasis> abdominal pain, constipation</para>
					</section>
					<section type="none" id="sidelem4x3933">
						<sec_title>GU:</sec_title>
						<para> Urinary incontinence, UTI, frequency</para>
					</section>
					<section type="none" id="sidelem4x3938">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia,</emphasis> anemia, <emphasis style="bold">myelosuppression, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3948">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3955">
						<sec_title>MISC:</sec_title>
						<para> Headache, fatigue, asthenia, fever, edema, back pain, weight increase, diplopia</para>
					</section>
					<section type="none" id="sidelem4x3960">
						<sec_title>RESP:</sec_title>
						<para> URI, pharyngitis, sinusitis, coughing</para>
					</section>
					<section type="none" id="sidelem4x3965">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3972">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption complete, rapid; crosses blood-brain barrier; excreted in urine, feces; half-life 1.8 hr; peak 1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3977">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—radiation, other antineoplastics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, platelet inhibitors, thrombolytics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody reaction—live virus vaccines, toxoids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of digoxin</para>
				<section type="none" id="sidelem4x3996">
					<section type="none" id="sidelem4x3997">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> drug absorption</para>
					</section>
					<section type="none" id="sidelem4x4004">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, platelets, WBC, neutrophils</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4011">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4014">
					<section type="none" id="sidelem4x4015">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4020">
								<item>
									<label>•</label>
									<para>Tumor response during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4028">
							<label>•</label>
							<sec_title>
								<route>CBC on day 22 (21 days after 1st dose), CBC weekly until recovery if ANC is &lt;1.5 × 109/L and platelets &lt;100 × 109/L; do not administer to patients who do not tolerate 100 mg/m2; myelosuppression usually occurs late during the treatment cycle</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x4043">
							<label>•</label>
							<sec_title>
								<route>Seizures throughout treatment; mental status</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4046">
								<item>
									<label>•</label>
									<para>Monitor temperature; may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4051">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH), as needed or monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4056">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, petechiae, mucosa or orifices</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4061">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4065">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4071">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4076">
								<item>
									<label>•</label>
									<para>To report signs of infection: fever, sore throat, flulike symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4081">
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4086">
								<item>
									<label>•</label>
									<para>To report bleeding; to avoid use of razors, commercial mouthwash</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4094">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (D); not to breastfeed</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active" ru="yes">
			<mono_name> temsirolimus (Rx)</mono_name>
			<info>
				<pronunciation>(tem-sir-oh′li-mus)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41040">Torisel</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier</class>
				<class type="chem"> Kinase inhibitor, mTOR antagonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="uses" id="sidelem4x4114">
				<sec_title>Uses:</sec_title>
				<para>Renal cell carcinoma</para>
			</section>
			<section type="contra" id="sidelem4x4119">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding; hypersensitivity to this product or to sirolimus; polysorbate 80</para>
				<section type="none" id="sidelem4x4124">
					<section type="none" id="sidelem4x4125">
						<sec_title>Precautions:</sec_title>
						<para> Children &lt;13 yr, females, severe pulmonary/renal/hepatic disease (bilirubin &gt;1-1.5×ULN or AST &gt;ULN but bilirubin ≤ULN), diabetes mellitus, hyperkalemia, hyperuricemia, hypertension, bone marrow suppression, hypertriglyceridemia/hyperlipidemia, surgery, brain tumors</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4130">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4138">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x4138">
							<item>
								<label>•</label>
								<para> 25 mg over 30-60 min weekly; treat until disease progression or severe toxicity occurs</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4142">
					<section type="none" id="sidelem4x4143">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x4151">
							<label>•</label>
							<sec_title>Adult<route> IV (mild impairment) bilirubin &gt;1-1.5×ULN or AST &gt;ULN but bilirubin ≤ULN; reduce to 15 mg/wk; (moderate or severe impairment, do not use)</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ha="yes">
			<mono_name> tenecteplase (TNK-tPA) (Rx)</mono_name>
			<info>
				<pronunciation>(ten-ek′ta-place)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41610">TNKase</tradename>
				</tradenames>
				<class type="func"> Thrombolytic</class>
				<class type="chem"> Tissue plasminogen activator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4171">
				<sec_title>Action:</sec_title>
				<para>Activates conversion of plasminogen to plasmin (fibrinolysin): plasmin breaks down clots (fibrin), fibrinogen, factors V, VII; occlusion of venous access lines</para>
			</section>
			<section type="uses" id="sidelem4x4176">
				<sec_title>Uses:</sec_title>
				<para>Acute myocardial infarction, coronary artery thrombosis</para>
			</section>
			<section type="contra" id="sidelem4x4181">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, arteriovenous malformation, aneurysm, active bleeding, intracranial/intraspinal surgery or trauma within 2 mo, CNS neoplasms, severe hypertension, severe renal/hepatic disease, history of CVA, increased ICP/stroke</para>
				<section type="none" id="sidelem4x4186">
					<section type="none" id="sidelem4x4187">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, arterial emboli from left side of heart, hypocoagulation, subacute bacterial endocarditis, rheumatic valvular disease, cerebral embolism/thrombosis/hemorrhage, intraarterial diagnostic procedure or surgery (10 days), recent major surgery, dysrhythmias, hypertension</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4193">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4196">
					<section type="none" id="sidelem4x4197">
						<sec_title>Total dose, max 50 mg based on patient’s weight</sec_title>
						<section type="none" id="sidelem4x4205">
							<label>•</label>
							<sec_title>
								<route>Adult &lt;60 kg IV BOL</route>
							</sec_title>
							<para>
								<list id="lidelem4x4205">
									<item>
										<label>•</label>
										<para> 30 mg, give over 5 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4212">
							<label>•</label>
							<sec_title>Adult ≥60-&lt;70 kg<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x4212">
									<item>
										<label>•</label>
										<para> 35 mg, give over 5 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4219">
							<label>•</label>
							<sec_title>Adult ≥70-&lt;80 kg<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x4219">
									<item>
										<label>•</label>
										<para> 40 mg, give over 5 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4226">
							<label>•</label>
							<sec_title>Adult ≥80-&lt;90 kg<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x4226">
									<item>
										<label>•</label>
										<para> 45 mg, give over 5 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4233">
							<label>•</label>
							<sec_title>Adult ≥90 kg<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x4233">
									<item>
										<label>•</label>
										<para> 50 mg, give over 5 sec, max 50 mg total dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4237">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj, lyophilized 50 mg</para>
					</section>
					<section type="none" id="sidelem4x4242">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4245">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4249">
									<item>
										<label>•</label>
										<para>As soon as thrombi identified; not useful for thrombi &gt;1 wk old</para>
									</item>
									<item>
										<label>•</label>
										<para>Cryoprecipitate or fresh frozen plasma if bleeding occurs</para>
									</item>
									<item>
										<label>•</label>
										<para>Heparin after fibrinogen level &gt;100 mg/dl; heparin infusion to increase PTT to 1.5-2× baseline for 3-7 days; IV heparin with loading dose is recommended</para>
									</item>
									<item>
										<label>•</label>
										<para>Aseptically withdraw 10 ml of sterile water for inj from diluent vial; use red cannula syringe-filling device; inject all contents of syringe into product vial; direct into powder, swirl, withdraw correct dose; discard any unused sol; stand shield with dose vertically on flat surface and passively recap red cannula; remove entire shield assembly by twisting counter-clockwise; give by IV BOL</para>
									</item>
									<item>
										<label>•</label>
										<para>IV therapy: use upper-extremity vessel that is accessible to manual compression</para>
									</item>
									<item>
										<label>•</label>
										<para>If product not used immediately, refrigerate; use within 8 hr; not compatible with dextrose; flush dextrose-containing lines with saline before and after administration</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4280">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4283">
					<section type="none" id="sidelem4x4284">
						<sec_title>CV:</sec_title>
						<para> Dysrhythmias, hypotension, pulmonary edema, <emphasis style="bold">pulmonary embolism, cardiogenic shock, cardiac arrest, heart failure, myocardial reinfarction, myocardial rupture, tamponade, pericarditis, pericardial effusion, thrombosis, CVA</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4291">
						<sec_title>HEMA:</sec_title>
						<para> Decreased Hct, <emphasis style="bold">bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4298">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, phlebitis at IV infusion site, itching, flushing</para>
					</section>
					<section type="none" id="sidelem4x4303">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">GI, GU, intracranial, retroperitoneal bleeding, surface bleeding, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4310">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4313">
					<section type="none" id="sidelem4x4314">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, half-life 20-24 min, metabolized by liver</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4319">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—aspirin, indomethacin, phenylbutazone, anticoagulants, antithrombolytics, glycoprotein IIb/IIIa inhibitors, dipyridamole, clopidogrel, ticlopidine, NSAIDs, cefamandole, cefoperazone, cefoTEtan, SSRIs, SNRIs</para>
				<section type="none" id="sidelem4x4326">
					<section type="none" id="sidelem4x4327">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> risk of bleeding—feverfew, garlic, ginger, ginkgo, green tea, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x4334">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> INR, PT, PTT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4341">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4344">
					<section type="none" id="sidelem4x4345">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4353">
							<label>•</label>
							<sec_title>Allergy</sec_title>
							<para>
								<list id="lidelem4x4353">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergy:</emphasis> fever, rash, itching, chills; mild reaction may be treated with antihistamines</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4360">
							<label>•</label>
							<sec_title>
								<route>Cholesterol embolism, blue-toe syndrome, renal failure, MI, cerebral/spinal cord/bowel/retinal infarction, hypertension; can be fatal</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4364">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding during 1st hr of treatment; hematuria, hematemesis, bleeding from mucous membranes, epistaxis, ecchymosis; may require tranfusion (rare), continue to assess for bleeding for 24 hr</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4369">
								<item>
									<label>•</label>
									<para>Blood studies (Hct, platelets, PTT, PT, TT, aPTT) before starting therapy; PT or aPTT must be &lt;2× control before starting therapy; PTT or PT q3-4hr during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4374">
								<item>
									<label>•</label>
									<para>Hypersensitive reactions: fever, rash, dyspnea; product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4379">
								<item>
									<label>•</label>
									<para>VS, B/P, pulse, respirations, neurologic signs, temperature at least q4hr; temperature &gt;104° F (40° C) indicates internal bleeding; systolic pressure increase &gt;25 mm Hg should be reported to prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4386">
								<item>
									<para>
										<emphasis alert="nurse">Neurologic changes that may indicate intracranial bleeding</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4392">
								<item>
									<para>
										<emphasis alert="nurse">Retroperitoneal bleeding: back pain, leg weakness, diminished pulses</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4397">
								<item>
									<label>•</label>
									<para>Bed rest during entire course of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4402">
								<item>
									<label>•</label>
									<para>Avoidance of venous or arterial puncture, inj, rectal temperature, any invasive treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4407">
								<item>
									<label>•</label>
									<para>Treatment of fever with acetaminophen or aspirin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4412">
								<item>
									<label>•</label>
									<para>Pressure for 30 sec to minor bleeding sites; inform prescriber if this does not attain hemostasis; apply pressure dressing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4417">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4421">
								<item>
									<label>•</label>
									<para>Therapeutic response: resolution of MI</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4427">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4432">
								<item>
									<label>•</label>
									<para>About proper dental care to avoid bleeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4440">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately of sudden, severe headache</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4443">
								<item>
									<label>•</label>
									<para>To notify prescriber of bleeding; hypersensitivity; fast, slow, or uneven heart rate; feeling of faintness; blood in urine, stools; nose bleeds</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>tenofovir (Rx)</mono_name>
			<info>
				<pronunciation>(ten-oh-foh′veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x44530">Viread</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nucleoside reverse transcriptase inhibitor (NRTI)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x4463">
				<sec_title>Action:</sec_title>
				<para>Inhibits replication of HIV virus by competing with the natural substrate and then incorporating into cellular DNA by viral reverse transcriptase, thereby terminating cellular DNA chain</para>
			</section>
			<section type="uses" id="sidelem4x4468">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 infection with at least 2 other antiretrovirals, hepatitis B</para>
			</section>
			<section type="contra" id="sidelem4x4473">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Lactic acidosis</bbw>
				</para>
				<section type="none" id="sidelem4x4488">
					<section type="none" id="sidelem4x4489">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal disease, CCr &lt;60 ml/min, osteoporosis, immune reconstitution syndrome</para>
						<para>
							<bbw>Hepatic disease, hepatitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4504">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4512">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4512">
							<item>
								<label>•</label>
								<para> 300 mg/day with meal; if used with didanosine, give tenofovir 2 hr before or 1 hr after didanosine</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4519">
					<label>•</label>
					<sec_title>Child ≥2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4519">
							<item>
								<label>•</label>
								<para> 8 mg/kg daily approximate; ≥35 kg 300 mg daily; 28-34 kg 250 mg daily; 22-27 kg 200 mg daily; 17-21 kg 150 mg daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4523">
					<section type="none" id="sidelem4x4524">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4532">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-49 ml/min, 300 mg q48hr; CCr 10-29 ml/min, 300 mg q72-96hr; CCr &lt;10 ml/min, not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4535">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 150, 200, 250, 300 mg; oral powder 40 mg/scoop</para>
					</section>
					<section type="none" id="sidelem4x4540">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4545">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4550">
								<item>
									<label>•</label>
									<para>2 hr before or 1 hr after didanosine (if used)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4555">
								<item>
									<label>•</label>
									<para>Store at 25° C (77° F)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4563">
							<label>•</label>
							<sec_title>Oral powder</sec_title>
							<para>
								<list id="lidelem4x4563">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral powder:</emphasis> use scoop provided, mix powder into 2-4 oz (<emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis>-<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> cup) of applesauce, yogurt, do not mix with liquid, product will not mix, product is bitter, use immediately after mixing, clean scoop</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4579">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4582">
					<section type="none" id="sidelem4x4583">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, asthenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4590">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> anorexia, <emphasis style="italic">flatulence, abdominal pain,</emphasis><emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4602">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure, renal tubular acidosis/necrosis, Fanconi syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4609">
						<sec_title>HEMA:</sec_title>
						<para> Neutropenia, osteopenia</para>
					</section>
					<section type="none" id="sidelem4x4614">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4623">
						<sec_title>META:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis,</emphasis> hypokalemia, hypophosphatemia</para>
					</section>
					<section type="none" id="sidelem4x4631">
						<sec_title>MS:</sec_title>
						<para> Myopathy, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4638">
						<sec_title>SYST:</sec_title>
						<para> Lipodystrophy</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4644">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, distributed to extravascular space, excreted unchanged in urine 70%-80%, terminal half-life 17 hr, peak 1-2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4649">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> tenofovir level—cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of didanosine when given with tenofovir</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tenofovir level—any product that decreases renal function</para>
			</section>
			<section type="considerations" id="sidelem4x4664">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4667">
					<section type="none" id="sidelem4x4668">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4673">
								<item>
									<label>•</label>
									<para>Viral load, CD4+ T-cell count, plasma HIV RNA, serum creatinine/BUN/phosphate</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4681">
							<para>
								<list id="lidelem4x4681">
									<item>
										<label>•</label>
										<para>Resistance testing at start of therapy and at treatment failure
<bbw>
												<emphasis alert="lifethreat">Hepatitis exacerbations:</emphasis> Monitor hepatic studies: AST, ALT, bilirubin; amylase, lipase, triglycerides periodically during treatment</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4694">
								<item>
									<label>•</label>
									<para>Bone, renal toxicity: if bone abnormalities are suspected, obtain tests; serum phosphorus, creatinine
<bbw>Lactic acidosis, severe hepatomegaly with steatosis, Fanconi syndrome: obtain baseline liver function tests; if elevated, discontinue treatment; discontinue even if liver function tests normal but lactic acidosis, hepatomegaly present; may be fatal</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4708">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4712">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in signs, symptoms of HIV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4718">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4723">
								<item>
									<label>•</label>
									<para>To take without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4728">
								<item>
									<label>•</label>
									<para>That GI complaints resolve after 3-4 wk of treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4736">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed while taking this product</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4739">
								<item>
									<label>•</label>
									<para>That product must be taken daily even if patient feels better</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4744">
								<item>
									<label>•</label>
									<para>That follow-up visits must be continued because serious toxicity may occur; that blood counts must be done q2wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4749">
								<item>
									<label>•</label>
									<para>That product will control symptoms but is not a cure for HIV; that patient is still infectious, may pass HIV virus on to others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4754">
								<item>
									<label>•</label>
									<para>That other products may be necessary to prevent other infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4759">
								<item>
									<label>•</label>
									<para>That changes in body fat distribution may occur
<bbw>To notify prescriber of symptoms of lactic acidosis</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>terazosin (Rx)</mono_name>
			<info>
				<pronunciation>(ter-ay′zoe-sin)</pronunciation>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> α-Adrenergic blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4786">
				<sec_title>Action:</sec_title>
				<para>Decreases total vascular resistance, which is responsible for a decrease in B/P; this occurs by the blockade of α<emphasis style="inf">1</emphasis>-adrenoreceptors</para>
			</section>
			<section type="uses" id="sidelem4x4794">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, as a single agent or in combination with diuretics or β-blockers; BPH</para>
			</section>
			<section type="contra" id="sidelem4x4799">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x4804">
					<section type="none" id="sidelem4x4805">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, prostate cancer, syncope</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4810">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4813">
					<section type="none" id="sidelem4x4814">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x4822">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4822">
									<item>
										<label>•</label>
										<para> 1 mg at bedtime, may increase dose slowly to desired response; max 20 mg/day divided q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4826">
						<sec_title>Benign prostatic hyperplasia</sec_title>
						<section type="none" id="sidelem4x4834">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4834">
									<item>
										<label>•</label>
										<para> 1 mg at bedtime, gradually increase up to 5-10 mg; max 20 mg divided q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4838">
						<sec_title>Available forms:</sec_title>
						<para> Caps 1, 2, 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x4844">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4848">
								<item>
									<label>•</label>
									<para>Give dose at bedtime; patient should not operate machinery because fainting may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>If treatment is interrupted for several days, restart with initial dose</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food; feeding tube: place cap in 60 ml of warm tap water; stir until liquid spills from ruptured shell (5 min); stir until cap dissolves; draw solution into oral syringe; give through feeding tube; flush with water</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4869">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4872">
					<section type="none" id="sidelem4x4873">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache, drowsiness,</emphasis> anxiety, depression, vertigo, weakness, fatigue, syncope</para>
					</section>
					<section type="none" id="sidelem4x4881">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, orthostatic hypotension,</emphasis> tachycardia, <emphasis style="italic">edema,</emphasis> rebound hypertension</para>
					</section>
					<section type="none" id="sidelem4x4892">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, epistaxis, tinnitus, dry mouth, red sclera, nasal congestion, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x4897">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, constipation, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x4905">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, incontinence, impotence, priapism</para>
					</section>
					<section type="none" id="sidelem4x4910">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough, pharyngitis, nasal congestion</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4915">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 9-12 hr; protein binding 90%-94%; metabolized in liver; excreted in urine, feces, peak 2-3 hr, onset 15 min, duration 24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4920">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effects—β-blockers, nitroglycerin, verapamil, other antihypertensives, alcohol, phosphodiesterase (PDE5) inhibitors (vardenafil, tadalafil, sildenafil)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypotensive effects—estrogens, NSAIDs, sympathomimetics, salicylates</para>
				<section type="none" id="sidelem4x4931">
					<section type="none" id="sidelem4x4932">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x4943">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC, platelets, albumin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4950">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4953">
					<section type="none" id="sidelem4x4954">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4962">
							<label>•</label>
							<sec_title>BPH</sec_title>
							<para>
								<list id="lidelem4x4962">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">BPH:</emphasis> urinary patterns (hesitancy, frequency, change in stream, dribbling, dysuria, urgency)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4969">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x4969">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> crackles, dyspnea, orthopnea q30min; orthostatic B/P, pulse, jugular venous distention q4hr; weight daily, I&amp;O</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4973">
								<item>
									<label>•</label>
									<para>BUN, uric acid if patient receiving long-term therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4978">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4982">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, edema in feet, legs; decreased symptoms of BPH</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4988">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4993">
								<item>
									<label>•</label>
									<para>That fainting occasionally occurs after 1st dose; not to drive or operate machinery for 4 hr after 1st dose or after an increase in dose; to take 1st dose at bedtime</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4998">
								<item>
									<label>•</label>
									<para>To rise slowly from sitting or lying position</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5003">
								<item>
									<label>•</label>
									<para>Not to discontinue abruptly; not to drink alcohol</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5011">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x5011">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> to continue with regimen including diet, exercise</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>terbinafine oral (Rx)</mono_name>
			<info>
				<pronunciation>(ter-bin′a-feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50200">Lamisil</tradename>
				</tradenames>
				<class type="func"> Antifungal</class>
				<class type="chem"> Synthetic allylamine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5030">
				<para>
					<confusion>
						<tradename id="tnidelem4x50300">terbinafine</tradename>
						<drug type="generic" refid="idelem4x50300">terbutaline</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5037">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell-membrane permeability of fungi such as <emphasis style="italic">Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, Microsporum canis, Microsporum audouinii, Microsporum gypseum, Candida;</emphasis> broad-spectrum antifungal</para>
			</section>
			<section type="uses" id="sidelem4x5045">
				<sec_title>Uses:</sec_title>
				<para>(Oral) onychomycosis of toenail or fingernail due to dermatophytes, tinea capititis/corporis/cruris/pedis/versicolor</para>
				<section type="none" id="sidelem4x5050">
					<section type="none" id="sidelem4x5051">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cutaneous candidiasis, tinea versicolor</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5056">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x5061">
					<section type="none" id="sidelem4x5062">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, chronic/active hepatic disease, renal disease GFR ≤50 ml/min, immunosuppression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5067">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5075">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5075">
							<item>
								<label>•</label>
								<para> 250 mg/day × 6 wk (fingernail); × 12 wk (toenail)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5079">
					<section type="none" id="sidelem4x5080">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250 mg; oral granules 125, 187.5 mg</para>
					</section>
					<section type="none" id="sidelem4x5085">
						<section type="none" id="sidelem4x5086">
							<sec_title>Administer:</sec_title>
							<section type="none" id="sidelem4x5094">
								<label>•</label>
								<sec_title>PO</sec_title>
								<para>
									<list id="lidelem4x5094">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">PO:</emphasis> without regard to food</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5098">
									<item>
										<label>•</label>
										<para>Store at &lt;25° C (77° F); protect from light</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5106">
								<label>•</label>
								<sec_title>Granules</sec_title>
								<para>
									<list id="lidelem4x5106">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Granules:</emphasis> take with food; sprinkle packet contents on pudding or nonacidic soft food; swallow without chewing; do not use fruit-based foods</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5110">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5113">
					<section type="none" id="sidelem4x5114">
						<sec_title>CNS:</sec_title>
						<para> Depression</para>
					</section>
					<section type="none" id="sidelem4x5119">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing impairment</para>
					</section>
					<section type="none" id="sidelem4x5124">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, dyspepsia, vertigo, abdominal pain, nausea, hepatitis</para>
					</section>
					<section type="none" id="sidelem4x5129">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5136">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x5144">
						<sec_title>MISC:</sec_title>
						<para> Headache, hepatic enzyme changes, taste, visual/olfactory disturbance</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5149">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr, &gt;99% protein binding, half-life 36 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5154">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of dextromethorphan</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> terbinafine clearance—rifampin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> clearance of cycloSPORINE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> terbinafine clearance—cimetidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> metabolism of—CYP2D6 (antidysrthymics IC, III, amoxapine, atomoxetine, cloZAPine</para>
				<section type="none" id="sidelem4x5177">
					<section type="none" id="sidelem4x5178">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x5182">
								<item>
									<label>•</label>
									<para>Side effects: cola nut, guarana, yerba maté, tea (black, green), coffee</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5188">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5195">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5198">
					<section type="none" id="sidelem4x5199">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5203">
								<item>
									<label>•</label>
									<para>Hepatic studies (ALT, AST) before beginning treatment; do not use in presence of hepatic disease</para>
								</item>
								<item>
									<label>•</label>
									<para>CBC in treatment &gt;6 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>Continuing infection: increased size, number of lesions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5219">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5223">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size, number of lesions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5229">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5234">
								<item>
									<label>•</label>
									<para>That treatment may take 10 wk (toenail), 4 wk (fingernail)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5242">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of nausea, vomiting, fatigue, jaundice, dark urine, clay-colored stool, RUQ pain; may indicate hepatic dysfunction</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>terbinafine topical</mono_name>
			<section type="none" id="sidelem4x5248">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>terbutaline (Rx)</mono_name>
			<info>
				<pronunciation>(ter-byoo′ta-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x52570">
						<country code="CAN">Bricanyl </country>
					</tradename>
				</tradenames>
				<class type="func"> Selective β-agonist; bronchodilator</class>
				<class type="chem"> Catecholamine</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5272">
				<para>
					<confusion>
						<tradename id="tnidelem4x52720">terbutaline</tradename>
						<drug type="generic" refid="idelem4x52720">TOLBUTamide/terbinafine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5276">
				<sec_title>Action:</sec_title>
				<para>Relaxes bronchial smooth muscle by direct action on β<emphasis style="inf">2</emphasis>-adrenergic receptors through the accumulation of cAMP at β-adrenergic receptor sites; bronchodilation, diuresis, CNS, cardiac stimulation occur; relaxes uterine smooth muscle</para>
			</section>
			<section type="uses" id="sidelem4x5285">
				<sec_title>Uses:</sec_title>
				<para>Bronchospasm</para>
				<section type="none" id="sidelem4x5290">
					<section type="none" id="sidelem4x5291">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Premature labor, nonresponsive status asthmaticus in children (IV)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5296">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, closed-angle glaucoma, tachydysrhythmias</para>
				<section type="none" id="sidelem4x5301">
					<section type="none" id="sidelem4x5302">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, cardiac disorders, hyperthyroidism, diabetes mellitus, prostatic hypertension, hypertension, seizure disorder</para>
						<para>
							<bbw>Labor</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5317">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5320">
					<section type="none" id="sidelem4x5321">
						<sec_title>Bronchospasm</sec_title>
						<section type="none" id="sidelem4x5329">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5329">
									<item>
										<label>•</label>
										<para> 2.5-5 mg q8hr;  0.25 mg q15-30min, max 0.5 mg in 4 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5339">
							<label>•</label>
							<sec_title>Adolescent ≤15 yr and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5339">
									<item>
										<label>•</label>
										<para> 2.5 mg tid, max 7.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5346">
							<label>•</label>
							<sec_title>Child 6-11 yr (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5346">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg q8hr, may increase slowly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5350">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x5358">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-50 ml/min, 50% of dose; CCr &lt;10 ml/min, avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5361">
						<sec_title>Tocolytic (preterm labor) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5369">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5369">
									<item>
										<label>•</label>
										<para> 0.25 mg q20min to 6 hr, hold if pulse &gt;120 bpm</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5373">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5 mg; inj 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x5378">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5382">
								<item>
									<label>•</label>
									<para>With food; may be crushed</para>
								</item>
								<item>
									<label>•</label>
									<para>2 hr before bedtime to avoid sleeplessness</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5393">
							<sec_title>IV route (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x5397">
									<item>
										<label>•</label>
										<para>Only used if subcut is ineffective</para>
									</item>
									<item>
										<label>•</label>
										<para>IV after diluting each 5 mg/1 L D<emphasis style="inf">5</emphasis>W for infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>IV, run 5 mcg/min; may increase 5 mcg q10min, titrate to response; after <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, taper dose by 5 mcg; switch to PO as soon as possible</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature; do not use discolored sol</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Insulin (regular)</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5431">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5434">
					<section type="none" id="sidelem4x5435">
						<sec_title>CNS:</sec_title>
						<para> Tremors, anxiety, insomnia, headache, dizziness, stimulation</para>
					</section>
					<section type="none" id="sidelem4x5440">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, hypertension, dysrhythmias, <emphasis style="bold">cardiac arrest, QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5447">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x5452">
						<sec_title>META:</sec_title>
						<para> Hypokalemia, hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x5457">
						<sec_title>RESP:</sec_title>
						<para> Paradoxical bronchospasm, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5462">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5465">
					<section type="none" id="sidelem4x5466">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 1-2 hr, duration 4-8 hr, half-life 3.4 hr</para>
					</section>
					<section type="none" id="sidelem4x5477">
						<sec_title>SUBCUT:</sec_title>
						<para> Onset 6-15 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, duration 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 hr, half-life 5.7 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5494">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: hypertensive crisis—MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of both products—other sympathomimetics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action—β-blockers; do not use together</para>
				<section type="none" id="sidelem4x5508">
					<section type="none" id="sidelem4x5509">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—green tea (large amounts), guarana</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5516">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5519">
					<section type="none" id="sidelem4x5520">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5525">
								<item>
									<label>•</label>
									<para>Respiratory function: vital capacity, forced expiratory volume, ABGs, B/P, pulse, respiratory pattern, lung sounds, sputum before and after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5530">
								<item>
									<label>•</label>
									<para>Tolerance in patients receiving long-term therapy; dose may have to be changed; monitor for rebound bronchospasm</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5536">
								<item>
									<para>
										<emphasis alert="nurse">Paradoxical bronchospasm: dyspnea, wheezing; keep emergency equipment nearby</emphasis>
<bbw>Labor: maternal heart rate, B/P, contraction, fetal heart rate; can inhibit uterine contractions, labor; monitor for hypoglycemia, do not use injectable product for prevention or treatment over 72 hr in preterm labor, do not use oral product for preterm labor</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5550">
								<item>
									<label>•</label>
									<para>Increase in fluids of &gt;2 L/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5556">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5560">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of dyspnea, wheezing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5566">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5570">
								<item>
									<label>•</label>
									<para>Not to use OTC medications because extra stimulation may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>About all aspects of product; to avoid smoking, smoke-filled rooms, persons with respiratory infections</para>
								</item>
								<item>
									<label>•</label>
									<para>To increase fluids by &gt;2 L/day; to allow 15 min between inhalation of product and inhaled product containing steroid</para>
								</item>
								<item>
									<label>•</label>
									<para>To take on time; if missed, not to make up after 1 hr; to wait until next dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>terconazole vaginal antifungal</mono_name>
			<section type="none" id="sidelem4x5594">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>teriflunomide</mono_name>
			<info>
				<pronunciation>(ter′i-floo′noe-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x56030">Aubagio</tradename>
				</tradenames>
				<class type="func"> Multiple sclerosis agent</class>
				<class type="chem"> Pyrimidine synthesis inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x5613">
				<sec_title>Action:</sec_title>
				<para>Antiproliferative effects including peripheral T- and B-lymphocytes, might reduce inflammatory demyelination</para>
			</section>
			<section type="uses" id="sidelem4x5618">
				<sec_title>Uses:</sec_title>
				<para>Reduction of the frequency of relapses or remitting MS</para>
			</section>
			<section type="contra" id="sidelem4x5623">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Pregnancy (X)</bbw>
				</para>
				<section type="none" id="sidelem4x5638">
					<section type="none" id="sidelem4x5639">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, alcoholism, diabetes mellitus, eosinophilic pneumonia, hepatitis, jaundice, male-mediated teratogenicity, pneumonitis, pulmonary disease/fibrosis, sarcoidosis, TB, vaccination</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5654">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5662">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5662">
							<item>
								<label>•</label>
								<para> 7 or 14 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5666">
					<section type="none" id="sidelem4x5667">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 7, 14 mg</para>
					</section>
					<section type="none" id="sidelem4x5672">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5675">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5679">
									<item>
										<label>•</label>
										<para>May be taken without regard to food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5685">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5688">
					<section type="none" id="sidelem4x5689">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, headache</para>
					</section>
					<section type="none" id="sidelem4x5694">
						<sec_title>CV:</sec_title>
						<para> Palpitations, hypertension, <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5701">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, conjunctivitis, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x5706">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, cystitis</para>
					</section>
					<section type="none" id="sidelem4x5711">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, lymphopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5718">
						<sec_title>INTEG:</sec_title>
						<para> Acne vulgaris, alopecia, pruritus</para>
					</section>
					<section type="none" id="sidelem4x5723">
						<sec_title>META:</sec_title>
						<para> Weight loss</para>
					</section>
					<section type="none" id="sidelem4x5728">
						<sec_title>MISC:</sec_title>
						<para>  Infection, cystitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5733">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding &gt;99%, median half-life 18-19 days, peak 1-4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5738">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5746">
					<label>•</label>
					<sec_title>
						<route>Do not use with leflunomide, live virus vaccines</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> teriflunomide effect—cycloSPORINE, eltrombopag, gefitinib</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hepatotoxicity—methotrexate, HMG-CoA reductase inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hematologic toxicity—zidovudine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—oral contraceptives, repaglinide, pioglitazone, rosiglitazone, PACLitaxel, naproxen, topotecan, bosentan, furosemide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—warfarin, alosetron, DULoxetine, theophylline, tiZANidine, quiNINE, tamoxifen, bendamustine, rasagiline, rOPINIRole, selegiline, propafenone, mexiletine, lidocaine, anagrelide, cloZAPine, cinacalcet, caffeine, monitor closely</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of teriflunomide—cholestyramine, activated charcoal</para>
			</section>
			<section type="considerations" id="sidelem4x5773">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5776">
					<section type="none" id="sidelem4x5777">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5781">
								<item>
									<label>•</label>
									<para>CNS symptoms: anxiety, confusion, vertigo</para>
								</item>
								<item>
									<label>•</label>
									<para>GI status: diarrhea, vomiting, abdominal pain</para>
								</item>
								<item>
									<label>•</label>
									<para>Cardiac status: tachycardia, palpitations, vasodilation, chest pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5798">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5802">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of MS</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5808">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5813">
								<item>
									<label>•</label>
									<para>That blurred vision can occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5821">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (X)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5824">
								<item>
									<label>•</label>
									<para>Not to change dosing or stop taking without advice of prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>teriparatide (Rx)</mono_name>
			<info>
				<pronunciation>(tah-ree-par′ah-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x58340">Forteo</tradename>
				</tradenames>
				<class type="func"> Parathyroid hormone (rDNA)</class>
				<class type="chem"> Teriparatide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5844">
				<sec_title>Action:</sec_title>
				<para>Contains human recombinant parathyroid hormone to stimulate new bone growth</para>
			</section>
			<section type="uses" id="sidelem4x5849">
				<sec_title>Uses:</sec_title>
				<para>Postmenopausal women with osteoporosis, men with primary or hypogonadal osteoporosis who are at high risk for fracture, glucocorticoid-induced osteoporosis</para>
				<section type="none" id="sidelem4x5854">
					<section type="none" id="sidelem4x5855">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hypoparathyroidism</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5860">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, increased baseline risk for osteosarcoma (Paget’s disease, open epiphyses; previous bone radiation), bone metastases, history of skeletal malignancies, other metabolic bone diseases, preexisting hypercalcemia</para>
				<section type="none" id="sidelem4x5865">
					<section type="none" id="sidelem4x5866">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, urolithiasis, hypotension, use &gt;2 yr, cardiac disease</para>
						<para>
							<bbw>Secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5881">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5889">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x5889">
							<item>
								<label>•</label>
								<para> 20 mcg/day up to 2 yr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5893">
					<section type="none" id="sidelem4x5894">
						<sec_title>Available forms:</sec_title>
						<para> Prefilled pen delivery device (delivers 20 mcg/day)</para>
					</section>
					<section type="none" id="sidelem4x5899">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5902">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x5906">
									<item>
										<label>•</label>
										<para>Give by SUBCUT using disposable pen only; inject in thigh or abdomen; lightly pinch fold of skin; insert needle; release skin; inject at 90-degree angle over 5 sec; rotate inj sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Have patient sit or lie down; orthostatic hypotension may occur</para>
									</item>
									<item>
										<label>•</label>
										<para>Protect from freezing, light; refrigerate pen</para>
									</item>
									<item>
										<label>•</label>
										<para>Store refrigerated; do not freeze; may be used for 28 days after first inj</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5927">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5930">
					<section type="none" id="sidelem4x5931">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, insomnia, depression, vertigo</para>
					</section>
					<section type="none" id="sidelem4x5936">
						<sec_title>CV:</sec_title>
						<para> Hypertension, angina, syncope</para>
					</section>
					<section type="none" id="sidelem4x5941">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, dyspepsia, vomiting, constipation</para>
					</section>
					<section type="none" id="sidelem4x5946">
						<sec_title>INTEG:</sec_title>
						<para> Rash, sweating</para>
					</section>
					<section type="none" id="sidelem4x5951">
						<sec_title>MISC:</sec_title>
						<para> Pain, asthenia, hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x5956">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, leg cramps, back/leg pain, weakness, <emphasis style="bold">osteosarcoma (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5963">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, cough, pharyngitis, pneumonia, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5968">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5971">
					<section type="none" id="sidelem4x5972">
						<sec_title>SUBCUT:</sec_title>
						<para> Extensively and rapidly absorbed, metabolized by liver, excreted by kidneys, terminal half-life 1 hr, onset rapid, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5983">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin toxicity: digoxin</para>
				<section type="none" id="sidelem4x5990">
					<section type="none" id="sidelem4x5991">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> calcium, uric acid, urinary calcium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> phosphorous, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6002">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6005">
					<section type="none" id="sidelem4x6006">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Secondary malignancy: osteosarcoma, dependent on length of treatment; those at higher risk for osteosarcoma should not use this product</bbw>
						</para>
						<para>
							<list id="lidelem4x6021">
								<item>
									<label>•</label>
									<para>Uric acid, magnesium, creatinine, BUN, urine pH, vit D, phosphate for normal serum levels; serum calcium may be transiently increased after dosing (max at 4-6 hr after dose)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6026">
								<item>
									<label>•</label>
									<para>Bone pain, headache, fatigue, changes in LOC, leg cramps</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6034">
							<label>•</label>
							<sec_title>Signs of persistent hypercalcemia</sec_title>
							<para>
								<list id="lidelem4x6034">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Signs of persistent hypercalcemia:</emphasis> nausea, vomiting, constipation, lethargy, muscle weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6038">
								<item>
									<label>•</label>
									<para>Nutritional status: diet for sources of vit D (milk, some seafood), calcium (dairy products, dark green vegetables), phosphates (dairy products)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6043">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6047">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased bone mineral density</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6053">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6057">
								<item>
									<label>•</label>
									<para>About the symptoms of hypercalcemia</para>
								</item>
								<item>
									<label>•</label>
									<para>About foods rich in calcium, vit D</para>
								</item>
								<item>
									<label>•</label>
									<para>How to use delivery device, dispose of needles; not to share pen with others; to use at same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>To sit or lie down if dizziness or fast heartbeat occurs after 1st few doses</para>
								</item>
								<item>
									<label>•</label>
									<para>To rotate administration sites</para>
								</item>
								<item>
									<label>•</label>
									<para>To store pen in refrigerator; pen may be used for 28 days</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>tesamorelin</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x60910">Egrifta</tradename>
				</tradenames>
				<class type="func"> Pituitary hormone, growth hormone modifiers</class>
			</info>
			<section type="actions" id="sidelem4x6097">
				<sec_title>Action:</sec_title>
				<para>Binds to growth hormone (GH) releasing factor receptors on the pituitary somatotroph cells; binding stimulates the production, release of endogenous GH</para>
			</section>
			<section type="uses" id="sidelem4x6102">
				<sec_title>Uses:</sec_title>
				<para>Treatment of excess abdominal fat in HIV-infected patients with lipodystrophy</para>
			</section>
			<section type="contra" id="sidelem4x6107">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or mannitol, neoplastic disease, pregnancy X, <emphasis style="italic">disruption of the hypothalamic-pituitary axis</emphasis> (hypothalamic-pituitary-adrenal (HPA) suppression) due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, radiation therapy of the head or head trauma, IV/IM administration</para>
				<section type="none" id="sidelem4x6115">
					<section type="none" id="sidelem4x6116">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, CABG, diabetes, diabetic retinopathy, edema, geriatric patients, children, infants, adolescents</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6121">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6129">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x6129">
							<item>
								<label>•</label>
								<para> 2 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6133">
					<section type="none" id="sidelem4x6134">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 1 mg</para>
					</section>
					<section type="none" id="sidelem4x6139">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6142">
							<sec_title>Subcut route:</sec_title>
							<para>
								<list id="lidelem4x6146">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before use</para>
									</item>
									<item>
										<label>•</label>
										<para>To reconstitute, use 2, 1 mg vials, inject 2.1 ml sterile water for inj into the first 1 mg vial; use syringe with needle already attached; to avoid foaming, push plunger in slowly with needle on a slight angle so sterile water goes down the inside wall of vial; with needle and syringe attached to vial, keep vial upright and gently roll vial for 30 sec until mixed; do not shake; withdraw 2.1 ml of the reconstituted sol and add to second 1 mg vial; roll, do not shake</para>
									</item>
									<item>
										<label>•</label>
										<para>To administer, take syringe out of vial, place needle cap on its side against a clean flat surface, do not touch needle, hold syringe and slide needle into cap, push cap all the way or until it snaps shut; do not touch cap until it covers needle completely; remove needle, insert a 0.5-inch 27-G safety injection needle onto syringe; use immediately; throw away any unused product or used sterile water for inj, sol should be clear, do not use if discolored, cloudy, or has particles; slight foaming is acceptable; inject subcut into abdomen; avoid scar tissues, bruises, or navel; rotate inj sites in abdomen; slowly push plunger down until all sol has been injected</para>
									</item>
									<item>
										<label>•</label>
										<para>After removing needle from skin, flip back needle shield until it snaps, covering the injection needle completely; keep pressing until you hear a click, which means the injection needle is protected</para>
									</item>
									<item>
										<label>•</label>
										<para>Use a piece of sterile gauze to rub the inj site clean; if bleeding, apply pressure to site with gauze for 30 sec; if bleeding continues, apply a bandage to site</para>
									</item>
									<item>
										<label>•</label>
										<para>Properly dispose of used syringe, needles, vial, and sterile water for injection bottle in a sharps container</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6177">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6180">
					<section type="none" id="sidelem4x6181">
						<sec_title>CNS:</sec_title>
						<para> Depression, peripheral neuropathy paresthesias, hypoesthesia, spasms, flushing, night sweats, insomnia, headache</para>
					</section>
					<section type="none" id="sidelem4x6186">
						<sec_title>CV:</sec_title>
						<para> Chest pain, palpitations, hypertension, edema, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x6191">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, upper abdominal pain, dyspepsia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x6196">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, urticaria, rash, flushing, injection site reactions</para>
					</section>
					<section type="none" id="sidelem4x6201">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, joint swelling, stiffness, myalgias, carpal tunnel syndrome</para>
					</section>
					<section type="none" id="sidelem4x6206">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory tract infection</para>
					</section>
					<section type="none" id="sidelem4x6211">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6218">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 26 min in healthy patients, 38 min in those with HIV infection; peak 0.15 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6223">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—simvastatin, ritonavir, cortisone, predniSONE</para>
			</section>
			<section type="considerations" id="sidelem4x6230">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6233">
					<section type="none" id="sidelem4x6234">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6242">
							<label>•</label>
							<sec_title>Lipodystrophy</sec_title>
							<para>
								<list id="lidelem4x6242">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Lipodystrophy:</emphasis> Assess for sunken cheeks, thinning arms and legs, fat accumulation in the abdomen, jaws, and back of neck; after treatment these should lessen</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6246">
								<item>
									<label>•</label>
									<para>Monitor glycosylated hemoglobin A1c (HbA1c), serum IGF-1 concentrations, ophthalmologic exam</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6251">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6255">
								<item>
									<label>•</label>
									<para>Decreasing lipodystrophy in HIV patients</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>testosterone cypionate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62640">Depo-Testosterone</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="29" status="active">
			<mono_name>testosterone enanthate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62690">Delatestryl</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="30" status="active">
			<mono_name>testosterone gel (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62742">AndroGel</tradename>
					<tradename id="tnidelem4x62741">FORTESTA</tradename>
					<tradename id="tnidelem4x62740">Testim</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="31" status="active">
			<mono_name>testosterone pellets (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62790">Testopel</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="32" status="active">
			<mono_name>testosterone transdermal (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62840">Androderm</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="33" status="active">
			<mono_name>testosterone buccal (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62890">Striant</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="34" status="active">
			<mono_name>testosterone topical solution, gel</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62944">AndroGel</tradename>
					<tradename id="tnidelem4x62943">Axiron</tradename>
					<tradename id="tnidelem4x62942">Fortesta</tradename>
					<tradename id="tnidelem4x62941">Testim</tradename>
					<tradename id="tnidelem4x62940">Vogelxo</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="35" status="active">
			<mono_name>testosterone nasal gel</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x62990">Natesto</tradename>
				</tradenames>
				<class type="func"> Androgenic anabolic steroid</class>
				<class type="chem"> Halogenated testosterone derivative</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="3">III</schedule></class>
			</info>
			<section type="actions" id="sidelem4x6311">
				<sec_title>Action:</sec_title>
				<para>Increases weight by building body tissue; increases potassium, phosphorus, chloride, nitrogen levels, bone development</para>
			</section>
			<section type="uses" id="sidelem4x6316">
				<sec_title>Uses:</sec_title>
				<para>Female breast cancer, hypogonadism, eunuchoidism, male climacteric, oligospermia, impotence, vulvar dystrophies, low testosterone levels, delayed male puberty (inj)</para>
				<section type="none" id="sidelem4x6321">
					<section type="none" id="sidelem4x6322">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Weight loss in AIDS patients, andropause, anemia, cryptorchidism, lichen sclerosis, microphallus, transsexualism</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6328">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, severe cardiac/renal/hepatic disease, hypersensitivity, genital bleeding (rare), male breast/prostate cancer</para>
				<section type="none" id="sidelem4x6333">
					<section type="none" id="sidelem4x6334">
						<sec_title>Precautions:</sec_title>
						<para> Diabetes mellitus, CV disease, MI, urinary tract disorders, prostate cancer, hypercalcemia</para>
						<para>
							<bbw>Children, accidental exposure</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6349">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6352">
					<section type="none" id="sidelem4x6353">
						<sec_title>Replacement</sec_title>
						<section type="none" id="sidelem4x6361">
							<label>•</label>
							<sec_title>Adult<route> IM (enanthate or cypionate)</route></sec_title>
							<para>
								<list id="lidelem4x6361">
									<item>
										<label>•</label>
										<para> 50-400 mg q2-4wk; topical sol (Axiron) 60 mg (2 pump actuations); apply each <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6370">
							<label>•</label>
							<sec_title>Adult (male) and child<route> SUBCUT (pellets)</route></sec_title>
							<para>
								<list id="lidelem4x6370">
									<item>
										<label>•</label>
										<para> 150-450 mg (2-6 pellets) inserted q3-6mo</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6377">
							<label>•</label>
							<sec_title>Adult<route> TRANSDERMAL (Testoderm, Androderm)</route></sec_title>
							<para>
								<list id="lidelem4x6377">
									<item>
										<label>•</label>
										<para> 4-6 mg applied q24hr;  1% 5 mg applied q24hr, once daily; 1.62% 40.5 mg (2 pump actuations) every <emphasis style="smallcaps">am</emphasis>; topical sol  30 mg/actuation  1 buccal system (30 mg) to the gum region q12hr before meals/<emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6395">
							<sec_title>Breast cancer</sec_title>
							<section type="none" id="sidelem4x6403">
								<label>•</label>
								<sec_title>Adult<route> IM</route></sec_title>
								<para>
									<list id="lidelem4x6403">
										<item>
											<label>•</label>
											<para> 200-400 mg q2-4wk (cypionate or enanthate)</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x6407">
						<sec_title>Delayed male puberty</sec_title>
						<section type="none" id="sidelem4x6415">
							<label>•</label>
							<sec_title>Child &gt;12 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6415">
									<item>
										<label>•</label>
										<para> ≤100 mg/mo for ≤6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6419">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Enanthate:</emphasis> inj 200 mg/ml; <emphasis style="bold">cypionate:</emphasis> inj 100, 200 mg/ml; pellets 75 mg; <emphasis style="bold">transdermal</emphasis> 2, 4, mg/24 hr; <emphasis style="bold">gel</emphasis> 1%, 1.62%, 10 mg/actuation; <emphasis style="bold">buccal system</emphasis> 30 mg; <emphasis style="bold">topical sol</emphasis> 30 mg/actuation</para>
					</section>
					<section type="none" id="sidelem4x6442">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6447">
								<item>
									<label>•</label>
									<para>Titrated dose; use lowest effective dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6452">
								<item>
									<label>•</label>
									<para>IM inj deep into upper outer quadrant of gluteal muscle</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6460">
							<label>•</label>
							<sec_title>Transdermal patches</sec_title>
							<para>
								<list id="lidelem4x6460">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Transdermal patches:</emphasis> Testoderm to skin of scrotum; Androderm to skin of back, upper arms, thighs, abdomen; area must be dry shaved; may be reapplied after bathing, swimming</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6467">
							<label>•</label>
							<sec_title>Gel</sec_title>
							<para>
								<list id="lidelem4x6467">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Gel:</emphasis> products not interchangeable; dosage and administration for AndroGel 1% differs from that of AndroGel 1.62%; apply daily to clean, dry area on shoulders, upper arms, or abdomen; women, children should not touch treated skin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6471">
							<sec_title>Buccal system route</sec_title>
							<para>
								<list id="lidelem4x6475">
									<item>
										<label>•</label>
										<para>Do not chew or swallow buccal system</para>
									</item>
									<item>
										<label>•</label>
										<para>Rotate sites; place above incisor tooth on either side of mouth</para>
									</item>
									<item>
										<label>•</label>
										<para>Open packet; place rounded side of surface against gum and hold firmly in place with finger over lip for 30 sec; if product falls off, replace with new system; discard in trash can away from children or pets</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6491">
							<sec_title>Topical solution route</sec_title>
							<para>
								<list id="lidelem4x6495">
									<item>
										<label>•</label>
										<para>Using the provided applicator, apply the solution to clean, dry, intact skin of the axilla, preferably at the same time each morning; do not apply to any other part of the body; allow the solution to dry completely before dressing; if an antiperspirant or deodorant is used, apply at least 2 min before applying the solution; the pump must be primed before the first use by fully depressing the pump mechanism 3×; discard any solution that is released during the priming; to dispense the solution, position the nozzle over the applicator cup and carefully depress the pump once fully; the cup should be filled with no more than 1 pump actuation (30 mg); with the applicator upright, place it up into the axilla and wipe steadily down and up into the axilla; do not use fingers or hand to rub the solution; if multiple applications are necessary for the required dose, alternate application between the left and right axilla; when repeat application to the same axilla is necessary, allow the solution to dry completely before the next application; after use, rinse the applicator under running water and pat dry with tissue; wash hands with soap and water</para>
									</item>
									<item>
										<label>•</label>
										<para>Following application, allow the site to dry before putting on clothing</para>
									</item>
									<item>
										<label>•</label>
										<para>Direct contact of the medicated skin with the skin of another person can result in the transfer of residual testosterone and absorption by the other person; to reduce accidental transfer, the patient should cover the application site(s) with clothing (e.g., a T-shirt) after the solution has dried; the application site should be washed with soap and water before any skin-to-skin contact regardless of the length of time since application; in the case of direct contact, the other person should wash the area of contact with soap and water as soon as possible</para>
									</item>
									<item>
										<label>•</label>
										<para>Patients should be advised that the topical solution is flammable; therefore, fire, flame, and smoking should be avoided during use</para>
									</item>
									<item>
										<label>•</label>
										<para>Advise patients to avoid swimming or washing the application site until 2 hr following application of solution</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6523">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6526">
					<section type="none" id="sidelem4x6527">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, fatigue, tremors, paresthesias, flushing, sweating, anxiety, lability, insomnia, carpal tunnel syndrome</para>
					</section>
					<section type="none" id="sidelem4x6532">
						<sec_title>CV:</sec_title>
						<para> Increased B/P</para>
					</section>
					<section type="none" id="sidelem4x6537">
						<sec_title>EENT:</sec_title>
						<para> Conjunctival edema, nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x6542">
						<sec_title>ENDO:</sec_title>
						<para> Abnormal glucose tolerance test</para>
					</section>
					<section type="none" id="sidelem4x6547">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, constipation, weight gain, <emphasis style="bold">cholestatic jaundice</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6554">
						<sec_title>GU:</sec_title>
						<para> Hematuria, amenorrhea, vaginitis, decreased libido, decreased breast size, clitoral hypertrophy, testicular atrophy, gynecomastia, large prostate</para>
					</section>
					<section type="none" id="sidelem4x6559">
						<sec_title>HEMA:</sec_title>
						<para> Polycythemia</para>
					</section>
					<section type="none" id="sidelem4x6564">
						<sec_title>INTEG:</sec_title>
						<para> Rash, acneiform lesions, oily hair/skin, flushing, sweating, acne vulgaris, alopecia, hirsutism</para>
					</section>
					<section type="none" id="sidelem4x6569">
						<sec_title>MS:</sec_title>
						<para> Cramps, spasms</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6574">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6577">
					<section type="none" id="sidelem4x6578">
						<sec_title>PO:</sec_title>
						<para> Metabolized in liver; excreted in urine, breast milk; crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6583">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x6587">
						<item>
							<label>•</label>
							<para>Edema: ACTH, adrenal steroids, buPROPion</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of oxyphenbutazone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> PT—anticoagulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> glucose levels may alter need for oral antidiabetics, insulin</para>
				<section type="none" id="sidelem4x6605">
					<section type="none" id="sidelem4x6606">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum cholesterol, blood glucose, urine glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> serum calcium, serum potassium, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">3</emphasis>, thyroid <emphasis style="sup">131</emphasis>I uptake test, urine 17-OHCS, 17-KS, PBI</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6626">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6629">
					<section type="none" id="sidelem4x6630">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6635">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber if weekly weight gain &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6640">
								<item>
									<label>•</label>
									<para>B/P q4hr, Hgb/HCT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6645">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6650">
								<item>
									<label>•</label>
									<para>Growth rate, bone age in children; growth rate may be uneven (linear/bone growth) with extended use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6655">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chlorine, calcium; cholesterol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6660">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6665">
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms, jaundice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6670">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, aggression</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6678">
							<label>•</label>
							<sec_title>Signs of masculinization in female</sec_title>
							<para>
								<list id="lidelem4x6678">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Signs of masculinization in female:</emphasis> increased libido, deepening of voice, decreased breast tissue, enlarged clitoris, menstrual irregularities; male: gynecomastia, impotence, testicular atrophy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6685">
							<label>•</label>
							<sec_title>Hypercalcemia</sec_title>
							<para>
								<list id="lidelem4x6685">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercalcemia:</emphasis> lethargy, polyuria, polydipsia, nausea, vomiting, constipation; product may have to be decreased</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6692">
							<label>•</label>
							<sec_title>
								<route>Hypoglycemia</route>
							</sec_title>
							<para>
								<list id="lidelem4x6692">
									<item>
										<label>•</label>
										<para> in diabetic patients; oral antidiabetic action is increased</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6696">
								<item>
									<label>•</label>
									<para>Diet with increased calories, protein; decrease sodium if edema occurs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6701">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6705">
								<item>
									<label>•</label>
									<para>Therapeutic response: 4-6 wk with osteoporosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6711">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6715">
								<item>
									<label>•</label>
									<para>That product must be combined with complete health plan: diet, rest, exercise</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases, if edema occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>About changes in sex characteristics: priapism, gynecomastia, increased libido</para>
								</item>
								<item>
									<label>•</label>
									<para>That women should report menstrual irregularities, voice changes, acne, facial hair growth; if pregnancy is planned or suspected</para>
								</item>
								<item>
									<label>•</label>
									<para>That 1-3-mo course is necessary for response with breast cancer</para>
								</item>
								<item>
									<label>•</label>
									<para>About the proper application of patches</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>tetracaine ophthalmic</mono_name>
			<section type="none" id="sidelem4x6750">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>tetracaine topical</mono_name>
			<section type="none" id="sidelem4x6757">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>tetracycline (Rx)</mono_name>
			<info>
				<pronunciation>(tet-ra-sye′kleen)</pronunciation>
				<class type="func"> Broad-spectrum antiinfective</class>
				<class type="chem"> Tetracycline</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x6774">
				<sec_title>Action:</sec_title>
				<para>Inhibits protein synthesis and phosphorylation in microorganisms; bacteriostatic</para>
			</section>
			<section type="uses" id="sidelem4x6779">
				<sec_title>Uses:</sec_title>
				<para>Syphilis, <emphasis style="italic">Chlamydia trachomatis,</emphasis> gonorrhea, lymphogranuloma venereum; uncommon gram-positive, gram-negative organisms; rickettsial infections</para>
			</section>
			<section type="contra" id="sidelem4x6787">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, children &lt;8 yr, hypersensitivity to tetracyclines</para>
				<section type="none" id="sidelem4x6792">
					<section type="none" id="sidelem4x6793">
						<sec_title>Precautions:</sec_title>
						<para> Renal/hepatic disease, UV exposure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6798">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6801">
					<section type="none" id="sidelem4x6802">
						<sec_title>Susceptible gram-positive/gram-negative infections</sec_title>
						<section type="none" id="sidelem4x6810">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6810">
									<item>
										<label>•</label>
										<para> 250-500 mg q6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6817">
							<label>•</label>
							<sec_title>Child &gt;8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6817">
									<item>
										<label>•</label>
										<para> 25-50 mg/kg/day in divided doses q6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6821">
						<sec_title>Chlamydia trachomatis</sec_title>
						<section type="none" id="sidelem4x6829">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6829">
									<item>
										<label>•</label>
										<para> 500 mg qid × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6833">
						<sec_title>Syphilis</sec_title>
						<section type="none" id="sidelem4x6841">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6841">
									<item>
										<label>•</label>
										<para> 500 mg qid × 2 wk; if syphilis duration &gt;1 yr, must treat 28 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6845">
						<sec_title>Brucellosis</sec_title>
						<section type="none" id="sidelem4x6853">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6853">
									<item>
										<label>•</label>
										<para> 500 mg q6hr × 3 wk with  1 g streptomycin bid × 1st wk, then daily × 2nd wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6860">
						<sec_title>Urethral, endocervical, rectal infections <emphasis style="italic">(C. trachomatis)</emphasis></sec_title>
						<section type="none" id="sidelem4x6870">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6870">
									<item>
										<label>•</label>
										<para> 500 mg qid × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6874">
						<sec_title>Acne</sec_title>
						<section type="none" id="sidelem4x6882">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6882">
									<item>
										<label>•</label>
										<para> 250 mg q6hr, then 125-500 mg/day or every other day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6886">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6894">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 51-90 ml/min, give dose q8-12hr; CCr 10-50 ml/min, give dose q12-24hr; CCr &lt;10 ml/min, give dose q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6897">
						<sec_title>Available forms:</sec_title>
						<para> Caps 250, 500 mg</para>
					</section>
					<section type="none" id="sidelem4x6902">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6906">
								<item>
									<label>•</label>
									<para>After C&amp;S obtained</para>
								</item>
								<item>
									<label>•</label>
									<para>2 hr before or after iron products; 1 hr after antacid products</para>
								</item>
								<item>
									<label>•</label>
									<para>Should be given on empty stomach (1 hr before or 2 hr after meals)</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6927">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6930">
					<section type="none" id="sidelem4x6931">
						<sec_title>CNS:</sec_title>
						<para> Fever, headache, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x6936">
						<sec_title>CV:</sec_title>
						<para> Pericarditis</para>
					</section>
					<section type="none" id="sidelem4x6941">
						<sec_title>EENT:</sec_title>
						<para> Dysphagia, glossitis, decreased calcification, discoloration of deciduous teeth, oral candidiasis, oral ulcers</para>
					</section>
					<section type="none" id="sidelem4x6946">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> abdominal pain, <emphasis style="italic">vomiting, diarrhea,</emphasis> anorexia, enterocolitis, <emphasis style="bold">hepatotoxicity,</emphasis> flatulence, abdominal cramps, epigastric burning, stomatitis, <emphasis style="bold">hepatitis, pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6962">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Increased BUN,</emphasis><emphasis style="bold">azotemia, acute renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6971">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Eosinophilia, neutropenia, thrombocytopenia, leukocytosis, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6978">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, urticaria, photosensitivity, increased pigmentation,</emphasis><emphasis style="bold">exfoliative dermatitis,</emphasis> pruritus, <emphasis style="bold">angioedema, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6990">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Increased intracranial pressure,</emphasis> candidiasis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6998">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7001">
					<section type="none" id="sidelem4x7002">
						<sec_title>PO:</sec_title>
						<para> Peak 2-3 hr; duration 6 hr; half-life 6-12 hr; excreted in urine, breast milk; crosses placenta; 65% protein bound</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7009">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Fatal nephrotoxicity: methoxyflurane</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of warfarin, digoxin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of tetracycline—antacids, sodium bicarbonate, alkali products, iron, cimetidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of penicillins</para>
				<section type="none" id="sidelem4x7029">
					<section type="none" id="sidelem4x7030">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x7034">
								<item>
									<label>•</label>
									<para>Photosensitivity: dong quai</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7040">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> tetracycline effect—dairy products</para>
					</section>
					<section type="none" id="sidelem4x7047">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7054">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7057">
					<section type="none" id="sidelem4x7058">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7064">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC count, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE is given</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7069">
								<item>
									<label>•</label>
									<para>Signs of anemia: Hct, Hgb, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7074">
								<item>
									<label>•</label>
									<para>I&amp;O ratio</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7079">
								<item>
									<label>•</label>
									<para>Blood studies: PT, CBC, AST, ALT, BUN, creatinine if on prolonged therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7087">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x7087">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash, itching, pruritus</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7095">
							<label>•</label>
							<sec_title>Serious skin reactions<route> angioedema, Stevens-Johnson syndrome, exfoliative dermatitis; report immediately after stopping product</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7098">
								<item>
									<label>•</label>
									<para>Nausea, vomiting, diarrhea; administer antiemetic, antacids as ordered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7104">
								<item>
									<para>
										<emphasis alert="nurse">Superinfection: fever, malaise, redness, pain, swelling, drainage, perineal itching, diarrhea, changes in cough or sputum if on prolonged therapy</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7109">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7113">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of lesions, negative C&amp;S, resolution of infection, prevention of malaria</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7119">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7124">
								<item>
									<label>•</label>
									<para>To avoid sun exposure; that sunscreen does not seem to decrease photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7129">
								<item>
									<label>•</label>
									<para>That all prescribed medication must be taken to prevent superinfection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7134">
								<item>
									<label>•</label>
									<para>To avoid milk products, antacids or to separate by 2 hr; to take with full glass of water; to take 1 hr before bedtime to prevent esophageal ulceration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7139">
								<item>
									<label>•</label>
									<para>That tooth discoloration may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7147">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately of diarrhea with pus, mucus, fever, abdominal pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7151">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber if pregnancy is planned or suspected, pregnancy (D)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7159">
							<label>•</label>
							<sec_title>
								<route>Not to use outdated products, Fanconi syndrome (nephrotoxicity) may occur</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="39" status="active">
			<mono_name>tetrahydrozoline nasal agent</mono_name>
			<section type="none" id="sidelem4x7165">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>tetrahydrozoline ophthalmic</mono_name>
			<section type="none" id="sidelem4x7172">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>theophylline (Rx)</mono_name>
			<info>
				<pronunciation>(thee-off′i-lin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x71813">
						<country code="CAN">Phyllocontin </country>
					</tradename>
					<tradename id="tnidelem4x71812">Theochron</tradename>
					<tradename id="tnidelem4x71811">Theo-24</tradename>
					<tradename id="tnidelem4x71810">Uniphyl</tradename>
				</tradenames>
				<class type="func"> Bronchodilator, spasmolytic</class>
				<class type="chem"> Methylxanthine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7194">
				<sec_title>Action:</sec_title>
				<para>Exact mechanism unknown, relaxes smooth muscle of respiratory system by blocking phosphodiesterase, which increases cAMP; increased cAMP alters intracellular calcium ion movements; produces bronchodilation, increased pulmonary blood flow, relaxation of respiratory tract</para>
			</section>
			<section type="uses" id="sidelem4x7199">
				<sec_title>Uses:</sec_title>
				<para>Bronchial asthma, bronchospasm associated with chronic bronchitis, emphysema, apnea during infancy for respiratory/myocardial stimulation</para>
				<section type="none" id="sidelem4x7204">
					<section type="none" id="sidelem4x7205">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Methotrexate toxicity, sleep apnea, status asthmaticus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7210">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to xanthines, tachydysrhythmias</para>
				<section type="none" id="sidelem4x7215">
					<section type="none" id="sidelem4x7216">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, cor pulmonale, hepatic disease, diabetes mellitus, hyperthyroidism, hypertension, seizure disorder, irritation of the rectum/lower colon, alcoholism, active peptic ulcer disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7221">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7224">
					<section type="none" id="sidelem4x7225">
						<sec_title>Reversible airway obstruction (bronchospasm prophylaxis) associated with asthma or chronic obstructive pulmonary disease (COPD, emphysema, chronic bronchitis)</sec_title>
						<para>Calculate initial mg/kg dose based on ideal body weight as theophylline distributes poorly into body fat</para>
					</section>
					<section type="none" id="sidelem4x7230">
						<sec_title>Acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases (COPD) along with inhaled <emphasis style="bold">β</emphasis>-2 selective agonists and systemic corticosteroids</sec_title>
						<section type="none" id="sidelem4x7241">
							<label>•</label>
							<sec_title>Adult &lt;60 yr/adolescent ≥16 yr<route> IV CONT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7241">
									<item>
										<label>•</label>
										<para> expressed in theophylline; initially, 0.4 mg/kg/hr; max 900 mg/day (otherwise healthy nonsmokers); patients who smoke may require an increased dose; give 0.2 mg/kg/hr (≥400 mg/day) in CHF, cor pulmonale, liver dysfunction, sepsis with multiorgan failure, shock; reduced doses may be needed in patients receiving other drugs that decrease theophylline clearance; adjust dosage based on serum concentrations</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7248">
							<label>•</label>
							<sec_title>Adult ≥60 yr<route> IV CONT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7248">
									<item>
										<label>•</label>
										<para> initially, 0.3 mg/kg/mg/kg/hr; give 0.2 mg/kg/hr in CHF, cor pulmonale, liver dysfunction, sepsis with multiorgan failure, shock; reduced doses may be needed in patients receiving other drugs that decrease theophylline clearance; adjust dosage based on serum concentrations; max 400 mg/day unless serum concentration and patient condition require a higher dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7255">
							<label>•</label>
							<sec_title>Child ≥12 yr/adolescent ≤15 yr<route> IV CONT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7255">
									<item>
										<label>•</label>
										<para> initially, 0.5 mg/kg/hr (healthy nonsmokers (up to 900 mg/day); 0.7 mg/kg/hr in smokers; 0.2 mg/kg/hr (up to 400 mg/day) in cardiac decompensation, cor pulmonale, liver dysfunction, sepsis with multiorgan failure, or shock); adjust dosage based on serum concentrations</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7262">
							<label>•</label>
							<sec_title>Child 9-11 yr<route> IV CONT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7262">
									<item>
										<label>•</label>
										<para> initially, 0.7 mg/kg/hr; reduced doses may be needed in patients receiving other drugs that decrease theophylline clearance; give 0.2 mg/kg/hr (up to 400 mg/day) in cardiac decompensation, cor pulmonale, liver dysfunction, sepsis with multiorgan failure, or shock; adjust dosage based on serum concentrations</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7269">
							<label>•</label>
							<sec_title>Child 1-8 yr<route> IV CONT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7269">
									<item>
										<label>•</label>
										<para> initially, 0.8 mg/kg/hr; reduced doses may be needed in patients receiving other drugs that decrease theophylline clearance; 0.2 mg/kg/hr (up to 400 mg/day) in cardiac decompensation, cor pulmonale, liver dysfunction, sepsis with multiorgan failure, or shock; adjust dosage based on serum concentrations</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7276">
							<label>•</label>
							<sec_title>Infant 6-52 wk<route> IV CONT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7276">
									<item>
										<label>•</label>
										<para> calculate initial dosage using the following equation: (0.008 × age in wk) + 0.21 = theophylline dosage in mg/kg/hr IV; reduced doses may be needed in patients with risk factors for reduced theophylline clearance (cimetidine therapy, cardiac or liver dysfunction, renal impairment in infant &lt;3 mo); adjust dosage based on serum concentrations</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7280">
						<sec_title>For maintenance therapy of asthma or COPD</sec_title>
						<section type="none" id="sidelem4x7288">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7288">
									<item>
										<label>•</label>
										<para> (expressed in theophylline and reg release products) PO initially, 300 mg/day in divided doses q6-8hr; after 3 days, if tolerated, increase dose to 400 mg/day in divided doses q6-8hr; after 3 more days, if tolerated, increase dose to 600 mg/day PO in divided doses q6-8hr; adjust dose to maintain therapeutic range; doses of 400-1600 mg/day may be needed, max 400 mg/day in patients with risk factors for decreased theophylline clearance (elderly patients &gt;60 yr); NIH recommends initial dose for asthma of 10 mg/kg/day (max: 300 mg/day) titrated to serum concentration of 5-15 mcg/ml (usual max: 800 mg/day in ≥12 yr and 16 mg/kg/day in children 1-11 yr)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7297">
							<label>•</label>
							<sec_title>Child/adolescent ≤15 yr old and ≤45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7297">
									<item>
										<label>•</label>
										<para> initially, 12-14 mg/kg (max 300 mg) per day in divided doses q4-6hr; after 3 days, if tolerated, may increase to 16 mg/kg (max 400 mg) per day in divided doses q4-6hr; after 3 more days, if tolerated and if needed, increase dose to 20 mg/kg (max 600 mg) per day in divided doses q4-6hr; adjust dose to maintain therapeutic range (doses of 10-36 mg/kg/day in child 1-9 yr may be needed); max 16 mg/kg (400 mg) per day in patients with risk factors for decreased theophylline clearance or who cannot receive recommended serum concentration monitoring; NIH recommends initial dose for asthma of 10 mg/kg/day (max 300 mg/day) titrated to serum concentration of 5-15 mcg/ml (usual max 800 mg/day in patients ≥12 yr and 16 mg/kg/day in children 1-11 yr)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7304">
							<label>•</label>
							<sec_title>Neonate/infant ≤52 wk<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7304">
									<item>
										<label>•</label>
										<para> calculate initial dose using the following equation: [(0.2 × age in wk) + 5] × (kg body weight) = theophylline dosage in mg/day; in infants ≤26 wk, divide dose and administer q8hr and in infant &gt;26 wk, divide dose and give q6hr; adjust dose to maintain a steady-state serum concentration of 5-10 mcg/ml in neonates and 10-15 mcg/ml in infants; NIH recommends initial dose for asthma of 10 mg/kg/day titrated to theophylline serum concentration of 5-15 mcg/ml, max in mg/kg/day = [(0.2 × age in weeks) + 5]</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7308">
								<item>
									<label>•</label>
									<para>Extended-release products are to be used only for chronic disease management; do not use in treatment of acute symptoms of asthma and reversible bronchospasm</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7316">
							<label>•</label>
							<sec_title>Adult/adolescents/child ≥12 yr and &gt;45 kg<route> (Theo-24 Cap) PO</route></sec_title>
							<para>
								<list id="lidelem4x7316">
									<item>
										<label>•</label>
										<para> initially, 300-400 mg/day q24hr; evening dosing is not recommended; after 3 days, if tolerated, increase to 400-600 mg/day q24hr; adjust dose to maintain therapeutic range; doses of 400-1600 mg/day may be needed; max 400 mg/day in patients with decreased theophylline clearance, (elderly &gt;60 yr), and in those who cannot receive recommended serum concentration monitoring</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7323">
							<label>•</label>
							<sec_title>Child &gt;12 yr/adolescent &lt;16 yr and &lt;45 kg<route> (Theo-24 Cap) PO</route></sec_title>
							<para>
								<list id="lidelem4x7323">
									<item>
										<label>•</label>
										<para> initially, 12-14 mg/kg (max 300 mg) per day q24hr; evening dosing is not recommended; after 3 days, if tolerated, may increase to 16 mg/kg (max 400 mg) per day; after 3 more days, if tolerated and if needed, increase to 20 mg/kg (max 600 mg) per day; adjust dose to maintain therapeutic range; max 16 mg/kg/day up to 400 mg/day in patients with decreased theophylline clearance</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7327">
						<sec_title>Treatment of methotrexate toxicity (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7335">
							<label>•</label>
							<sec_title>Adult/adolescents/child ≥3 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7335">
									<item>
										<label>•</label>
										<para> 2.5 mg/kg over 45-60 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7339">
						<sec_title>Available forms:</sec_title>
						<para> Inj 250 mg/10 ml, 500 mg/20 ml, 100 mg/100 ml in 0.45% NaCl, 200 mg/100 ml in 0.45% NaCl; rect supp 250, 500 mg; tabs 100, 200 mg; ext rel tab 100, 200, 300, 400, 450, 600 mg; ext rel cap 100, 200, 300, 400; elixir 80 mg/15 ml</para>
					</section>
					<section type="none" id="sidelem4x7344">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7348">
								<item>
									<label>•</label>
									<para>Avoid IM inj; pain and tissue damage may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7354">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7358">
									<item>
										<label>•</label>
										<para>Avoid giving with food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7364">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7369">
									<item>
										<label>•</label>
										<para>Only clear sol; flush IV line before dose</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x7377">
								<label>•</label>
								<sec_title>
									<route>diluted</route>
								</sec_title>
								<para>
									<list id="lidelem4x7377">
										<item>
											<label>•</label>
											<para>May be  for IV infusion in 100-200 ml in D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">10</emphasis>W, D<emphasis style="inf">20</emphasis>W, 0.9% NaCl, 0.45% NaCl, LR</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x7394">
								<label>•</label>
								<sec_title>
									<route>Give</route>
								</sec_title>
								<para>
									<list id="lidelem4x7394">
										<item>
											<label>•</label>
											<para> loading dose over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; max rate of infusion 25 mg/min, use infusion pump; after loading dose, give by cont infusion</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x7404">
									<item>
										<label>•</label>
										<para>Store diluted sol for 24 hr if refrigerated</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Heparin, metoclopramide, PENTobarbital, thiopental</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Allopurinol, amifostine, amphotericin B, amrinone, aztreonam, cefTAZidime, cholesteryl sulfate complex, cimetidine, cladribine, DOXOrubicin liposome, enalaprilat, esmolol, famotidine, filgrastim, fluconazole, fludarabine, foscarnet, gallium, granisetron, heparin sodium with hydrocortisone sodium succinate, labetalol, melphalan, meropenem, netilmicin, PACLitaxel, pancuronium, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, tolazoline, vecuronium</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7419">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7422">
					<section type="none" id="sidelem4x7423">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, restlessness, insomnia, <emphasis style="italic">dizziness,</emphasis><emphasis style="bold">seizures,</emphasis> headache, light-headedness, muscle twitching, tremors</para>
					</section>
					<section type="none" id="sidelem4x7433">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, sinus tachycardia,</emphasis> hypotension, flushing, <emphasis style="bold">dysrhythmias,</emphasis> edema</para>
					</section>
					<section type="none" id="sidelem4x7444">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> diarrhea, dyspepsia, anal irritation (suppositories), epigastric pain, reflux, anorexia</para>
					</section>
					<section type="none" id="sidelem4x7452">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, SIADH</para>
					</section>
					<section type="none" id="sidelem4x7457">
						<sec_title>INTEG:</sec_title>
						<para> Flushing, urticaria</para>
					</section>
					<section type="none" id="sidelem4x7462">
						<sec_title>MISC:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x7467">
						<sec_title>RESP:</sec_title>
						<para> Tachypnea, increased respiratory rate</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7472">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver (caffeine); excreted in urine; crosses placenta; appears in breast milk; half-life 6.5-10.5 hr; half-life increased in geriatric patients, hepatic disease, CHF, neonates, premature infants; protein binding 40%, crosses into CSF</para>
				<section type="none" id="sidelem4x7477">
					<section type="none" id="sidelem4x7478">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis> hr, peak 1-2 hr, duration 6-8 hr, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x7489">
						<sec_title>PO-ER:</sec_title>
						<para> Onset unknown, peak 4-7 hr, duration 8-12 hr, well absorbed slowly</para>
					</section>
					<section type="none" id="sidelem4x7494">
						<sec_title>IV:</sec_title>
						<para> Onset rapid, duration 6-8 hr</para>
					</section>
					<section type="none" id="sidelem4x7499">
						<sec_title>RECT:</sec_title>
						<para> Onset erratic, peak 1-2 hr, duration 6-8 hr, supp absorbed erratically, sol absorbed quickly</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7504">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x7509">
						<item>
							<label>•</label>
							<para>Dose-dependent reversal of neuromuscular blockade</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x7517">
					<label>•</label>
					<sec_title>Increase</sec_title>
					<para>
						<list id="lidelem4x7517">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Increase:</emphasis> dysrhythmias: halothane</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<list id="lidelem4x7521">
						<item>
							<label>•</label>
							<para>May increase or decrease theophylline levels: carBAMazepine, loop diuretics, isoniazid</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of theophylline, toxicity—cimetidine, nonselective β-blockers, erythromycin, clarithromycin, oral contraceptives, corticosteroids, interferons, fluoroquinolones, disulfiram, mexiletine, fluvoxaMINE, high doses of allopurinol, influenza vaccines, interferon, benzodiazepines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—tetracyclines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> elimination—smoking</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of theophylline—nicotine products, adrenergics, barbiturates, phenytoin, ketoconazole, rifampin</para>
				<section type="none" id="sidelem4x7546">
					<section type="none" id="sidelem4x7547">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effects—cola tree, guarana, yerba maté, tea (black, green), horsetail, ginseng, Siberian ginseng</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effects—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x7558">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—xanthines</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> elimination by low-carbohydrate, high-protein diet; charcoal-broiled beef</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> elimination by high-carbohydrate, low-protein diet</para>
					</section>
					<section type="none" id="sidelem4x7573">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> plasma-free fatty acids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7580">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7583">
					<section type="none" id="sidelem4x7584">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7588">
								<item>
									<label>•</label>
									<para>Theophylline blood levels (therapeutic level is 10-20 mcg/ml); toxicity may occur with small increase above 20 mcg/ml, especially in geriatric patients; whether theophylline was given recently (24 hr)</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor I&amp;O; diuresis occurs; dehydration may occur in geriatric patients or children</para>
								</item>
								<item>
									<label>•</label>
									<para>Liver function tests: periodically, lower doses may be required in those with moderate to severe hepatic disease</para>
								</item>
								<item>
									<label>•</label>
									<para>Respiratory rate, rhythm, depth; auscultate lung fields bilaterally; notify prescriber of abnormalities, monitor pulmonary function tests</para>
								</item>
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria; if these occur, product should be discontinued</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7615">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7619">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dyspnea, respiratory stimulation for infants, clear lung fields bilaterally</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7625">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7630">
								<item>
									<label>•</label>
									<para>To take doses as prescribed; not to skip dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7635">
								<item>
									<label>•</label>
									<para>To check OTC medications, current prescription medications for ePHEDrine; will increase CNS stimulation; not to drink alcohol or caffeine products (tea, coffee, chocolate, colas); to avoid large amounts of charcoal-grilled beef</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7640">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities; dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7645">
								<item>
									<label>•</label>
									<para>If GI upset occurs, to take product with 8 oz water; to avoid food because absorption may be decreased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7651">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber immediately about toxicity: insomnia, anxiety, nausea, vomiting, rapid pulse, seizures, flushing, headache, diarrhea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7656">
								<item>
									<label>•</label>
									<para>To notify prescriber about changes in smoking habits because a change in dose may be required; to avoid smoking because it decreases drug blood levels and terminal half-life</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7661">
								<item>
									<label>•</label>
									<para>To increase fluids to 2 L/day to decrease secretion viscosity</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="42" status="active">
			<mono_name>thiamine (vit B1) (<emphasis style="smallcaps">po-otc; iv, im</emphasis>-Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x76750">Vitamin B-1</tradename>
				</tradenames>
				<class type="func"> Vit B</class>
				<class type="chem"> Water soluble</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7687">
				<para>
					<confusion>
						<tradename id="tnidelem4x76870">thiamine</tradename>
						<drug type="generic" refid="idelem4x76870">Tenormin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7691">
				<sec_title>Action:</sec_title>
				<para>Needed for pyruvate metabolism, carbohydrate metabolism</para>
			</section>
			<section type="uses" id="sidelem4x7696">
				<sec_title>Uses:</sec_title>
				<para>Vit B<emphasis style="inf">1</emphasis> deficiency or polyneuritis, cheilosis adjunct with thiamine beriberi, Wernicke-Korsakoff syndrome, pellagra, metabolic disorders, alcoholism</para>
			</section>
			<section type="contra" id="sidelem4x7704">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x7709">
					<section type="none" id="sidelem4x7710">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7715">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7718">
					<section type="none" id="sidelem4x7719">
						<sec_title>RDA</sec_title>
						<section type="none" id="sidelem4x7727">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7727">
									<item>
										<label>•</label>
										<para> (males) 1.2-1.5 mg; (females) 1.1 mg; (pregnancy) 1.4 mg; (breastfeeding) 1.4 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7734">
							<label>•</label>
							<sec_title>Child 9-13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7734">
									<item>
										<label>•</label>
										<para> 0.9 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7741">
							<label>•</label>
							<sec_title>Child 4-8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7741">
									<item>
										<label>•</label>
										<para> 0.6 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7748">
							<label>•</label>
							<sec_title>Child 1-3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7748">
									<item>
										<label>•</label>
										<para> 0.5 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7755">
							<label>•</label>
							<sec_title>Infant 7 mo-1 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7755">
									<item>
										<label>•</label>
										<para> 0.3 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7762">
							<label>•</label>
							<sec_title>Neonate and infant ≤6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7762">
									<item>
										<label>•</label>
										<para> 0.2 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7766">
						<sec_title>Beriberi</sec_title>
						<section type="none" id="sidelem4x7774">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7774">
									<item>
										<label>•</label>
										<para> 5-30 mg daily or in 3 divided doses × 1 mo;  5-30 mg daily or in 3 divided doses, then convert to </para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7786">
							<label>•</label>
							<sec_title>Infant/child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7786">
									<item>
										<label>•</label>
										<para> 10-50 mg daily × 2 wk, then 5-10 mg daily × 1 mo;  10-25 mg/day × 2 wk, then 5-10 mg daily × 1 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7793">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 100, 250, 500 mg; inj 100 mg/ml; enteric-coated tabs 20 mg</para>
					</section>
					<section type="none" id="sidelem4x7798">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7801">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x7805">
									<item>
										<label>•</label>
										<para>By IM inj; rotate sites if pain and inflammation occur; do not mix with alkaline sol; <emphasis style="sans-serif">Z</emphasis>-track to minimize pain</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7814">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x7818">
									<item>
										<label>•</label>
										<para>Undiluted at 100 mg/ml over 5 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7824">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7828">
									<item>
										<label>•</label>
										<para>Diluted in compatible IV sol</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Famotidine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7838">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7841">
					<section type="none" id="sidelem4x7842">
						<sec_title>CNS:</sec_title>
						<para> Weakness, restlessness</para>
					</section>
					<section type="none" id="sidelem4x7847">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Collapse, pulmonary edema,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x7855">
						<sec_title>EENT:</sec_title>
						<para> Tightness of throat</para>
					</section>
					<section type="none" id="sidelem4x7860">
						<sec_title>GI:</sec_title>
						<para> Hemorrhage, <emphasis style="italic">nausea, diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7867">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Angioneurotic edema,</emphasis> cyanosis, sweating, warmth</para>
					</section>
					<section type="none" id="sidelem4x7875">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7882">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7885">
					<section type="none" id="sidelem4x7886">
						<sec_title>PO/INJ:</sec_title>
						<para> Unused amounts excreted in urine (unchanged)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7892">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7895">
					<section type="none" id="sidelem4x7896">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7904">
							<label>•</label>
							<sec_title>Anaphylaxis (IV only)<route> swelling of face, eyes, lips, throat, wheezing</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7910">
							<label>•</label>
							<sec_title>Thiamine deficiency</sec_title>
							<para>
								<list id="lidelem4x7910">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Thiamine deficiency:</emphasis> anorexia, weakness/pain, depression, confusion, blurred vision, tachycardia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7914">
								<item>
									<label>•</label>
									<para>Nutritional status: yeast, beef, liver, whole or enriched grains, legumes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7919">
								<item>
									<label>•</label>
									<para>Application of cold to help decrease pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7924">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7928">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting, anorexia, insomnia, tachycardia, paresthesias, depression, muscle weakness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7934">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7938">
								<item>
									<label>•</label>
									<para>About the necessary foods to be included in diet: yeast, beef, liver, legumes, whole grains</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="43" status="active" ru="yes">
			<mono_name> thioridazine (Rx)</mono_name>
			<info>
				<pronunciation>(thye-or-rid′a-zeen)</pronunciation>
				<class type="func"> Antipsychotic (typical)</class>
				<class type="chem"> Phenothiazine piperidine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7959">
				<para>
					<confusion>
						<tradename id="tnidelem4x79590">thioridazine</tradename>
						<drug type="generic" refid="idelem4x79590">thiothixene/Thorazine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7963">
				<sec_title>Action:</sec_title>
				<para>Depresses cerebral cortex, hypothalamus, limbic system, which control activity, aggression; blocks neurotransmission produced by dopamine at synapse; exhibits strong α-adrenergic and anticholinergic blocking action; mechanism for antipsychotic effects is unclear</para>
			</section>
			<section type="uses" id="sidelem4x7968">
				<sec_title>Uses:</sec_title>
				<para>Psychotic disorders, schizophrenia, behavioral problems in children, anxiety, major depressive disorders, organic brain syndrome</para>
				<section type="none" id="sidelem4x7973">
					<section type="none" id="sidelem4x7974">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Behavioral symptoms associated with dementia in geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7979">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;2 yr, hypersensitivity, coma, CNS depression</para>
				<para>
					<bbw>QT prolongation, cardiac dysrhythmias</bbw>
				</para>
				<section type="none" id="sidelem4x7994">
					<section type="none" id="sidelem4x7995">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, seizure disorders, hypertension, hepatic/pulmonary disease, renal failure, BPH, glaucoma, phenothiazine hypersensitivity, suicidal ideation, smoking, Reye’s syndrome, Parkinson’s disease</para>
						<para>
							<bbw>Cardiac disease, dementia, AV block, bundle branch block, torsades de pointes</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8010">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8013">
					<section type="none" id="sidelem4x8014">
						<sec_title>Psychosis</sec_title>
						<section type="none" id="sidelem4x8022">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8022">
									<item>
										<label>•</label>
										<para> 25-100 mg tid, max 800 mg/day; dose gradually increased to desired response, then reduced to minimum maintenance</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8026">
						<sec_title>Depression/behavioral problems/organic brain syndrome</sec_title>
						<section type="none" id="sidelem4x8034">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8034">
									<item>
										<label>•</label>
										<para> 25 mg tid, range from 10 mg bid-qid to 50 mg tid-qid, max 800 mg/day for short period</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8041">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8041">
									<item>
										<label>•</label>
										<para> 10-25 mg daily-tid, increase 4-7 days by 10-25 mg to desired dose, max 800 mg/day for short period</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8048">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8048">
									<item>
										<label>•</label>
										<para> 0.5-3 mg/kg/day in divided doses, max 3 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8052">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 25, 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x8057">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8061">
								<item>
									<label>•</label>
									<para>Antiparkinsonian agent on order from prescriber for EPS</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use with CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>Antacids separated by 2 hr or more</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container; avoid contact with skin</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8082">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8085">
					<section type="none" id="sidelem4x8086">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">EPS: pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia,</emphasis><emphasis style="bold">seizures,</emphasis><emphasis style="italic">headache,</emphasis> confusion, <emphasis style="bold">neuroleptic malignant syndrome,</emphasis> dizziness, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x8101">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, <emphasis style="bold">cardiac arrest,</emphasis> ECG changes, <emphasis style="bold">tachycardia, QT prolongation, torsades de pointes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8111">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, glaucoma, dry eyes</para>
					</section>
					<section type="none" id="sidelem4x8116">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dry mouth, nausea, vomiting, anorexia, constipation,</emphasis> diarrhea, jaundice, weight gain</para>
					</section>
					<section type="none" id="sidelem4x8124">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, urinary frequency, enuresis, impotence, amenorrhea, gynecomastia, ejaculation dysfunction, priapism</para>
					</section>
					<section type="none" id="sidelem4x8129">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">leukopenia, leukocytosis, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8136">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> photosensitivity, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x8144">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Laryngospasm,</emphasis> dyspnea, <emphasis style="bold">respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8154">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8157">
					<section type="none" id="sidelem4x8158">
						<sec_title>PO:</sec_title>
						<para> Onset erratic; peak 2-4 hr; metabolized by liver; excreted in urine, breast milk; crosses placenta; half-life 26-36 hr; 91%-99% protein binding</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8163">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x8169">
						<item>
							<para>
								<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone), CYP2D6 inhibitors</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x8174">
						<item>
							<label>•</label>
							<para>Oversedation: other CNS depressants, alcohol, barbiturate anesthetics</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—anticholinergics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antiparkinson’s agent effects</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> thioridazine effect—lithium, barbiturates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—centrally acting antihypertensives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—aluminum hydroxide, magnesium hydroxide antacids</para>
				<section type="none" id="sidelem4x8199">
					<section type="none" id="sidelem4x8200">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, prolactin, bilirubin, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hct/Hgb, platelets, granulocytes, leukocytes, neutrocytes, eosinophils</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8211">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8214">
					<section type="none" id="sidelem4x8215">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8220">
								<item>
									<label>•</label>
									<para>Mental status before 1st dose, affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8225">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; palpate bladder if low urinary output occurs, urinary retention may be the cause</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8230">
								<item>
									<label>•</label>
									<para>Bilirubin, CBC, LFTs monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8235">
								<item>
									<label>•</label>
									<para>Urinalysis recommended before and during prolonged therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8240">
								<item>
									<label>•</label>
									<para>B/P standing, lying; include pulse and respirations q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8245">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8253">
							<label>•</label>
							<sec_title>
								<route>EPS</route>
							</sec_title>
							<para>
								<list id="lidelem4x8253">
									<item>
										<label>•</label>
										<para> including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8258">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignancy syndrome: altered mental status, muscle rigidity, increased CPK, hyperthermia, dyspnea, fatigue</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8264">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG, ejection fraction; assess for chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8269">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; increase bulk, water in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8274">
								<item>
									<label>•</label>
									<para>Supervised ambulation if needed until stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for long periods</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8279">
								<item>
									<label>•</label>
									<para>Sips of water, candy, gum for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8284">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8288">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8294">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8299">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension occurs frequently; to rise from sitting or lying position gradually; to avoid hazardous activities until stabilized on medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8304">
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths because hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8309">
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of thioridazine because EPS may result; that product should be withdrawn slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8314">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber; that serious product interactions may occur; to avoid use with alcohol because increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8321">
								<item>
									<label>•</label>
									<para>To use sunscreen to prevent burns</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8326">
								<item>
									<label>•</label>
									<para>About compliance with product regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8331">
								<item>
									<label>•</label>
									<para>About the necessity for meticulous oral hygiene because oral candidiasis may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8339">
							<label>•</label>
							<sec_title>
								<route>To report sore throat, malaise, fever, bleeding, mouth sores; if these occur, CBC should be drawn and product discontinued; that product may cause vision impairment, should be reported to prescriber</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8345">
							<label>•</label>
							<sec_title>
								<route>That in hot weather, heat stroke may occur; to take extra precautions to stay cool</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8348">
								<item>
									<label>•</label>
									<para>That product may cause discoloration of urine</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x8353">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if orally ingested, provide an airway; do not induce vomiting; CV monitoring, continuous ECG</para>
			</section>
		</monograph>
<monograph id="44" status="active" ru="yes">
			<mono_name> thyroid USP (desiccated) (Rx)</mono_name>
			<info>
				<pronunciation>(thye′roid)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x83653">Armour Thyroid</tradename>
					<tradename id="tnidelem4x83652">Bio-Throid</tradename>
					<tradename id="tnidelem4x83651">Nature Thyroid</tradename>
					<tradename id="tnidelem4x83650">NP Thyroid</tradename>
				</tradenames>
				<class type="func"> Thyroid hormone</class>
				<class type="chem"> Active thyroid hormone in natural state and ratio</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="actions" id="sidelem4x8375">
				<sec_title>Action:</sec_title>
				<para>Increases metabolic rates, increases cardiac output, O<emphasis style="inf">2</emphasis> consumption, body temperature, blood volume; growth, development at cellular level</para>
			</section>
			<section type="uses" id="sidelem4x8383">
				<sec_title>Uses:</sec_title>
				<para>Hypothyroidism, cretinism (juvenile hypothyroidism), myxedema</para>
			</section>
			<section type="contra" id="sidelem4x8388">
				<sec_title>Contraindications:</sec_title>
				<para>Adrenal insufficiency, MI, thyrotoxicosis, porcine protein hypersensitivity</para>
				<para>
					<bbw>Obesity treatment</bbw>
				</para>
				<section type="none" id="sidelem4x8403">
					<section type="none" id="sidelem4x8404">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>), breastfeeding, geriatric patients, angina pectoris, hypertension, ischemia, cardiac disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8409">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8412">
					<section type="none" id="sidelem4x8413">
						<sec_title>Hypothyroidism</sec_title>
						<section type="none" id="sidelem4x8421">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8421">
									<item>
										<label>•</label>
										<para> 30 mg/day, increased by 15 mg/mo until desired response; maintenance dose 60-120 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8428">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8428">
									<item>
										<label>•</label>
										<para> 7.5-15 mg/day, increase dose q6-8wk until desired response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8432">
						<sec_title>Cretinism/juvenile hypothyroidism</sec_title>
						<section type="none" id="sidelem4x8440">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8440">
									<item>
										<label>•</label>
										<para> 15 mg/day, then 30 mg/day after 2 wk, then 60 mg/day after another 2 wk; maintenance dose 60-180 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8444">
						<sec_title>Myxedema</sec_title>
						<section type="none" id="sidelem4x8452">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8452">
									<item>
										<label>•</label>
										<para> 15 mg/day, double dose q2wk, maintenance 60-180 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8456">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 16, 32, 60, 65, 98, 130, 195, 260, 325 mg; enteric-coated tabs 32, 65, 130 mg; sugarcoated tabs 32, 65, 130, 195 mg; caps 65, 130, 195, 325 mg</para>
					</section>
					<section type="none" id="sidelem4x8461">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8465">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> if possible as single dose to decrease sleeplessness; separate iron, calcium products by 4 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>At same time each day to maintain product level</para>
								</item>
								<item>
									<label>•</label>
									<para>Only for hormone imbalances; not to be used for obesity, male infertility, menstrual disorders, lethargy</para>
								</item>
								<item>
									<label>•</label>
									<para>Lowest dose that relieves symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Removal of medication 4 wk before RAIU test</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8494">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8497">
					<section type="none" id="sidelem4x8498">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, tremors,</emphasis> headache, <emphasis style="bold">thyroid storm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8508">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Tachycardia, palpitations, angina, dysrhythmias,</emphasis> hypertension, <emphasis style="bold">cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8518">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, increased or decreased appetite, cramps</para>
					</section>
					<section type="none" id="sidelem4x8523">
						<sec_title>MISC:</sec_title>
						<para> Menstrual irregularities, weight loss, sweating, heat intolerance, fever</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8528">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8531">
					<section type="none" id="sidelem4x8532">
						<sec_title>PO:</sec_title>
						<para> Peak 12-48 hr, half-life 6-7 days</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8538">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of anticoagulants, sympathomimetics, tricyclics, catecholamines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> thyroid absorption—bile acid sequestrants, aluminum, magnesium, calcium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> thyroid effects—estrogens</para>
				<section type="none" id="sidelem4x8553">
					<section type="none" id="sidelem4x8554">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> thyroid effect—soy</para>
					</section>
					<section type="none" id="sidelem4x8561">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK, LDH, AST, PBI, blood glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> thyroid function tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8572">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8575">
					<section type="none" id="sidelem4x8576">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Obesity treatment:</emphasis> use can lead to serious or life-threatening toxicity</bbw>
						</para>
						<para>
							<list id="lidelem4x8592">
								<item>
									<label>•</label>
									<para>B/P, pulse before each dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8597">
								<item>
									<label>•</label>
									<para>I&amp;O ratio</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8602">
								<item>
									<label>•</label>
									<para>Weight daily in same clothing, using same scale, at same time of day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8607">
								<item>
									<label>•</label>
									<para>Height, growth rate of child</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8612">
								<item>
									<label>•</label>
									<para>T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, which are decreased; radioimmunoassay of TSH, which is increased; radio uptake, which is decreased if dosage is too low</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8623">
								<item>
									<label>•</label>
									<para>PT may require decreased anticoagulant; check for bleeding, bruising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8631">
							<label>•</label>
							<sec_title>Hyperthyroidism</sec_title>
							<para>
								<list id="lidelem4x8631">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperthyroidism:</emphasis> increased nervousness, excitability, irritability; may indicate too high of a dose of medication, usually after 1-3 wk of treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8638">
							<label>•</label>
							<sec_title>Hypothyroidism</sec_title>
							<para>
								<list id="lidelem4x8638">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypothyroidism:</emphasis> lethargy, cold intolerance, weight gain, constipation, muscle cramps; may indicate too low of a dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8642">
								<item>
									<label>•</label>
									<para>Cardiac status: angina, palpitation, chest pain, change in VS</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8647">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8651">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of depression; increased weight loss, diuresis, pulse, appetite; absence of constipation, peripheral edema, cold intolerance; pale, cool, dry skin; brittle nails, alopecia, coarse hair, menorrhagia, night blindness, paresthesias, syncope, stupor, coma, rosy cheeks</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8657">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8661">
								<item>
									<label>•</label>
									<para>That hair loss will occur in child, is temporary</para>
								</item>
								<item>
									<label>•</label>
									<para>To report excitability, irritability, anxiety; indicates overdose</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to switch brands unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That strong odor is normal</para>
								</item>
								<item>
									<label>•</label>
									<para>That hypothyroid child will show almost immediate behavior/personality change</para>
								</item>
								<item>
									<label>•</label>
									<para>That treatment product is not to be taken to reduce weight</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC preparations with iodine; to read labels</para>
								</item>
								<item>
									<label>•</label>
									<para>To separate iron, calcium products by 4 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid iodine food, iodized salt, soybeans, tofu, turnips, some seafood, some bread</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="45" status="active">
			<mono_name>tiaGABine (Rx)</mono_name>
			<info>
				<pronunciation>(tie-ah-ga′been)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x87120">Gabitril</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8718">
				<para>
					<confusion>
						<tradename id="tnidelem4x87180">tiaGABine</tradename>
						<drug type="generic" refid="idelem4x87180">tiZANidine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8722">
				<sec_title>Action:</sec_title>
				<para>Inhibits reuptake and metabolism of GABA, may increase seizure threshold; structurally similar to GABA; tiaGABine binding sites in neocortex, hippocampus</para>
			</section>
			<section type="uses" id="sidelem4x8727">
				<sec_title>Uses:</sec_title>
				<para>Adjunct treatment of partial seizures in adults and children ≥12 yr</para>
			</section>
			<section type="contra" id="sidelem4x8732">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x8737">
					<section type="none" id="sidelem4x8738">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr, geriatric patients, renal/hepatic disease, suicidal thoughts/behaviors, status epilepticus, mania, bipolar disorder, abrupt discontinuation, depression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8744">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8754">
					<label>•</label>
					<sec_title>Adult (those receiving an enzyme-inducing antiepileptic product)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8754">
							<item>
								<label>•</label>
								<para> 4 mg/day in divided doses, may increase by 4-8 mg/wk until desired response, max 56 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8761">
					<label>•</label>
					<sec_title>Child 12-18 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8761">
							<item>
								<label>•</label>
								<para> 4 mg/day, may increase by 4 mg at beginning of wk 2; may increase by 4-8 mg/wk until desired response; max 32 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8765">
					<section type="none" id="sidelem4x8766">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x8774">
							<label>•</label>
							<sec_title>Adult<route> PO reduce dose or increase dosing interval</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8777">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2, 4, 12, 16 mg</para>
					</section>
					<section type="none" id="sidelem4x8782">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8786">
								<item>
									<label>•</label>
									<para>Store at room temperature, away from heat and light</para>
								</item>
								<item>
									<label>•</label>
									<para>Use with food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8797">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8800">
					<section type="none" id="sidelem4x8801">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, anxiety,</emphasis> somnolence, ataxia, confusion, <emphasis style="italic">asthenia,</emphasis> unsteady gait, depression, <emphasis style="bold">suicidal ideation, seizures,</emphasis> tremors, hostility, EEG changes</para>
					</section>
					<section type="none" id="sidelem4x8815">
						<sec_title>CV:</sec_title>
						<para> Vasodilation, tachycardia, hypertension</para>
					</section>
					<section type="none" id="sidelem4x8820">
						<sec_title>ENDO:</sec_title>
						<para> Goiter, hypothyroidism</para>
					</section>
					<section type="none" id="sidelem4x8825">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, increased appetite</para>
					</section>
					<section type="none" id="sidelem4x8830">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> alopecia, hyperhidrosis</para>
					</section>
					<section type="none" id="sidelem4x8838">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x8843">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, coughing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8848">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption &gt;95%; peak 45 min; protein binding 96%; metabolized in the liver via CYP3A4; half-life 7-9 hr without enzyme inducers, 2-5 hr with enzyme inducers</para>
			</section>
			<section type="interactions" id="sidelem4x8853">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x8857">
						<item>
							<label>•</label>
							<para>Lower doses may be needed when used with valproate</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants, alcohol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> tiaGABine effect—sevelamer</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—carBAMazepine, PHENobarbital, phenytoin, primidone</para>
				<section type="none" id="sidelem4x8875">
					<section type="none" id="sidelem4x8876">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> rate of absorption—high-fat meal</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8883">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8886">
					<section type="none" id="sidelem4x8887">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8892">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, urine creatinine q3mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8897">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8905">
							<label>•</label>
							<sec_title>Seizures<route> location, duration, presence of aura; assess for weakness</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8911">
							<label>•</label>
							<sec_title>
								<route>Withdraw gradually to prevent seizures</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8917">
							<label>•</label>
							<sec_title>
								<route>May cause status epilepticus and unexplained death</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8921">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber, hypomania may be present before suicide attempt</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8926">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during early part of treatment; dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8931">
								<item>
									<label>•</label>
									<para>Seizure precautions: padded side rails; move objects that may harm patient</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8936">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8940">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity; document on patient’s chart</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8946">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8951">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name and phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8956">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8961">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8966">
								<item>
									<label>•</label>
									<para>To take with food</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8974">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; avoid breastfeeding</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8980">
							<label>•</label>
							<sec_title>
								<route>To report suicidal thoughts, behaviors immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active" ha="yes">
			<mono_name> ticagrelor</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x89880">Brilinta</tradename>
				</tradenames>
				<class type="func"> Platelet inhibitor</class>
				<class type="chem"> ADP receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8998">
				<sec_title>Action:</sec_title>
				<para>Reversibly bind to the platelet receptor, preventing platelet activation</para>
			</section>
			<section type="uses" id="sidelem4x9004">
				<sec_title>Uses:</sec_title>
				<para>Arterial thromboembolism prophylaxis in acute coronary syndrome (ACS) (unstable angina, acute MI), including in patients undergoing percutaneous coronary intervention (PCI)</para>
			</section>
			<section type="contra" id="sidelem4x9009">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe hepatic disease</para>
				<para>
					<bbw>Bleeding, intracranial bleeding</bbw>
				</para>
				<section type="none" id="sidelem4x9024">
					<section type="none" id="sidelem4x9025">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, infants, neonates, children, GI bleeding, hepatic disease, abrupt discontinuation</para>
						<para>
							<bbw>Coronary artery bypass graft surgery (CABG), surgery</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9040">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9048">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9048">
							<item>
								<label>•</label>
								<para> loading dose 180 mg with aspirin (usually 325 mg PO); then give 90 mg bid with aspirin 75-100 mg/day, do not give maintenance doses of aspirin &gt;100 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9052">
					<section type="none" id="sidelem4x9053">
						<sec_title>Available forms:</sec_title>
						<para> Tab 90 mg</para>
					</section>
					<section type="none" id="sidelem4x9058">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9061">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x9065">
									<item>
										<label>•</label>
										<para>May be taken without regard to food</para>
									</item>
									<item>
										<label>•</label>
										<para>Discontinue 5-7 days before surgery</para>
									</item>
									<item>
										<label>•</label>
										<para>May be crushed (90 mg tab) and mixed with purified water, 100 mg (PO) or 50 ml (NG); ensure entire dose is given by flushing mortar, syringe, NG tube with 2 additional 50 ml of water</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature, in original container in dry place</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9086">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9089">
					<section type="none" id="sidelem4x9090">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x9095">
						<sec_title>CV:</sec_title>
						<para> Hypertension, hypotension, chest pain, atrial fibrillation, bradyarrhythmias, syncope, ventricular pauses</para>
					</section>
					<section type="none" id="sidelem4x9100">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x9105">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Serious, fatal bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9112">
						<sec_title>MISC:</sec_title>
						<para> Back pain, hyperuricemia, gynecomastia</para>
					</section>
					<section type="none" id="sidelem4x9117">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9122">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absolute bioavailability 36%, protein binding (&gt;99%), metabolism by CYP3A4, weak P-glycoprotein substrates and inhibitors, elimination for product and metabolite are hepatic and biliary, 84% excreted in feces, 26% in urine, half-life is 7 hr for ticagrelor, 9 hr for metabolite, maximum inhibition of platelet aggregation (IPA) effect 2 hr, maintained ≥8 hr, peak 1.5 hr product, 2.5 hr metabolite</para>
			</section>
			<section type="interactions" id="sidelem4x9127">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> bleeding risk—CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, lopinavir, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, delavirdine, isoniazid, dalfopristin, quinupristin, tipranavir)</bbw>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ticagrelor action—CYP3A4 inducers (rifampin, dexamethasone, phenytoin, carBAMazepine, PHENobarbital)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—simvastatin, lovastatin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, platelet inhibitors</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> digoxin</para>
				<section type="none" id="sidelem4x9158">
					<section type="none" id="sidelem4x9159">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum creatinine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9166">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9169">
					<section type="none" id="sidelem4x9170">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9178">
							<label>•</label>
							<sec_title>Thromboembolism<route> Monitor CBC with differential with platelet count baseline and periodically during treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x9204">
							<label>•</label>
							<sec_title>Abrupt discontinuation<route> do not discontinue abruptly, may increase risk for MI, stent thrombosis, death</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9207">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9211">
								<item>
									<label>•</label>
									<para>Prevention of thromboembolism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9217">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9222">
								<item>
									<label>•</label>
									<para>To take only as prescribed; not to skip or double doses; if a dose is missed, to take next dose at scheduled time
<bbw>To notify prescriber of chills, fever, bruising, bleeding; not to use aspirin ≥100 mg/day</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9236">
								<item>
									<label>•</label>
									<para>Not to use any prescription, OTC products, herbs without approval of prescriber; products with aspirin, NSAIDs may cause bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9241">
								<item>
									<label>•</label>
									<para>To notify all health care providers of product use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9246">
								<item>
									<label>•</label>
									<para>That product can be taken without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9251">
								<item>
									<label>•</label>
									<para>That it may take longer for bleeding to stop</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9259">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x9265">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="47" status="active">
			<mono_name>ticarcillin/clavulanate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x92710">Timentin</tradename>
				</tradenames>
				<class type="func"> Broad-spectrum antiinfective</class>
				<class type="chem"> Extended-spectrum penicillin, β-lactamase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x9281">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell-wall replication of susceptible organisms; osmotically unstable cell-wall swells, bursts from osmotic pressure; clavulanate inhibits β-lactamase and protects against enzymatic degradation of ticarcillin</para>
			</section>
			<section type="uses" id="sidelem4x9286">
				<sec_title>Uses:</sec_title>
				<para>Respiratory, soft-tissue, and urinary tract infections; bacterial septicemia; effective for gram-positive cocci <emphasis style="italic">(Staphylococcus aureus, Streptococcus faecalis, Streptococcus pneumoniae),</emphasis> gram-negative cocci <emphasis style="italic">(Neisseria gonorrhoeae),</emphasis> gram-positive bacilli <emphasis style="italic">(Clostridium perfringens, Clostridium tetani),</emphasis> gram-negative bacilli <emphasis style="italic">(Bacteroides, Fusobacterium nucleatum, Escherichia coli, Proteus mirabilis, Salmonella, Morganella morganii, Proteus rettgeri, Enterobacter, Pseudomonas aeruginosa, Serratia);</emphasis> and <emphasis style="italic">Peptococcus, Peptostreptococcus,</emphasis> and <emphasis style="italic">Eubacterium</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x9308">
				<sec_title>Contraindications:</sec_title>
				<para>Neonates, hypersensitivity to penicillins</para>
				<section type="none" id="sidelem4x9313">
					<section type="none" id="sidelem4x9314">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), hypersensitivity to cephalosporins, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9319">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9322">
					<section type="none" id="sidelem4x9323">
						<sec_title>Systemic/urinary tract infections, moderate/severe infections</sec_title>
						<section type="none" id="sidelem4x9331">
							<label>•</label>
							<sec_title>Adult ≥60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x9331">
									<item>
										<label>•</label>
										<para> 3.1 g q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9338">
							<label>•</label>
							<sec_title>Adult &lt;60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x9338">
									<item>
										<label>•</label>
										<para> 200-300 mg/kg/day q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9345">
							<label>•</label>
							<sec_title>Child &gt;60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x9345">
									<item>
										<label>•</label>
										<para> 3.1 g q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9352">
							<label>•</label>
							<sec_title>Child &lt;60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x9352">
									<item>
										<label>•</label>
										<para> 200-300 mg/kg/day q4hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9359">
							<label>•</label>
							<sec_title>Full-term neonates/infants &lt;3 mo (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9359">
									<item>
										<label>•</label>
										<para> 50 mg/kg q4hr for severe infections;  50 mg/kg q6hr for mild to moderate infections</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9366">
						<sec_title>Mild to moderate infections</sec_title>
						<section type="none" id="sidelem4x9374">
							<label>•</label>
							<sec_title>Child ≥60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x9374">
									<item>
										<label>•</label>
										<para> 3.1 g q6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9381">
							<label>•</label>
							<sec_title>Child &lt;60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x9381">
									<item>
										<label>•</label>
										<para> 200 mg/kg/day q6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9385">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9393">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION loading dose 3.1 g; CCr 60 ml/min, 3.1 g q4hr; CCr 30-60 ml/min, 2 g q4hr; CCr 10-30 ml/min, 2 g q8hr; CCr &lt;10 ml/min, 2 g q12hr; CCr &lt;10 ml/min with hepatic dysfunction, 2 g q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9396">
						<sec_title>Available forms:</sec_title>
						<para> Inj 3 g ticarcillin, 0.1 g clavulanate; IV infusion 3 g ticarcillin, 0.1 g clavulanate; powder for inj 3 g ticarcillin, 0.1 g clavulanate</para>
					</section>
					<section type="none" id="sidelem4x9401">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9405">
								<item>
									<label>•</label>
									<para>Product after C&amp;S, give ≥q1hr before bactericidal antiinfectives, change IV site q48hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9412">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9416">
									<item>
										<label>•</label>
										<para>After diluting ≤3.1 g/13 ml of sterile water or NaCl (200 mg/ml), shake; may further dilute in ≥50-100 ml NS, D<emphasis style="inf">5</emphasis>W, or LR sol and run over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Store reconstituted sol 12-24 hr at room temperature, or 3-7 days refrigerated</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Allopurinol, amifostine, amikacin, anidulafungin, atropine, aztreonam, bivalirudin, bumetanide, ceFAZolin, cefepime, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, clindamycin, cyclophosphamide, cycloSPORINE, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, DOPamine, DOXOrubicin liposome, doxycycline, enalaprilat, EPINEPHrine, esmolol, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, imipenem/cilastatin, insulin, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, melphalan, meperidine, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, milrinone, morphine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, palonosetron, pantoprazole, PEMEtrexed, penicillin G potassium, perphenazine, phenylephrine, procainamide, propofol, propranolol, ranitidine, remifentanil, sargramostim, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, tirofiban, tobramycin, vasopressin, verapamil, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9440">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9443">
					<section type="none" id="sidelem4x9444">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, <emphasis style="bold">seizures,</emphasis> confusion, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x9452">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea;</emphasis> increased AST, ALT; abdominal pain, glossitis, colitis, <emphasis style="bold">pseudomembranous colitis, hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9462">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, increased bleeding time, <emphasis style="bold">bone marrow depression, granulocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9469">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, <emphasis style="bold">toxic epidermal necrolysis,</emphasis> pain at injection site</para>
					</section>
					<section type="none" id="sidelem4x9477">
						<sec_title>META:</sec_title>
						<para> Hypokalemia, hypernatremia</para>
					</section>
					<section type="none" id="sidelem4x9482">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome,</emphasis> overgrowth of organisms</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9490">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9493">
					<section type="none" id="sidelem4x9494">
						<sec_title>IV:</sec_title>
						<para> Peak 30-45 min, duration 4 hr, half-life 64-68 min, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9499">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: bleeding—anticoagulants</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> methotrexate level—methotrexate, uric acid, bilirubicin, BUN, creatining, alk, phos, LDH</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ticarcillin concentrations—probenecid, sulfipyrazone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antimicrobial effect of ticarcillin—tetracyclines, aminoglycosides IV, chloramphenicol, macrolides, sulfonamides</para>
				<para>
					<emphasis style="bold">Decrease: effect—oral contraceptives,</emphasis> erythromycin</para>
				<section type="none" id="sidelem4x9523">
					<section type="none" id="sidelem4x9524">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine glucose, urine protein, Coombs’ test</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, sodium, eosinophils, INR bleeding time</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, potassium, platelets, WBC, granulocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9539">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9542">
					<section type="none" id="sidelem4x9543">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9548">
								<item>
									<label>•</label>
									<para>Infection: WBC, wound, temperature, sputum, urine, baseline and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9554">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC count, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE is given</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9560">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis; anaphylaxis: wheezing, rash, laryngeal edema; have emergency equipment nearby</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9565">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9570">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, RBC, Hct, Hgb, bleeding time, platelets, baseline and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9575">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, creatinine, sodium, potassium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9581">
								<item>
									<label>•</label>
									<para>Skin eruptions after administration of penicillin to 1 wk after discontinuing product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9586">
								<item>
									<label>•</label>
									<para>EPINEPHrine, suction, tracheostomy set, endotracheal intubation equipment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9591">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9595">
								<item>
									<label>•</label>
									<para>Therapeutic response: resolution of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9601">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x9609">
							<label>•</label>
							<sec_title>
								<route>To report persistent diarrhea with blood, pus, mucus, or fever</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9612">
								<item>
									<label>•</label>
									<para>That culture may be taken after completed course of medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9617">
								<item>
									<label>•</label>
									<para>To report sore throat, fever, fatigue (may indicate superinfection); CNS effects (anxiety, depression, hallucinations, seizures)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9622">
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9630">
							<label>•</label>
							<sec_title>
								<route>To use alternative birth control method instead of hormonal</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x9633">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Withdraw product, maintain airway, administer EPINEPHrine, O<emphasis style="inf">2</emphasis>, IV corticosteroids for anaphylaxis</para>
			</section>
		</monograph>
<monograph id="48" status="active">
			<mono_name>ticlopidine (Rx)</mono_name>
			<info>
				<pronunciation>(tye-cloe′pi-deen)</pronunciation>
				<class type="func"> Platelet aggregation inhibitor</class>
				<class type="chem"> Thienopyridine compound</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x9654">
				<sec_title>Action:</sec_title>
				<para>Irreversible inhibition of platelet aggregation through antagonism of ADP</para>
			</section>
			<section type="uses" id="sidelem4x9659">
				<sec_title>Uses:</sec_title>
				<para>Reducing the risk for stroke in high-risk patients</para>
				<section type="none" id="sidelem4x9664">
					<section type="none" id="sidelem4x9665">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Intermittent claudication, chronic arterial occlusion, subarachnoid hemorrhage, uremic patients with AV shunts/fistulas, open heart surgery, coronary artery bypass grafts, primary glomerulonephritis, sickle cell disease, diabetic retinopathy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9670">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe hepatic disease, active bleeding, coagulopathy</para>
				<para>
					<bbw>Agranulocytosis, neutropenia, thrombocytopenia, thrombotic thrombocytopenic purpura (TTP)</bbw>
				</para>
				<section type="none" id="sidelem4x9685">
					<section type="none" id="sidelem4x9686">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, past hepatic disease, renal disease, increased bleeding risk, peptic ulcer disease, surgery</para>
						<para>
							<bbw>Anemia, hematologic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9701">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9709">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9709">
							<item>
								<label>•</label>
								<para> 250 mg bid with food</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9713">
					<section type="none" id="sidelem4x9714">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250 mg</para>
					</section>
					<section type="none" id="sidelem4x9719">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9723">
								<item>
									<label>•</label>
									<para>With food to decrease gastric symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Discontinue when absolute neutrophil count falls during treatment to &lt;1200/mm<emphasis style="sup">3</emphasis> or platelets &lt;80,000/mm<emphasis style="sup">3</emphasis>; may use methylPREDNISolone IV 20 mg to provide normal bleeding time in 2 hr</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9740">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9743">
					<section type="none" id="sidelem4x9744">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, weakness</para>
					</section>
					<section type="none" id="sidelem4x9749">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, epistaxis</para>
					</section>
					<section type="none" id="sidelem4x9754">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, <emphasis style="italic">diarrhea,</emphasis> GI discomfort, <emphasis style="bold">cholestatic jaundice, hepatitis,</emphasis> increased cholesterol, LDL, VLDL, triglycerides</para>
					</section>
					<section type="none" id="sidelem4x9765">
						<sec_title>GU:</sec_title>
						<para> Hematuria</para>
					</section>
					<section type="none" id="sidelem4x9770">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding (epistaxis, hematuria, conjunctival hemorrhage, GI bleeding), agranulocytosis, neutropenia, thrombocytopenia, thrombotic thombocytopenic purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9777">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus</para>
					</section>
					<section type="none" id="sidelem4x9785">
						<sec_title>META:</sec_title>
						<para> Hypercholesterolemia, hypertriglyceridemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9790">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-3 hr; metabolized by liver; excreted in urine, feces; half-life increases with repeated dosing, initially 12-36 hr; antiplatelet effect 2-5 days; 98% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x9796">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of CYP2C19, CYP2DC substrates, phenytoin, fosphenytoin, ambrisentan, theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding tendencies—anticoagulants, salicylates, thrombolytics, NSAIDs, abciximab, eptifibatide, tirofiban, thrombin inhibitors, SSRIs, aspirin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of ticlopidine—cimetidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> plasma levels of ticlopidine—antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> plasma levels of digoxin, cycloSPORINE</para>
				<section type="none" id="sidelem4x9819">
					<section type="none" id="sidelem4x9820">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—ginger, ginkgo, garlic, feverfew, horse chestnut, green tea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9827">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9830">
					<section type="none" id="sidelem4x9831">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9835">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, creatinine with long-term therapy
<bbw>Blood dyscrasias, bone marrow depression, do not use in those with a history of these conditions; blood studies: CBC; CBC q2wk × 3 mo, Hct, Hgb, PT with long-term therapy</bbw>

<bbw>Bleeding time at baseline and throughout treatment; levels may be 2-5× normal limit</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9859">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9863">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of stroke</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9869">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9874">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment
<bbw>To report any unusual bleeding to prescriber</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9891">
							<label>•</label>
							<sec_title>
								<route>To report side effects such as diarrhea, skin rashes, subcut bleeding, signs of cholestasis (jaundiced skin and sclera, dark urine, light-colored stools)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x9897">
							<label>•</label>
							<sec_title>
								<route>That product should be discontinued 10-14 days before surgery; not to double a missed dose</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9900">
								<item>
									<label>•</label>
									<para>That there are many product and herbal interactions, to avoid all OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9905">
								<item>
									<label>•</label>
									<para>To take with food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="49" status="active">
			<mono_name>tigecycline (Rx)</mono_name>
			<info>
				<pronunciation>(tye-ge-sye′kleen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x99150">Tygacil</tradename>
				</tradenames>
				<class type="func"> Broad-spectrum antiinfective</class>
				<class type="chem"> Glycylcyclines</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x9925">
				<sec_title>Action:</sec_title>
				<para>Inhibits protein synthesis and phosphorylation in microorganisms; bacteriostatic structurally similar to the tetracyclines</para>
			</section>
			<section type="uses" id="sidelem4x9930">
				<sec_title>Uses:</sec_title>
				<para>Complicated skin/skin-structure infections <emphasis style="italic">(Escherichia coli, Enterococcus faecalis</emphasis> [vancomycin-susceptible only], <emphasis style="italic">Staphylococcus aureus, Streptococcus agalactiae, S. anginosus</emphasis> group, <emphasis style="italic">S. pyogenes, Bacteroides fragilis;</emphasis> complicated intraabdominal infections <emphasis style="italic">[Citrobacter freundii] Enterobacter cloacae, E. coli, Klebsiella oxytoca, K. pneumoniae, E. faecalis</emphasis> [vancomycin-susceptible only], <emphasis style="italic">S. aureus</emphasis> [methicillin-susceptible only], <emphasis style="italic">S. anginosus</emphasis> group, <emphasis style="italic">B. fragilis, Bacteroides thetaiotaomicron, B. uniformis, B. vulgatus, Clostridium perfringens, Peptostreptococcus micros);</emphasis> community-acquired pneumonia</para>
			</section>
			<section type="contra" id="sidelem4x9956">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, children &lt;18 yr, hypersensitivity to tigecycline</para>
				<section type="none" id="sidelem4x9961">
					<section type="none" id="sidelem4x9962">
						<sec_title>Precautions:</sec_title>
						<para> Renal/hepatic disease, hypersensitivity to tetracyclines, ventilator-associated/hospital-acquired pneumonias</para>
						<para>
							<bbw>Infection</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9976">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9984">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x9984">
							<item>
								<label>•</label>
								<para> 100 mg then 50 mg q12hr,  given over 30-60 min q12hr; given for 5-14 days, depending on infection</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9993">
					<section type="none" id="sidelem4x9994">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x10002">
							<label>•</label>
							<sec_title>Adult<route> IV (Child-Pugh C) 100 mg, then 25 mg q12hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10005">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj, lyophilized 50 mg</para>
					</section>
					<section type="none" id="sidelem4x10010">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10014">
								<item>
									<label>•</label>
									<para>Tigecycline allergy test before using, obtain C&amp;S, do not begin treatment before results or if susceptible organism is strongly suspected</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10020">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x10024">
									<item>
										<label>•</label>
										<para>Reconstitute each vial with 5.3 ml of 0.9% NaCl or D<emphasis style="inf">5</emphasis> (10 mg/ml); swirl to dissolve; immediately withdraw 5 ml of reconstituted sol and add to 100-ml IV bag for infusion (1 mg/ml); may be yellow or orange; if not, sol should be discarded; do not give if particulate matter is present, use a dedicated IV line or <emphasis style="sans-serif">Y</emphasis>-site, flush with NS before and after use, give over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container at room temperature, diluted sol at room temperature for up to 24 hr, 6 hr in vial, and remaining time in IV bag, ≤48 hr refrigerated</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B liposome, ampicillin, ampicillin/sulbactam, argatroban, azithromycin, aztreonam, bivalirudin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin hydrochloride, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, DOXOrubicin hydrochloride, DOXOrubicin liposome, droperidol, enalaprilat, EPINEPHrine, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem/cilastatin, insulin, irinotecan, isoproterenol, ketorolac, labetalol, lansoprazole, lepirudin, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methyldopa, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoMYcin, mitoXANtrone, morphine, moxifloxacin, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, pemtamidine, pentazocin, PENTobarbital, PHENobarbital, phenylephrine, piperacillin/tazobactam, potassium acetate/chloride/phosphate, procainamide, prochlorperazine, promethazine, propofol, propranolol, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphate, streptozocin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin/clavulanate, tirofiban, tobramycin, topotecan, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, vinBLAStine, vinCRIStine, vinorelbine, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10051">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10054">
					<section type="none" id="sidelem4x10055">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, insomnia</para>
					</section>
					<section type="none" id="sidelem4x10060">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, phlebitis</para>
					</section>
					<section type="none" id="sidelem4x10065">
						<sec_title>EENT:</sec_title>
						<para> Tooth discoloration</para>
					</section>
					<section type="none" id="sidelem4x10070">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> anorexia, constipation, dyspepsia, abdominal pain, <emphasis style="bold">hepatotoxicity, hepatic failure, pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10080">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukocytosis, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10087">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus, sweating, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x10095">
						<sec_title>META:</sec_title>
						<para> Increased ALT, AST, BUN, lactic acid, alk phos, amylase; hyperglycemia, hypokalemia, hypoproteinemia, bilirubinemia</para>
					</section>
					<section type="none" id="sidelem4x10100">
						<sec_title>MISC:</sec_title>
						<para> Back pain, fever, abnormal healing, abdominal pain, abscess, asthenia, infection, pain, peripheral edema, local reactions</para>
					</section>
					<section type="none" id="sidelem4x10105">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x10110">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10117">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Not extensively metabolized, 22% of unchanged product excreted in urine, terminal half-life 42 hr, primarily biliary excreted, protein binding 71%-89%</para>
			</section>
			<section type="interactions" id="sidelem4x10122">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of oral contraceptives</para>
				<section type="none" id="sidelem4x10133">
					<section type="none" id="sidelem4x10134">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase, LFTs, alk phos, BUN, creatinine, LDH, WBC, INR, PTT, PT</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, calcium, sodium, Hgb/Hct, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10145">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10148">
					<section type="none" id="sidelem4x10149">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Use only with confirmation of strongly suspected bacterial infection, do not use as a prophylactic</bbw>
						</para>
						<para>
							<list id="lidelem4x10165">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC level, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE is given</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10170">
								<item>
									<label>•</label>
									<para>Signs of anemia: Hct, Hgb, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10175">
								<item>
									<label>•</label>
									<para>Blood studies: PT, CBC, AST, ALT, BUN creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10181">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions: rash, itching, pruritus, angioedema</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10189">
							<label>•</label>
							<sec_title>Serious allergic skin reactions<route> Stevens-Johnson anaphylaxis</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10192">
								<item>
									<label>•</label>
									<para>Nausea, vomiting, diarrhea; administer antiemetic, antacids as ordered</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10200">
							<label>•</label>
							<sec_title>Toxicity<route> pseudotumor cerebri, photosensitivity, antianabolic actions (azotemia, BUN, hypophosphatemia, metabolic acidosis) tigecycline is structurally similar to tetracycline; pancreatitis, hyperamylasemia; (may be fatal) if these occur, discontinue, improvement usually occurs after product is discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x10206">
							<label>•</label>
							<sec_title>Overgrowth of infection</sec_title>
							<para>
								<list id="lidelem4x10206">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Overgrowth of infection:</emphasis> fever, malaise, redness, pain, swelling, drainage, perineal itching, diarrhea, changes in cough or sputum</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10210">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10214">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased temperature, absence of lesions, negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10220">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10225">
								<item>
									<label>•</label>
									<para>To avoid sun exposure; sunscreen does not seem to decrease photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10231">
								<item>
									<para>
										<emphasis alert="nurse">To avoid pregnancy while taking this product; fetal harm may occur; to avoid breastfeeding</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10236">
								<item>
									<label>•</label>
									<para>To report infection, increase in temperature; to report burning, pain at inj site</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10244">
							<label>•</label>
							<sec_title>
								<route>To report diarrhea, fatigue, abdominal pain</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="50" status="active">
			<mono_name>timolol (Rx)</mono_name>
			<info>
				<pronunciation>(tye′moe-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x102521">
						<country code="CAN">Apo-Timol </country>
					</tradename>
					<tradename id="tnidelem4x102520">
						<country code="CAN">Novo-Timol </country>
					</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Nonselective β-blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x10267">
				<sec_title>Action:</sec_title>
				<para>Competitively blocks stimulation of β-adrenergic receptor within vascular smooth muscle (decreases rate of SA node discharge, increases recovery time); slows conduction of AV node and decreases heart rate, which decreases O<emphasis style="inf">2</emphasis> consumption in myocardium; also decreases renin-aldosterone-angiotensin system; at high doses, inhibits β<emphasis style="inf">2</emphasis>-receptors in bronchial system</para>
			</section>
			<section type="uses" id="sidelem4x10278">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate hypertension, migraine prophylaxis, to decrease mortality after MI</para>
				<section type="none" id="sidelem4x10283">
					<section type="none" id="sidelem4x10284">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Tremors, angina pectoris</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10290">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to β-blockers, cardiogenic shock, heart block (2nd/3rd degree), sinus bradycardia, CHF, cardiac failure, severe COPD, asthma</para>
				<section type="none" id="sidelem4x10295">
					<section type="none" id="sidelem4x10296">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, major surgery, diabetes mellitus, COPD, well-compensated heart failure, nonallergic bronchospasm, peripheral vascular disease, thyroid/renal/hepatic disease</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10311">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10314">
					<section type="none" id="sidelem4x10315">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x10323">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10323">
									<item>
										<label>•</label>
										<para> 10 mg bid or 20 mg/day, may increase by 10 mg q7days, max 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10330">
							<label>•</label>
							<sec_title>Geriatric patients<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10330">
									<item>
										<label>•</label>
										<para> initiate dose cautiously</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10334">
						<sec_title>Myocardial infarction</sec_title>
						<section type="none" id="sidelem4x10342">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10342">
									<item>
										<label>•</label>
										<para> 10 mg bid beginning 1-4 wk after MI for ≥2 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10346">
						<sec_title>Migraine headache prevention</sec_title>
						<section type="none" id="sidelem4x10354">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10354">
									<item>
										<label>•</label>
										<para> 10 mg bid or 20 mg/day; may increase to 30 mg/day, 20 mg in <emphasis style="smallcaps">am</emphasis>, 10 mg in <emphasis style="smallcaps">pm</emphasis>; discontinue if not effective after 8 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10364">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20 mg</para>
					</section>
					<section type="none" id="sidelem4x10369">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10373">
								<item>
									<label>•</label>
									<para>PO before or immediately after meals, at bedtime; tab may be crushed or swallowed whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Reduced dosage in renal dysfunction</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10389">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10392">
					<section type="none" id="sidelem4x10393">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, dizziness,</emphasis> hallucinations, anxiety, fatigue, depression, headache</para>
					</section>
					<section type="none" id="sidelem4x10401">
						<sec_title>CV:</sec_title>
						<para> Hypotension, bradycardia, <emphasis style="bold">CHF,</emphasis> edema, chest pain, claudication, angina, AV block, ventricular dysrhythmias</para>
					</section>
					<section type="none" id="sidelem4x10409">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Visual changes;</emphasis> sore throat; <emphasis style="italic">double vision;</emphasis> dry, burning eyes</para>
					</section>
					<section type="none" id="sidelem4x10420">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, <emphasis style="bold">ischemic colitis,</emphasis> diarrhea, <emphasis style="italic">abdominal pain,</emphasis><emphasis style="bold">mesenteric arterial thrombosis,</emphasis> flatulence, constipation</para>
					</section>
					<section type="none" id="sidelem4x10436">
						<sec_title>GU:</sec_title>
						<para> Impotence, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x10441">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10448">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia, pruritus, fever</para>
					</section>
					<section type="none" id="sidelem4x10453">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x10458">
						<sec_title>MUSC:</sec_title>
						<para> <emphasis style="italic">Joint pain, muscle pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10465">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis><emphasis style="italic">dyspnea,</emphasis> cough, crackles, nasal stuffiness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10475">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr; half-life 4 hr; metabolized by liver; excreted in urine, breast milk; protein binding &lt;10%</para>
			</section>
			<section type="interactions" id="sidelem4x10480">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension, bradycardia—hydrALAZINE, methyldopa, prazosin, anticholinergics, alcohol, reserpine, nitrates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of β-blockers, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effects—NSAIDs, sympathomimetics, thyroid, salicylates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypoglycemic effects—insulin, sulfonylureas</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> bronchodilation—theophyllines</para>
				<section type="none" id="sidelem4x10503">
					<section type="none" id="sidelem4x10504">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> renal, hepatic studies, uric acid</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> glucose, insulin tolerance test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10515">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10518">
					<section type="none" id="sidelem4x10519">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Abrupt discontinuation:</emphasis> may result in myocardial ischemia, MI, severe hypotension, ventricular dysrhythmias in those with preexisting cardiovascular disease</bbw>
						</para>
						<section type="none" id="sidelem4x10538">
							<label>•</label>
							<sec_title>Headaches</sec_title>
							<para>
								<list id="lidelem4x10538">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Headaches:</emphasis> location, severity, duration, frequency at baseline and throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10542">
								<item>
									<label>•</label>
									<para>I&amp;O, weight daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10547">
								<item>
									<label>•</label>
									<para>B/P during initial treatment, periodically thereafter, pulse q4hr; note rate, rhythm, quality</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10552">
								<item>
									<label>•</label>
									<para>Apical/radial pulse before administration; notify prescriber of any significant changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10558">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10563">
								<item>
									<label>•</label>
									<para>Edema in feet, legs daily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10568">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10572">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P after 1-2 wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10578">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10583">
								<item>
									<label>•</label>
									<para>To take before or immediately after meals
<bbw>Not to discontinue product abruptly; to taper over 2 wk; may cause precipitate angina</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10597">
								<item>
									<label>•</label>
									<para>Not to use OTC products containing α-adrenergic stimulants (nasal decongestants, cold preparations) unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10602">
								<item>
									<label>•</label>
									<para>To report bradycardia, dizziness, confusion, depression, fever, sore throat, SOB to prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10607">
								<item>
									<label>•</label>
									<para>Product masks hypoglycemia; monitor blood sugar</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10612">
								<item>
									<label>•</label>
									<para>To take pulse at home; advise when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10617">
								<item>
									<label>•</label>
									<para>To avoid alcohol, smoking, sodium intake</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10622">
								<item>
									<label>•</label>
									<para>To comply with weight control, dietary adjustments, modified exercise program</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10627">
								<item>
									<label>•</label>
									<para>To carry emergency ID to identify product, allergies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10632">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness is present</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10640">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x10640">
									<item>
										<label>•</label>
										<para>To report symptoms of <emphasis style="bold">CHF:</emphasis> difficulty breathing, especially on exertion or when lying down; night cough; swelling of extremities</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10645">
								<item>
									<label>•</label>
									<para>To take medication at bedtime; to wear support hose to minimize effect of orthostatic hypotension</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10650">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, IV atropine for bradycardia, IV theophylline for bronchospasm, digoxin, O<emphasis style="inf">2</emphasis>, diuretic for cardiac failure, hemodialysis; administer vasopressor (norepinephrine)</para>
			</section>
		</monograph>
<monograph id="51" status="active">
			<mono_name>timolol (ophthalmic)</mono_name>
			<info>
				<pronunciation>(tie-moe′lol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x106633">Betimol</tradename>
					<tradename id="tnidelem4x106632">Istalol</tradename>
					<tradename id="tnidelem4x106631">Timoptic</tradename>
					<tradename id="tnidelem4x106630">Timoptic-XE</tradename>
				</tradenames>
				<class type="func"> Antiglaucoma</class>
				<class type="chem"> β-Blocker</class>
			</info>
			<section type="actions" id="sidelem4x10673">
				<sec_title>Action:</sec_title>
				<para>Can decrease aqueous humor and increase outflows</para>
			</section>
			<section type="uses" id="sidelem4x10678">
				<sec_title>Uses:</sec_title>
				<para>Treatment of chronic open-angle glaucoma and ocular hypertension</para>
			</section>
			<section type="contra" id="sidelem4x10683">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, AV block, heart failure, bradycardia, sick sinus syndrome, asthma</para>
				<section type="none" id="sidelem4x10688">
					<section type="none" id="sidelem4x10689">
						<sec_title>Precautions:</sec_title>
						<para> Abrupt discontinuation, pregnancy, breastfeeding, children, COPD, depression, diabetes mellitus, myasthenia gravis, hyperthyroidism, pulmonary disease, angle-closure glaucoma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10694">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10702">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x10702">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> instill 1 drop in each affected eye bid (0.25% solution) initially; if no response, 1 drop in each affected eye bid (0.5% solution) or 1 drop of gel in each affected eye daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10706">
					<section type="none" id="sidelem4x10707">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.25, 0.5%; ophthalmic gel 0.25%, 0.5%</para>
					</section>
					<section type="none" id="sidelem4x10712">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10716">
								<item>
									<label>•</label>
									<para>For ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>Wash hands before and after use</para>
								</item>
								<item>
									<label>•</label>
									<para>Tilt head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch; close eyes to spread drops; to avoid excessive systemic absorption, apply finger pressure on the lacrimal sac for 1-2 min after use</para>
								</item>
								<item>
									<label>•</label>
									<para>If &gt;1 topical ophthalmic drug product is being used, the drugs should be administered at least 5 min apart</para>
								</item>
								<item>
									<label>•</label>
									<para>Administer other topically applied ophthalmic medications at least 10 min before timolol gel-forming solution</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid contamination or the spread of infection, do not use dropper for more than one person</para>
								</item>
								<item>
									<label>•</label>
									<para>Some products contain the preservative benzalkonium chloride, which can be absorbed by soft contact lenses; remove contact lenses before administration of the solution; lenses may be reinserted 15 min after administration</para>
								</item>
								<item>
									<label>•</label>
									<para>Decreased intraocular pressure can take several weeks, monitor IOP after a month</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10763">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10766">
					<section type="none" id="sidelem4x10767">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia,</emphasis> headache, <emphasis style="italic">dizziness,</emphasis> anxiety, depression, headache, nightmares, <emphasis style="italic">fatigue</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10780">
						<sec_title>CV:</sec_title>
						<para> Palpitations, heart failure, hypotension</para>
					</section>
					<section type="none" id="sidelem4x10785">
						<sec_title>EENT:</sec_title>
						<para> Eye stinging/burning, tearing, photophobia, visual disturbances</para>
					</section>
					<section type="none" id="sidelem4x10790">
						<sec_title>GI:</sec_title>
						<para> Nausea, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x10795">
						<sec_title>PULM:</sec_title>
						<para> Bronchospasm</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10800">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 30 min, peak 1-2 hr, duration 12-24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x10805">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> β-blocking effect—oral β-blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> intraocular pressure reduction—topical miotics, dipivefrin, EPINEPHrine, carbonic anhydrase inhibitors; this may be beneficial</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P, severe—when abruptly stopping cloNIDine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> depression of AV nodal conduction, bradycardia, or hypotension—adenosine, cardiac glycosides, disopyramide, other antiarrhythmics, class 1C antiarrhythmic drugs (flecainide, propafenone, moricizine, encainide quiNIDine, calcium-channel blockers, or drugs that significantly depress AV nodal conduction)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> AV block nodal conduction, induce AV block—high doses of procainamide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—other antihypertensives</para>
			</section>
			<section type="considerations" id="sidelem4x10832">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10835">
					<section type="none" id="sidelem4x10836">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10842">
								<item>
									<para>
										<emphasis alert="nurse">Systemic absorption: When used in the eye, systemic absorption is common with the same adverse reactions and interactions</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10847">
								<item>
									<label>•</label>
									<para>Glaucoma: monitor intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10852">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10856">
								<item>
									<label>•</label>
									<para>Decreasing intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10862">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10866">
								<item>
									<label>•</label>
									<para>That product is for ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>To wash hands before and after use</para>
								</item>
								<item>
									<label>•</label>
									<para>To tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch; close eyes to spread drops</para>
								</item>
								<item>
									<label>•</label>
									<para>To apply finger pressure on the lacrimal sac for 1-2 min following use to prevent excessive systemic absorption</para>
								</item>
								<item>
									<label>•</label>
									<para>To administer drugs at least 5 min apart if more than one topical ophthalmic drug product is being used</para>
								</item>
								<item>
									<label>•</label>
									<para>To administer other topically applied ophthalmic medications at least 10 min before timolol gel-forming solution</para>
								</item>
								<item>
									<label>•</label>
									<para>To not use dropper for more than one person to avoid contamination or the spread of infection</para>
								</item>
								<item>
									<label>•</label>
									<para>That some products contain the preservative benzalkonium chloride, which may be absorbed by soft contact lenses; to remove contact lenses before administration of the solution; that lenses may be reinserted 15 min after administration</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="52" status="active" ha="yes">
			<mono_name> tinidazole (Rx)</mono_name>
			<info>
				<pronunciation>(tye-ni′da-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x109200">Tindamax</tradename>
				</tradenames>
				<class type="func"> Antiprotozoal</class>
				<class type="chem"> Nitroimidazole derivative</class>
			</info>
			<section type="actions" id="sidelem4x10930">
				<sec_title>Action:</sec_title>
				<para>Interferes with DNA/RNA synthesis in protozoa</para>
			</section>
			<section type="uses" id="sidelem4x10935">
				<sec_title>Uses:</sec_title>
				<para>Amebiasis, giardiasis, trichomoniasis</para>
				<section type="none" id="sidelem4x10940">
					<section type="none" id="sidelem4x10941">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Bacteroides</emphasis> sp., <emphasis style="italic">Clostridium</emphasis> sp., <emphasis style="italic">Eubacterium</emphasis> sp., <emphasis style="italic">Fusobacterium</emphasis> sp., <emphasis style="italic">Peptococcus</emphasis> sp., <emphasis style="italic">Peptostreptococcus</emphasis> sp., gingivitis, urethritis, <emphasis style="italic">Veillonella</emphasis> sp.</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10967">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy, breastfeeding; hypersensitivity to this product or nitroimidazole derivative</para>
				<section type="none" id="sidelem4x10972">
					<section type="none" id="sidelem4x10973">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, hepatic disease, CNS depression, blood dyscrasias, candidiasis, seizures, viral infection, alcoholism, pregnancy (C)</para>
						<para>
							<bbw>Secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10988">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10991">
					<section type="none" id="sidelem4x10992">
						<sec_title>Intestinal amebiasis/amebic involvement of the liver</sec_title>
						<section type="none" id="sidelem4x11000">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11000">
									<item>
										<label>•</label>
										<para> 2 g daily × 3 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11007">
							<label>•</label>
							<sec_title>Child ≥3 yr/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11007">
									<item>
										<label>•</label>
										<para> 50 mg/kg/day × 3 days, max 2 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11011">
						<sec_title>Giardiasis</sec_title>
						<section type="none" id="sidelem4x11019">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11019">
									<item>
										<label>•</label>
										<para> 2 g as a single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11026">
							<label>•</label>
							<sec_title>Child ≥3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11026">
									<item>
										<label>•</label>
										<para> 50 mg/kg as a single dose, max 2 g</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11030">
						<sec_title>Trichomoniasis</sec_title>
						<section type="none" id="sidelem4x11038">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11038">
									<item>
										<label>•</label>
										<para> 2 g as a single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11042">
						<sec_title>Bacterial vaginosis</sec_title>
						<section type="none" id="sidelem4x11050">
							<label>•</label>
							<sec_title>Adult (nonpregnant woman)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11050">
									<item>
										<label>•</label>
										<para> 2 g/day × 2 days with food or 1 g/day × 5 days with food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11054">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500 mg</para>
					</section>
					<section type="none" id="sidelem4x11059">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11063">
								<item>
									<label>•</label>
									<para>Tabs can be crushed and mixed with artificial cherry syrup for children</para>
								</item>
								<item>
									<label>•</label>
									<para>With food to increase plasma concentrations, minimize epigastric distress and other GI effects</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11074">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11077">
					<section type="none" id="sidelem4x11078">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis><emphasis style="bold">seizures,</emphasis><emphasis style="italic">peripheral neuropathy,</emphasis> malaise, fatigue</para>
					</section>
					<section type="none" id="sidelem4x11090">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, increased AST/ALT, constipation, abdominal pain, indigestion, altered taste</para>
					</section>
					<section type="none" id="sidelem4x11098">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia,</emphasis> neutropenia</para>
					</section>
					<section type="none" id="sidelem4x11106">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, urticaria, <emphasis style="italic">rash</emphasis>, oral candidiasis</para>
					</section>
					<section type="none" id="sidelem4x11114">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema,</emphasis> cramping</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11122">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; metabolized extensively in liver; excreted unchanged (20%-25%) in urine, (12%) feces; half-life 12-14 hr; crosses blood-brain barrier</para>
			</section>
			<section type="interactions" id="sidelem4x11133">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x11141">
					<label>•</label>
					<sec_title>
						<route>Do not use within 2 wk of disulfiram</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> tinidazole action—CYP3A4 inhibitors (cimetidine, ketoconazole): increased action of tinidazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of anticoagulants, cycloSPORINE, tacrolimus, fluorouracil, hydantoins, lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> tinidazole action—CYP3A4 inducers (PHENobarbital, rifampin, phenytoin); cholestyramine, oxytetracycline: decreased action of tinidazole</para>
				<section type="none" id="sidelem4x11156">
					<section type="none" id="sidelem4x11157">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase or decrease:</emphasis> tinidazole level—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x11164">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> triglycerides, LDH, AST/ALT, glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBCs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11175">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11178">
					<section type="none" id="sidelem4x11179">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11187">
							<label>•</label>
							<sec_title>Giardiasis</sec_title>
							<para>
								<list id="lidelem4x11187">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Giardiasis:</emphasis> obtain 3 stool samples several days apart beginning q3-4wk after treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11194">
							<label>•</label>
							<sec_title>Amebic liver abscess</sec_title>
							<para>
								<list id="lidelem4x11194">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Amebic liver abscess:</emphasis> monitor CBC, ESR, amebic gel diffusion test, ultrasound; also total and differential leukocyte count
<bbw>Secondary malignancy: avoid unnecessary use</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11207">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11212">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11217">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11221">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in infection as evidenced by negative culture</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11227">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11232">
								<item>
									<label>•</label>
									<para>To take with food to increase plasma concentrations, minimize epigastric distress and other GI effects; not to use alcoholic beverages during or for 3 days after treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11240">
							<label>•</label>
							<sec_title>Trichomoniasis</sec_title>
							<para>
								<list id="lidelem4x11240">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Trichomoniasis:</emphasis> both partners should be treated at the same time</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11244">
								<item>
									<label>•</label>
									<para>To avoid alcohol; may cause disulfiram reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11249">
								<item>
									<label>•</label>
									<para>To avoid doing hazardous activities until reaction is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11254">
								<item>
									<label>•</label>
									<para>That product causes unpleasant taste</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11259">
								<item>
									<label>•</label>
									<para>Not to use OTC, Rx, or herbal products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="53" status="active">
			<mono_name>tioconazole vaginal antifungal</mono_name>
			<section type="none" id="sidelem4x11267">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="54" status="active">
			<mono_name>tiotropium (Rx)</mono_name>
			<info>
				<pronunciation>(ty-oh′tro-pee-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x112761">Spiriva HandiHaler</tradename>
					<tradename id="tnidelem4x112760">Spiriva Respimat</tradename>
				</tradenames>
				<class type="func"> Anticholinergic, bronchodilator</class>
				<class type="chem"> Synthetic quaternary ammonium compound</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11286">
				<para>
					<confusion>
						<tradename id="tnidelem4x112860">Spiriva</tradename>
						<drug type="generic" refid="idelem4x112860">Inspra</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11290">
				<sec_title>Action:</sec_title>
				<para>Inhibits interaction of acetylcholine at receptor sites on the bronchial smooth muscle, thereby resulting in decreased cGMP and bronchodilation</para>
			</section>
			<section type="uses" id="sidelem4x11296">
				<sec_title>Uses:</sec_title>
				<para>COPD; for the long-term treatment and once-daily maintenance of bronchospasm associated with COPD, including chronic bronchitis and emphysema</para>
			</section>
			<section type="contra" id="sidelem4x11301">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, atropine, or its derivatives</para>
				<section type="none" id="sidelem4x11306">
					<section type="none" id="sidelem4x11307">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, closed-angle glaucoma, prostatic hypertrophy, bladder neck obstruction, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11312">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11320">
					<label>•</label>
					<sec_title>Adult<route> INH</route></sec_title>
					<para>
						<list id="lidelem4x11320">
							<item>
								<label>•</label>
								<para> content of 1 cap/day (18 mcg) using HandiHaler inhalation device or 2 INH (spray) (2.5 mcg each) daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11324">
					<section type="none" id="sidelem4x11325">
						<sec_title>Available forms:</sec_title>
						<para> Powder for INH 18 mcg in blister packs containing 6 caps with inhaler; 30 caps with inhaler; spray inhaler (Respimat) 2.5 mcg/spray</para>
					</section>
					<section type="none" id="sidelem4x11330">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11333">
							<sec_title>Inhalation route (caps)</sec_title>
							<section type="none" id="sidelem4x11341">
								<label>•</label>
								<sec_title>
									<route>Caps are for INH only; do not swallow</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x11344">
									<item>
										<label>•</label>
										<para>Immediately before administration, peel back foil until cap is visible and to “stop” line; remove cap from blister cavity; open dust cap of HandiHaler by pulling upward, then open mouthpiece; place cap in center chamber; firmly close mouthpiece until it clicks, leaving dust cap open</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11349">
									<item>
										<label>•</label>
										<para>When finished taking dose, remove used capsule and dispose of it; close mouthpiece and dust cap; store</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11354">
									<item>
										<label>•</label>
										<para>Rinse mouth after use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11359">
							<sec_title>Inhalation route (spray)</sec_title>
							<para>
								<list id="lidelem4x11363">
									<item>
										<label>•</label>
										<para>Insert cartridge into inhaler, prime inhaler, must reprime once if not used for &gt;3 days, if not used for &gt;21 days, prime until aerosol is visible, and 3 more times</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11369">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11372">
					<section type="none" id="sidelem4x11373">
						<sec_title>CNS:</sec_title>
						<para> Depression, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x11378">
						<sec_title>CV:</sec_title>
						<para> Chest pain, increased heart rate</para>
					</section>
					<section type="none" id="sidelem4x11383">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, blurred vision, glaucoma</para>
					</section>
					<section type="none" id="sidelem4x11388">
						<sec_title>GI:</sec_title>
						<para> Vomiting, abdominal pain, constipation, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x11393">
						<sec_title>GU:</sec_title>
						<para> Urinary difficulty, urinary retention, UTI</para>
					</section>
					<section type="none" id="sidelem4x11398">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11405">
						<sec_title>MISC:</sec_title>
						<para> Candidiasis, flulike syndrome, herpes zoster, infections, angina pectoris</para>
					</section>
					<section type="none" id="sidelem4x11410">
						<sec_title>MS:</sec_title>
						<para> Arthritis myalgic leg/skeletal pain</para>
					</section>
					<section type="none" id="sidelem4x11415">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, sinusitis, upper respiratory tract infection,</emphasis> epistaxis, pharyngitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11423">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 5-6 days in animals, does not cross blood-brain barrier, very little metabolized in the liver, excreted in urine, 72% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x11428">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x11432">
						<item>
							<label>•</label>
							<para>Anticholinergics: avoid use with other anticholinergics</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x11438">
					<section type="none" id="sidelem4x11439">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11446">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11449">
					<section type="none" id="sidelem4x11450">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11458">
							<label>•</label>
							<sec_title>Respiratory status</sec_title>
							<para>
								<list id="lidelem4x11458">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory status:</emphasis> dyspnea, rate, breath sounds before and during treatment; pulmonary function tests at baseline and periodically; upper respiratory infections, cough, sinusitis</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11462">
								<item>
									<label>•</label>
									<para>Tolerance over long-term therapy; dose may have to be increased or changed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11467">
								<item>
									<label>•</label>
									<para>Patient’s ability to use HandiHaler</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11472">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11476">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to breathe easier</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11482">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11487">
								<item>
									<label>•</label>
									<para>Signs of closed-angle glaucoma (eye pain, blurred vision, visual halos)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11492">
								<item>
									<label>•</label>
									<para>That product is used for long-term maintenance, not for immediate relief of breathing problems; that effect takes 20 min, lasts 24 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11497">
								<item>
									<label>•</label>
									<para>To avoid getting the powder in the eyes; may cause blurred vision and pupil dilation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11502">
								<item>
									<label>•</label>
									<para>To hold HandiHaler with mouthpiece upward; to press button in once, completely, and release; this allows for medication to be released</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11507">
								<item>
									<label>•</label>
									<para>To breathe out completely; not to breathe into mouthpiece at any time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11512">
								<item>
									<label>•</label>
									<para>To raise device to mouth and close lips tightly around mouthpiece</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11517">
								<item>
									<label>•</label>
									<para>With head upright, to breathe in slowly and deeply, but allow the cap to vibrate; to breathe until the lungs fill; to hold breath and remove mouthpiece; to resume normal breathing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11522">
								<item>
									<label>•</label>
									<para>To rinse mouth after use; to use hard candy or regular oral hygiene to reduce dry mouth</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11530">
							<label>•</label>
							<sec_title>
								<route>To report immediately blurred vision, eye pain, halos</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11533">
								<item>
									<label>•</label>
									<para>To keep caps in sealed blisters before use; to store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="55" status="active">
			<mono_name>tipranavir (Rx)</mono_name>
			<info>
				<pronunciation>(ti-pran′a-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x115430">Aptivus</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11553">
				<sec_title>Action:</sec_title>
				<para>Inhibits human immunodeficiency virus (HIV) protease, thereby preventing the maturation of the virus</para>
			</section>
			<section type="uses" id="sidelem4x11558">
				<sec_title>Uses:</sec_title>
				<para>HIV in combination with other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x11563">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Hepatic disease (Child-Pugh B, C)</bbw>
				</para>
				<section type="none" id="sidelem4x11578">
					<section type="none" id="sidelem4x11579">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal disease, history of renal stones, sulfa allergy, hemophilia, diabetes mellitus, pancreatitis, alcoholism, immune reconstitution syndrome, surgery, trauma, infection</para>
						<para>
							<bbw>Intracranial bleeding, hepatitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11595">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11604">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11604">
							<item>
								<label>•</label>
								<para> 500 mg coadministered with ritonavir 200 mg bid with food</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11611">
					<label>•</label>
					<sec_title>Adolescent and child ≥2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11611">
							<item>
								<label>•</label>
								<para> 14 mg/kg given with ritonavir 6 mg/kg bid or 375 mg/m<emphasis style="sup">2</emphasis> given with ritonavir 150 mg/m<emphasis style="sup">2</emphasis> bid, max 500 mg with ritonavir 200 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11621">
					<section type="none" id="sidelem4x11622">
						<sec_title>Available forms:</sec_title>
						<para> Caps 250 mg; oral sol 100 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x11627">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11631">
								<item>
									<label>•</label>
									<para>Not to be used in those who are treatment-naive</para>
								</item>
								<item>
									<label>•</label>
									<para>Swallow cap whole; do not break, crush, chew; store caps in refrigerator before use; after opening, store at room temperature; use within 60 days</para>
								</item>
								<item>
									<label>•</label>
									<para>After meals</para>
								</item>
								<item>
									<label>•</label>
									<para>In equal intervals around the clock to maintain blood levels</para>
								</item>
								<item>
									<label>•</label>
									<para>Give oral sol using calibrated dosing syringe or 5-ml oral syringe provided; store oral sol at room temperature; use within 60 days after opening bottle</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11657">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11660">
					<section type="none" id="sidelem4x11661">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia,</emphasis> dizziness, somnolence, fatigue, <emphasis style="italic">fever,</emphasis><emphasis style="bold">intracranial bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11673">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, abdominal pain, nausea, vomiting,</emphasis> anorexia, dry mouth, <emphasis style="bold">hepatitis B or C, fatalities when given with ritonavir, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11683">
						<sec_title>GU:</sec_title>
						<para> Nephrolithiasis</para>
					</section>
					<section type="none" id="sidelem4x11688">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, lipodystrophy, <emphasis style="bold">serious rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11698">
						<sec_title>MS:</sec_title>
						<para> Pain</para>
					</section>
					<section type="none" id="sidelem4x11703">
						<sec_title>OTHER:</sec_title>
						<para> Asthenia, <emphasis style="bold">insulin-resistant hyperglycemia,</emphasis><emphasis style="italic">hyperlipidemia,</emphasis><emphasis style="bold">ketoacidosis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11714">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 6 hr, peak 3 hr, plasma protein binding 99.9%, steady-state 7-10 days, metabolism CYP3A4, 80% fecal excretion</para>
			</section>
			<section type="interactions" id="sidelem4x11719">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Life-threatening dysrhythmias: amiodarone, astemizole, cisapride, ergots, flecainide, midazolam, pimozide, propafenone, quiNIDine, rifabutin, rifampin, terfenadine, triazolam</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: myopathy, rhabdomyolysis—HMG-CoA reductase inhibitors (lovastatin, simvastatin)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tipranavir levels—ketoconazole, delavirdine, itraconazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of both products—clarithromycin, zidovudine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of tipranavir—oral contraception</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> tipranavir levels—rifamycins, fluconazole, nevirapine, efavirenz</para>
				<section type="none" id="sidelem4x11746">
					<section type="none" id="sidelem4x11747">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> tipranavir levels—St. John’s wort; avoid concurrent use</para>
					</section>
					<section type="none" id="sidelem4x11754">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> tipranavir absorption—grapefruit juice; high-fat, high-protein foods</para>
					</section>
					<section type="none" id="sidelem4x11761">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, cholesterol, blood glucose, amylase, lipase, triglycerides</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11768">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11771">
					<section type="none" id="sidelem4x11772">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11777">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia; presence of other sexually transmitted diseases
<bbw>Hepatic studies: ALT, AST; total bilirubin, amylase; all may be elevated, discontinue in those with hepatic insufficiency or hepatitis or AST/ALT 10 × upper limit or AST/ALT 5-10 × ULN and total bilirubin 2.5 × ULN; assess for anorexia, nausea, jaundice, hepatomegaly, clay-colored stools</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11794">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x11794">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> Viral load, CD4, plasma HIV RNA, serum cholesterol profile, serum triglycerides during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11798">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11807">
							<label>•</label>
							<sec_title>Serious rash<route> if serious rash occurs, product should be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11813">
							<label>•</label>
							<sec_title>Immune reconstitution syndrome<route> has been reported with combination antiretroviral therapy, patients may develop pain (MAC, CMV, PcP, TB) and autoimmune disease months after treatment</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11827">
								<item>
									<label>•</label>
									<para>Cushingoid symptoms: buffalo hump, facial/peripheral wasting, breast enlargement, central obesity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11832">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11836">
								<item>
									<label>•</label>
									<para>Therapeutic response: improving CD4 counts, viral load</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11842">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11847">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11852">
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels for duration of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11858">
								<item>
									<para>
										<emphasis alert="nurse">That hyperglycemia may occur; to watch for increased thirst, weight loss, hunger, dry, itchy skin; to notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11863">
								<item>
									<label>•</label>
									<para>That product does not cure AIDS, only controls symptoms; not to donate blood</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11868">
								<item>
									<label>•</label>
									<para>Not to breastfeed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11873">
								<item>
									<label>•</label>
									<para>That redistribution of body fat may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11878">
								<item>
									<label>•</label>
									<para>Not to use with other products unless approved by prescriber, many drug interactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11883">
								<item>
									<label>•</label>
									<para>That product must be taken in combination with ritonavir</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11891">
							<label>•</label>
							<sec_title>
								<route>To stop product and notify prescriber if anorexia, nausea, vomiting, yellowing of skin or eyes, clay-colored stools, fatigue, pain in upper abdomen</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="56" status="active" ha="yes">
			<mono_name> tirofiban (Rx)</mono_name>
			<info>
				<pronunciation>(tie-roh-fee′ban)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x119010">Aggrastat</tradename>
				</tradenames>
				<class type="func"> Antiplatelet</class>
				<class type="chem"> Glycoprotein IIb/IIIa inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x11911">
				<sec_title>Action:</sec_title>
				<para>Antagonist of platelet glycoprotein (GP) IIb/IIIa receptor that prevents binding of fibrinogen and von Willebrand’s factor, which inhibits platelet aggregation</para>
			</section>
			<section type="uses" id="sidelem4x11916">
				<sec_title>Uses:</sec_title>
				<para>Acute coronary syndrome in combination with heparin</para>
			</section>
			<section type="contra" id="sidelem4x11921">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, active internal bleeding, stroke, major surgery, severe trauma within 30 days, intracranial neoplasm, aneurysm, hemorrhage, acute pericarditis, platelets &lt;100,000/mm<emphasis style="sup">3</emphasis>, history of thrombocytopenia, coagulopathy, systolic B/P &gt;180 mm Hg or diastolic B/P &gt; 110 mm Hg</para>
				<section type="none" id="sidelem4x11929">
					<section type="none" id="sidelem4x11930">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal disease, bleeding tendencies, hypertension, platelets &lt;150,000/mm<emphasis style="sup">3</emphasis></para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11937">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11945">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x11945">
							<item>
								<label>•</label>
								<para> 0.4 mcg/kg/min × 30 min, then 0.1 mcg/kg/min for 12-24 hr after angioplasty or atherectomy</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11949">
					<section type="none" id="sidelem4x11950">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x11958">
							<label>•</label>
							<sec_title>Adult<route> IV CCr &lt;30 ml/min, 0.2 mcg/kg/min × 30 min, then 0.05 mcg/kg/min during angiography and for 12-24 hr after angioplasty</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11961">
						<sec_title>Available forms:</sec_title>
						<para> Inj 50 ml vials; inj premixed bag 50 mcg/ml in 100, 250 ml</para>
					</section>
					<section type="none" id="sidelem4x11966">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11969">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x11973">
									<item>
										<label>•</label>
										<para>Do not use if particulates are present</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilute inj: withdraw and discard 100 ml from 500-ml bag of sterile 0.9% NaCl or D<emphasis style="inf">5</emphasis>W and replace this vol with 100 ml of tirofiban inj from 2 vials</para>
									</item>
									<item>
										<label>•</label>
										<para>Tirofiban inj for sol is premixed in containers of 500 ml 0.9% NaCl (50 mg/ml), infuse over 30 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Minimize other arterial/venous punctures; IM inj, catheter use, intubation, to reduce bleeding risk</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard unused solution after 24 hr from start of infusion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12004">
						<sec_title>Y-site compatibilities:</sec_title>
						<para> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, ampicillin, ampicillin/sulbactam, anidulafungin, argatroban, arsenic trioxide, atracurium, atropine, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, capreomycin, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposome, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, insulin, irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, methylhexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoXANtrone, morphine, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, piperacillin/tazobactam, potassium acetate, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quinupristin/dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate, streptozocin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin/clavulanate, tigecycline, tobramycin, topotecan, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12009">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12012">
					<section type="none" id="sidelem4x12013">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x12018">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, hypotension</para>
					</section>
					<section type="none" id="sidelem4x12023">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x12028">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12035">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12042">
						<sec_title>MISC:</sec_title>
						<para> Dissection, edema, pain in legs/pelvis, sweating</para>
					</section>
					<section type="none" id="sidelem4x12047">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12054">
				<sec_title>Pharmocokinetics</sec_title>
				<para>Half-life 2 hr; excretion via urine, feces; plasma clearance 20%-25% lower in geriatric patients with CAD; renal insufficiency decreases plasma clearance</para>
			</section>
			<section type="interactions" id="sidelem4x12059">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—aspirin, heparin, NSAIDs, abciximab, eptifibatide, clopidogrel, ticlopidine, dipyridamole, cefamandole, cefoTEtan, cefoperazone, valproic acid, heparins, thrombin inhibitors, SSRIs, SNRIs</para>
			</section>
			<section type="considerations" id="sidelem4x12066">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12069">
					<section type="none" id="sidelem4x12070">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="nurse">Bleeding: platelet counts, Hct, Hgb before treatment, within 6 hr of loading dose, and at least daily thereafter; watch for bleeding from puncture sites, catheters, or in stools, urine; discontinue if platelets &lt;100,000/mm<emphasis style="sup">3</emphasis></emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x12080">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12084">
								<item>
									<label>•</label>
									<para>Therapeutic response: treatment of acute coronary syndrome</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12090">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12094">
								<item>
									<label>•</label>
									<para>That it is necessary to quit smoking to prevent excessive vasoconstriction</para>
								</item>
								<item>
									<label>•</label>
									<para>About signs, symptoms of bleeding and low platelets</para>
								</item>
								<item>
									<label>•</label>
									<para>That there are many product and herbal interactions, do not use unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="57" status="active">
			<mono_name>tiZANidine (Rx)</mono_name>
			<info>
				<pronunciation>(ti-za′nih-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x121150">Zanaflex</tradename>
				</tradenames>
				<class type="func"> Skeletal muscle relaxant, α-adrenergic agonist</class>
				<class type="chem"> Imidazoline</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12128">
				<para>
					<confusion>
						<tradename id="tnidelem4x121280">tiZANidine</tradename>
						<drug type="generic" refid="idelem4x121280">tiaGABine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12132">
				<sec_title>Action:</sec_title>
				<para>Increases presynaptic inhibition of motor neurons and reduces spasticity by α<emphasis style="inf">2</emphasis>-adrenergic agonism</para>
			</section>
			<section type="uses" id="sidelem4x12140">
				<sec_title>Uses:</sec_title>
				<para>Acute/intermittent management of increased muscle tone associated with spasticity, symptoms of MS</para>
				<section type="none" id="sidelem4x12145">
					<section type="none" id="sidelem4x12146">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Tension headache, low back pain, trigeminal neuralgia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12151">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x12156">
					<section type="none" id="sidelem4x12157">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, hypotension, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12162">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12170">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12170">
							<item>
								<label>•</label>
								<para> 8 mg q6-8hr, max 36 mg/24 hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12174">
					<section type="none" id="sidelem4x12175">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x12183">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;25 ml/min, start with lower dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12186">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2, 4 mg; caps 2, 4, 6 mg</para>
					</section>
					<section type="none" id="sidelem4x12191">
						<sec_title>Administer</sec_title>
						<para>
							<list id="lidelem4x12195">
								<item>
									<label>•</label>
									<para>Consistently either with/without food; food may affect absorption</para>
								</item>
								<item>
									<label>•</label>
									<para>Titrate doses carefully</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use with other CNS depressants</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12211">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12214">
					<section type="none" id="sidelem4x12215">
						<sec_title>CNS:</sec_title>
						<para> Somnolence, dizziness, speech disorder, dyskinesia, nervousness, hallucination, psychosis</para>
					</section>
					<section type="none" id="sidelem4x12220">
						<sec_title>CV:</sec_title>
						<para> Hypotension, bradycardia</para>
					</section>
					<section type="none" id="sidelem4x12225">
						<sec_title>GI:</sec_title>
						<para> Dry mouth, vomiting, increased ALT, abnormal LFTs, constipation</para>
					</section>
					<section type="none" id="sidelem4x12230">
						<sec_title>OTHER:</sec_title>
						<para> Blurred vision, urinary frequency, pharyngitis, rhinitis, tremors, rash, muscle weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12235">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Completely absorbed, widely distributed, peak 1-2 hr, duration 3-6 hr, half-life 2.5 hr, protein binding 30%, metabolized by liver; excreted in urine, feces</para>
			</section>
			<section type="interactions" id="sidelem4x12240">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, other CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tiZANidine levels—other CYP1A2 inhibitors (acyclovir, amiodarone, famotidine, mexiletine, enoxacin, norfloxacin, propafenone, tacrine, verapamil, zileuton, oral contraceptives ciprofloxacin), fluvoxaMINE; avoid concurrent use</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of rasagiline</para>
				<section type="none" id="sidelem4x12259">
					<section type="none" id="sidelem4x12260">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x12267">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, AST, ALT, serum glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12274">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12277">
					<section type="none" id="sidelem4x12278">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12286">
							<label>•</label>
							<sec_title>
								<route>Muscle spasticity</route>
							</sec_title>
							<para>
								<list id="lidelem4x12286">
									<item>
										<label>•</label>
										<para> at baseline and throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12294">
							<label>•</label>
							<sec_title>Hypotension</sec_title>
							<para>
								<list id="lidelem4x12294">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypotension:</emphasis> gradual dosage increase should lessen hypotensive effects; have patient rise slowly from supine to upright; watch those patients receiving antihypertensives for increased effects</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12298">
								<item>
									<label>•</label>
									<para>Increased sedation, dizziness, hallucinations, psychosis; product may need to be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12303">
								<item>
									<label>•</label>
									<para>Vision by ophthalmic exam; corneal opacities may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12308">
								<item>
									<label>•</label>
									<para>Hepatic studies: 1, 3, 6 mo during treatment and periodically thereafter</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12313">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12317">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased muscle spasticity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12323">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12327">
								<item>
									<label>•</label>
									<para>To rise slowly from lying or sitting to upright position to prevent orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To ask for assistance if dizziness, sedation occur; to avoid drinking alcohol; to avoid operating machinery, driving until effects known</para>
								</item>
								<item>
									<label>•</label>
									<para>To discontinue gradually</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until reaction is known</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="58" status="active">
			<mono_name>tobramycin (Rx)</mono_name>
			<info>
				<pronunciation>(toe-bra-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x123581">TOBI</tradename>
					<tradename id="tnidelem4x123580">TOBI Podhaler</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Aminoglycoside</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x12368">
				<sec_title>Action:</sec_title>
				<para>Interferes with protein synthesis in bacterial cell by binding to ribosomal subunits, thereby causing inaccurate peptide sequences to form in protein chain causing bacterial death</para>
			</section>
			<section type="uses" id="sidelem4x12373">
				<sec_title>Uses:</sec_title>
				<para>Severe systemic infections of CNS, respiratory, GI, urinary tract, bone, skin, soft tissues; cystic fibrosis (nebulizer) for <emphasis style="italic">Acinetobacter calcoaceticus, Citrobacter</emphasis> sp., <emphasis style="italic">Enterobacter aerogenes, Enterobacter</emphasis> sp., <emphasis style="italic">Enterococcus</emphasis> sp., <emphasis style="italic">Escherichia coli, Haemophilus aegyptius, Haemophilus influenzae (beta-lactamase negative), Haemophilus influenzae (beta-lactamase positive), Klebsiella pneumoniae, Klebsiella</emphasis> sp., <emphasis style="italic">Moraxella lacunata, Morganella morganii, Neisseria</emphasis> sp., <emphasis style="italic">Proteus mirabilis, Proteus vulgaris, Providencia</emphasis> sp., <emphasis style="italic">Pseudomonas aeruginosa, Serratia</emphasis> sp., <emphasis style="italic">Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Staphylococcus</emphasis> sp., <emphasis style="italic">Streptococcus pneumoniae, Streptococcus</emphasis> sp.; may also be used for the following: <emphasis style="italic">Acinetobacter</emphasis> sp., <emphasis style="italic">Aeromonas</emphasis> sp., <emphasis style="italic">Bacillus anthracis, Salmonella</emphasis> sp., <emphasis style="italic">Shigella</emphasis> sp.</para>
				<section type="none" id="sidelem4x12417">
					<section type="none" id="sidelem4x12418">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Endocarditis, febrile neutropenia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12423">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to aminoglycosides</para>
				<para>
					<bbw>Pregnancy (D), severe renal disease</bbw>
				</para>
				<section type="none" id="sidelem4x12438">
					<section type="none" id="sidelem4x12439">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, geriatric patients, neonates, mild renal disease, myasthenia gravis, Parkinson’s disease</para>
						<para>
							<bbw>Hearing deficits, neuromuscular disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12454">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12462">
					<label>•</label>
					<sec_title>Adult<route> IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x12462">
							<item>
								<label>•</label>
								<para> 3 mg/kg/day in divided doses q8hr; may give up to 6 mg/kg/day in divided doses q8-12hr; once-daily dosing (pulse dosing) (unlabeled)  5-7 mg/kg, dosing intervals determined using nomogram, based on random levels drawn 8-12 hr after 1st dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12472">
					<label>•</label>
					<sec_title>Child<route> IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x12472">
							<item>
								<label>•</label>
								<para> 6-7.5 mg/kg/day in 3-4 equal divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12479">
					<label>•</label>
					<sec_title>Child ≥6 yr<route> NEB</route></sec_title>
					<para>
						<list id="lidelem4x12479">
							<item>
								<label>•</label>
								<para> 300 mg bid in repeating cycles of 28 days on/28 days off of product; give  over 10-15 min using a handheld PARI LC PLUS reusable nebulizer with DeVilbiss Pulmo-Aid compressor</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12489">
					<label>•</label>
					<sec_title>Neonate &lt;1 wk<route> IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x12489">
							<item>
								<label>•</label>
								<para> ≤4 mg/kg/day divided q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12494">
					<section type="none" id="sidelem4x12495">
						<sec_title>Cystic fibrosis with <emphasis style="italic">Pseudomonas aeruginosa</emphasis></sec_title>
						<section type="none" id="sidelem4x12505">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥6 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12505">
									<item>
										<label>•</label>
										<para> 2.5-3.3 mg/kg q8hr,  300 mg via inhalation bid × 28 days, then 28 days after;  (TOBI Podhaler) 112 mg bid ×28 day, then 28 days after; may repeat</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12515">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x12518">
							<sec_title>Conventional dosing:</sec_title>
							<section type="none" id="sidelem4x12526">
								<label>•</label>
								<sec_title>
									<route>Multiply the serum creatinine (mg/100 ml) by 6 to determine the dosing; to decrease the dose, divide the standard dose by the serum creatinine (mg/100 ml) to determine the lower recommended dose</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x12529">
							<sec_title>Interval adjustment of extended-interval dosing of 5 or 7 mg/kg (unlabeled):</sec_title>
							<section type="none" id="sidelem4x12537">
								<label>•</label>
								<sec_title>Adjust doses based on serum concentrations and organism MIC; CCr 40-59 ml/min<route> 5 or 7 mg/kg IV q36hr; CCr 20-39 ml/min</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x12540">
							<sec_title>Dose adjustment of extended dosing of 5 mg/kg (unlabeled)</sec_title>
							<section type="none" id="sidelem4x12548">
								<label>•</label>
								<sec_title>
									<route>IV</route>
								</sec_title>
								<para>
									<list id="lidelem4x12548">
										<item>
											<label>•</label>
											<para>Adjust doses based on serum concentrations and organism MIC: CCr &gt;80 ml/min: no dosage adjustment is needed: CCr 60-79 ml/min: 4 mg/kg  q24hr; CCr 50 ml/min: 3.5 mg/kg  q24hr; CrCl 40 ml/min: 2.5 mg/kg  q24hr; CrCl &lt;30 ml/min: use traditional dosing</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x12559">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10, 40 mg/ml; powder for inj 1.2 g; neb sol 300 mg/5 ml; powder for inh 28 mg</para>
					</section>
					<section type="none" id="sidelem4x12564">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12568">
								<item>
									<label>•</label>
									<para>After obtaining specimen for C&amp;S; begin treatment before results</para>
								</item>
								<item>
									<label>•</label>
									<para>Product in evenly spaced doses to maintain blood level; separate aminoglycosides and penicillins by ≥1 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Use only on susceptible organisms to prevent development of product-resistant bacteria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12584">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x12588">
									<item>
										<label>•</label>
										<para>IM inj in large muscle mass; rotate inj sites, aspirate</para>
									</item>
									<item>
										<label>•</label>
										<para>Draw peak 1 hr after dose, trough right before next dose; absorption erratic</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12599">
							<sec_title>Inhalation route: (TOBI Podhaler)</sec_title>
							<para>
								<list id="lidelem4x12603">
									<item>
										<label>•</label>
										<para>Use with Podhaler device; do not swallow caps; use device for 7 days, then discard</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep caps in blister pack until ready to use; administer other inhaled products or chest physiotherapy before</para>
									</item>
									<item>
										<label>•</label>
										<para>While holding base of Podhaler device, unscrew lid, stand upright, unscrew mouthpiece; while holding body, tear blister card in half lengthwise along precut lines, peel back foil, place cap in chamber at top of device, reattach mouthpiece and tighten; with mouthpiece pointed down, press blue button down with thumb, release, exhale completely, place mouth over mouthpiece, close lips, inhale with single breath, hold 5 sec, exhale normally away from device; after a few normal breaths, repeat, unscrew mouthpiece, and remove cap; cap should be empty; repeat process 3 more times (total 4 caps); after use, reattach mouthpiece and wipe with clean, dry cloth</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12619">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x12624">
									<item>
										<label>•</label>
										<para>Visually inspect sol; do not use if discolored or particulate is present</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x12632">
								<label>•</label>
								<sec_title>
									<route>Vantage vials are for IV only and only for exactly 60 or 80 mg</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x12635">
									<item>
										<label>•</label>
										<para>Diluted in 50-100 ml 0.9% NaCl D<emphasis style="inf">5</emphasis>W (D<emphasis style="inf">10</emphasis>W, Ringer’s, LR); infuse over 20-60 min; volume for pediatric patients needs and should be sufficient to allow for 20-60 min infusion</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, aldesleukin, alfentanil, alprostadil, amifostine, aminophylline, amiodarone, amsacrine, anidulafungin, ascorbic acid, atracurium, atropine, aztreonam, bivalirudin, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, chloramphenicol, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin hydrochloride, DOXOrubicin liposome, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, ertapenem, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, furosemide, gemcitabine, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, ifosfamide, imipenem/cilastatin, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins, nafcillin, nalbuphine, naloxone, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pantoprazole, papaverine, penicillin G, pentazocine, perphenazine, PHENobarbital, phentolamine, phenylephrine, phytonadione, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, remifentanil, riTUXimab, rocuronium, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tolazoline, trastuzumab, trimethaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12652">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12655">
					<section type="none" id="sidelem4x12656">
						<sec_title>CNS:</sec_title>
						<para> Confusion, depression, numbness, tremors, <emphasis style="bold">seizures,</emphasis> muscle twitching, <emphasis style="bold">neurotoxicity,</emphasis> dizziness, vertigo</para>
					</section>
					<section type="none" id="sidelem4x12667">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, palpitation</para>
					</section>
					<section type="none" id="sidelem4x12672">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="bold">Ototoxicity,</emphasis> deafness, visual disturbances, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x12680">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia;</emphasis> increased ALT, AST, bilirubin, hepatomegaly, <emphasis style="bold">hepatic necrosis,</emphasis> splenomegaly</para>
					</section>
					<section type="none" id="sidelem4x12691">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Oliguria, hematuria, renal damage, azotemia, renal failure, nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12698">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, leukopenia, eosinophilia,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x12706">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> burning, urticaria, dermatitis, alopecia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12714">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Plasma half-life 2-3 hr, prolonged in neonates; not metabolized; excreted unchanged in urine; crosses placental barrier; poor penetration into CSF</para>
				<section type="none" id="sidelem4x12719">
					<section type="none" id="sidelem4x12720">
						<sec_title>IM:</sec_title>
						<para> Onset rapid, peak 1 hr, duration 8 hr</para>
					</section>
					<section type="none" id="sidelem4x12725">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak 30 min, duration 8 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12730">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> ototoxicity, neurotoxicity, nephrotoxicity—other aminoglycosides, amphotericin B, polymyxin, vancomycin, ethacrynic acid, furosemide, mannitol, methoxyflurane, CISplatin, cephalosporins, bacitracin, acyclovir, penicillins, cidofovir</bbw>
				</para>
				<section type="none" id="sidelem4x12745">
					<section type="none" id="sidelem4x12746">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> eosinophils, BUN, creatinine, AST, ALT, LDH, alk phos, glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, calcium, sodium, magnesium, WBC, granulocytes, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12757">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12760">
					<section type="none" id="sidelem4x12761">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12766">
								<item>
									<label>•</label>
									<para>Weight before treatment; dosage is usually based on ideal body weight but may be calculated on actual body weight</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12771">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, urinalysis daily for proteinuria, cells, casts; report sudden change in urine output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12776">
								<item>
									<label>•</label>
									<para>VS during infusion; watch for hypotension, change in pulse</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12781">
								<item>
									<label>•</label>
									<para>IV site for thrombophlebitis, including pain, redness, swelling q30min; change site if needed; apply warm compresses to discontinued site
<bbw>Serum aminoglycoside concentration; serum peak drawn at 30-60 min after IV infusion or 60 min after IM inj, trough drawn just before next dose, peak 4-10 mcg/ml, trough 0.5-2 mcg/ml, increased level may lead to serious toxicity</bbw>

<bbw>Renal impairment: CCr, BUN, serum creatinine; lower dosage should be given in renal impairment (CCr &lt;80 ml/min); monitor electrolytes: potassium, sodium, chloride, magnesium monthly if patient receiving long-term therapy</bbw>

<bbw>Pregnancy: identify if pregnancy is planned or suspected, pregnancy (D)</bbw>

<bbw>Deafness by audiometric testing; ringing, roaring in ears; vertigo; assess hearing before, during, after treatment</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12826">
							<label>•</label>
							<sec_title>Overgrowth of infection</sec_title>
							<para>
								<list id="lidelem4x12826">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Overgrowth of infection:</emphasis> fever, malaise, redness, pain, swelling, perineal itching, diarrhea, stomatitis, change in cough, sputum</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12833">
							<label>•</label>
							<sec_title>Vestibular dysfunction</sec_title>
							<para>
								<list id="lidelem4x12833">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Vestibular dysfunction:</emphasis> nausea, vomiting, dizziness, headache; product should be discontinued if severe</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12837">
								<item>
									<label>•</label>
									<para>Adequate fluids of 2-3 L/day unless contraindicated to prevent irritation of tubules</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12842">
								<item>
									<label>•</label>
									<para>Supervised ambulation, other safety measures with vestibular dysfunction</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12847">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12851">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, draining wounds, negative C&amp;S after treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12857">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12861">
								<item>
									<label>•</label>
									<para>To promptly report headache, dizziness, symptoms of overgrowth of infection, renal impairment
<bbw>To report loss of hearing; ringing, roaring in ears; feeling of fullness in head</bbw>

<bbw>To notify prescriber if pregnancy is planned or suspected; pregnancy (D)</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until response is known</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12890">
						<sec_title>Nebulizer</sec_title>
						<para>
							<list id="lidelem4x12894">
								<item>
									<label>•</label>
									<para>To use other therapies first, then tobramycin, not to use if cloudy or contains particulates</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x12900">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Hemodialysis; monitor serum levels of product</para>
			</section>
		</monograph>
<monograph id="59" status="active">
			<mono_name>tobramycin ophthalmic</mono_name>
			<section type="none" id="sidelem4x12908">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="60" status="active">
			<mono_name>tocilizumab (Rx)</mono_name>
			<info>
				<pronunciation>(toe′si-liz′oo-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x129170">Actemra</tradename>
				</tradenames>
				<class type="func"> DMARDs (disease-modifying antirheumatoid drugs)/tumor necrosis factor (TNF) modifier</class>
			</info>
			<section type="actions" id="sidelem4x12923">
				<sec_title>Action:</sec_title>
				<para>Interleukin-6 (IL-6) receptor inhibiting monoclonal antibody</para>
			</section>
			<section type="uses" id="sidelem4x12928">
				<sec_title>Uses:</sec_title>
				<para>Rheumatoid arthritis, active systemic juvenile idiopathic arthritis</para>
			</section>
			<section type="contra" id="sidelem4x12933">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x12938">
					<section type="none" id="sidelem4x12939">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, pregnancy (C); risk for GI perforation, active hepatic disease, severe neutropenia/ thrombocytopenia, demyelinating disorders</para>
						<para>
							<bbw>Invasive fungal infection, active TB</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12954">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12957">
					<section type="none" id="sidelem4x12958">
						<sec_title>Monotherapy with or without methotrexate or other DMARDs, moderate-severe rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x12966">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12966">
									<item>
										<label>•</label>
										<para> 4 mg/kg over 1 hr q4wk, may increase to 8 mg/kg q4wk based on clinical response, max dose 800 mg/infusion; do not initiate if ANC &gt;2000, platelets &lt;100,000</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12973">
							<label>•</label>
							<sec_title>Adults &lt;100 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x12973">
									<item>
										<label>•</label>
										<para> 162 mg every other wk (monotherapy or in combination); increase to 162 mg weekly based on response</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12980">
							<label>•</label>
							<sec_title>Adults ≥100 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x12980">
									<item>
										<label>•</label>
										<para> 162 mg weekly (monotherapy or in combination)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x12984">
					<section type="none" id="sidelem4x12985">
						<sec_title>Juvenile idiopathic arthritis</sec_title>
						<section type="none" id="sidelem4x12993">
							<label>•</label>
							<sec_title>Child ≥2 yr/adolescent ≥30 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12993">
									<item>
										<label>•</label>
										<para> 8 mg/kg over 1 hr q2wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13000">
							<label>•</label>
							<sec_title>Child ≥2 yr/adolescent &lt;30 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x13000">
									<item>
										<label>•</label>
										<para> 10 mg/kg over 1 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13004">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 80 mg/4 ml, 200 mg/10 ml, 400 mg/20 ml</para>
					</section>
					<section type="none" id="sidelem4x13009">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x13012">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x13016">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter, discoloration before administration whenever sol and container permit; colorless to pale yellow liquid</para>
									</item>
									<item>
										<label>•</label>
										<para>From 100-ml infusion bag or bottle, withdraw vol of 0.9% sodium chloride inj equal to vol of tocilizumab sol required for patient’s dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Slowly add tocilizumab from each vial into infusion bag or bottle; gently invert bag to avoid foaming; fully diluted sols are compatible with polypropylene, polyethylene, polyvinyl chloride infusion bags and polypropylene, polyethylene, glass infusion bottles</para>
									</item>
									<item>
										<label>•</label>
										<para>Fully diluted sol for infusion may be stored refrigerated or at room temperature for ≤24 hr and should be protected from light; do not use unused product remaining in vials; no preservatives</para>
									</item>
									<item>
										<label>•</label>
										<para>Allow the fully diluted sol to reach room temperature before infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Give over 60 minutes with infusion set; do not administer as IV push or bolus</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not infuse concomitantly in same IV line with other drugs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13052">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13055">
					<section type="none" id="sidelem4x13056">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x13061">
						<sec_title>CV:</sec_title>
						<para> Hypertension</para>
					</section>
					<section type="none" id="sidelem4x13066">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Perforation,</emphasis> abdominal pain, gastritis, mouth ulcerations</para>
					</section>
					<section type="none" id="sidelem4x13074">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13081">
						<sec_title>INTEG:</sec_title>
						<para> Rash, infusion reactions</para>
					</section>
					<section type="none" id="sidelem4x13086">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory infections, nasopharyngitis, bronchitis</para>
					</section>
					<section type="none" id="sidelem4x13091">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serious infections, anaphylaxis,</emphasis> infusion-related reactions, antitocilizumab antibody formation, <emphasis style="bold">secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13101">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> product level—cycloSPORINE, theophylline warfarin</para>
				<section type="none" id="sidelem4x13116">
					<label>•</label>
					<sec_title>
						<route>Do not give with live virus vaccines</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x13122">
					<label>•</label>
					<sec_title>
						<route>Avoid use with TNF modifiers, DMARDs, immunosuppressives due to increased risk of infection</route>
					</sec_title>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13125">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life approx 6 days with single dose, approx 11 days with multiple (steady-state) doses</para>
			</section>
			<section type="considerations" id="sidelem4x13130">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13133">
					<section type="none" id="sidelem4x13134">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x13142">
							<label>•</label>
							<sec_title>Rheumatoid arthritis</sec_title>
							<para>
								<list id="lidelem4x13142">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Rheumatoid arthritis:</emphasis> ROM, pain, stiffness at baseline q1-2wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13149">
							<para>
								<list id="lidelem4x13149">
									<item>
										<label>•</label>
										<para>Blood studies: CBC with differential, LFTs, platelet count, serum lipid profile at baseline and periodically
<bbw>
												<emphasis alert="lifethreat">Infection</emphasis> before treatment and periodically; obtain TB screening before beginning treatment, invasive fungal infections; discontinue if infection occurs during administration; may use antituberculosis therapy before tocilizumab in past history of latent or active TB when adequate course of treatment cannot be confirmed and those with a negative TB with risk factors for infections</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13165">
							<label>•</label>
							<sec_title>Secondary malignancy<route> assess for malignancy periodically</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13168">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13172">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to move more easily with less pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13178">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13182">
								<item>
									<label>•</label>
									<para>That this treatment must continue unless safety or effectiveness is an issue</para>
								</item>
								<item>
									<label>•</label>
									<para>About reason for use and expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid live vaccines, bring immunizations up to date before treatment
<bbw>To report signs, symptoms of infection, including TB and hepatitis B, to avoid others with infections</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy or suspected pregnancy (C); not to use if breastfeeding, consider using a nonhormonal contraceptive because contraception may be decreased</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="61" status="active">
			<mono_name>tofacitinib</mono_name>
			<info>
				<pronunciation>(toe′fa-sye′ti-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x132180">Xeljanz</tradename>
				</tradenames>
				<class type="func"> Antirheumatic agent (disease modifying), immunomodulator/biologic DMARD</class>
				<class type="chem"> Janus kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x13228">
				<sec_title>Action:</sec_title>
				<para>Affects the signaling pathway of Janus kinase</para>
			</section>
			<section type="uses" id="sidelem4x13233">
				<sec_title>Uses:</sec_title>
				<para>Rheumatoid arthritis (moderately to severely active) in those who have taken methotrexate with inadequate response or intolerance</para>
			</section>
			<section type="contra" id="sidelem4x13238">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x13243">
					<section type="none" id="sidelem4x13244">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, neonates, infants, children, geriatric patients, neoplastic disease, ulcerative colitis, neutropenia, peptic ulcer disease, active infections, risk of lymphomas/leukemias, TB, posttransplant lymphoproliferative disorder (PTLD), kidney disease, diabetes mellitus, HIV, hypercholesterolemia, herpes virus infection reactivation, Asian patients</para>
						<para>
							<bbw>Infection, secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13259">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13267">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13267">
							<item>
								<label>•</label>
								<para> 5 mg bid if receiving potent CYP3A4 inhibitor, then 5 mg/day if receiving moderate CYP3A4 inhibitor and 2C19 inhibitors</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13271">
					<section type="none" id="sidelem4x13272">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5 mg</para>
					</section>
					<section type="none" id="sidelem4x13277">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x13280">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x13284">
									<item>
										<label>•</label>
										<para>Without regard to food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13290">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13293">
					<section type="none" id="sidelem4x13294">
						<sec_title>CNS:</sec_title>
						<para> Headache, paresthesias, insomnia, fatigue</para>
					</section>
					<section type="none" id="sidelem4x13299">
						<sec_title>CV:</sec_title>
						<para> Hypertension</para>
					</section>
					<section type="none" id="sidelem4x13304">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, nausea, <emphasis style="bold">liver damage,</emphasis> dyspepsia, vomiting, diarrhea, gastritis, <emphasis style="bold">GI perforation, steatosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13314">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia,</emphasis> lymphocytosis, lymphopenia, <emphasis style="bold">neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13324">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x13329">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Increased cancer risk, risk of infection (TB, invasive fungal infections, other opportunistic infections), may be fatal, posttransplant lymphoproliferative disorder (PTLD)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13336">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 70%, protein binding 40% (albumin), metabolism mediated by CYP3A4, half-life 3 hr, peak 0.5-1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x13341">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>Do not use with TNF modifiers, vaccines, potent immunosuppressants, other biologic DMARDS</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tofacinib effect—CYP3A4 inhibitors (amprenavir, boceprevir, delavirdine, ketoconazole, indinavir, itraconazole, dalfopristin/quinupristin, ritonavir, tipranavir, fluconazole, isoniazid, miconazole)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> tofacinib effect—CYP3A4 inducers (rifampin, rifapentine, rifabutin, primidone, phenytoin, PHENobarbital, nevirapine, nafcillin, modafinil, griseofulvin, etravirine, efavirenz, barbiturates, bexarotene, bosentan, carBAMazepine, enzalutamide, dexamethasone)</para>
				<section type="none" id="sidelem4x13362">
					<section type="none" id="sidelem4x13363">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, cholesterol</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> neutrophils, lymphocytes, Hct, Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13375">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13378">
					<section type="none" id="sidelem4x13379">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13384">
								<item>
									<label>•</label>
									<para>Monitor lipid profile, Hct/Hgb WBC, LFTs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13392">
							<label>•</label>
							<sec_title>RA</sec_title>
							<para>
								<list id="lidelem4x13392">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">RA:</emphasis> Pain, stiffness, ROM, swelling of joints before, during treatment
<bbw>
												<emphasis alert="lifethreat">Active infection, including localized infection:</emphasis> evaluate and test patients for latent or active TB before use; treat with antimycobacterials before use of product; this product increases the risk of serious including fatal infections (pulmonary or extrapulmonary TB; invasive fungal infections; and bacterial, viral, and opportunistic infections); during and after use, monitor for infection including TB in those who tested negative for latent TB before use; if a serious infection develops, interrupt receipt until the infection is controlled, reactivation of viral infections is higher in Asian patients</bbw>

<bbw>
												<emphasis alert="lifethreat">Secondary malignancy:</emphasis> lymphoma and other malignancies have been noted with product use</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13419">
								<item>
									<para>
										<emphasis alert="nurse">Epstein–Barr virus–associated posttransplant lymphoproliferative disorder (PTLD): in kidney transplant patients when used with this product and immunosupressives</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13427">
							<label>•</label>
							<sec_title>Liver disease</sec_title>
							<para>
								<list id="lidelem4x13427">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Liver disease:</emphasis> not recommended in severe liver disease, impairment; dose modification is needed with moderate liver impairment, monitor LFTs</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13432">
								<item>
									<para>
										<emphasis alert="nurse">GI perforation: assess in those with diverticulitis, peptic ulcer disease, or ulcerative colitis</emphasis>
<bbw>
											<emphasis alert="lifethreat">Immunosuppression:</emphasis> obtain neutrophil and lymphocyte counts before use; do not start the product in lymphocyte count &lt;500 cells/mm3 or ANC &lt;1000 cells/mm3; for ANC &gt;1000 cells/mm3, monitor neutrophil counts after 4-8 wk and every 3 mo thereafter; lymphocyte count &gt;500 cells/mm3, monitor lymphocyte counts every 3 mo</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13461">
								<item>
									<para>
										<emphasis alert="nurse">Anemia: determine Hgb, do not start in Hgb &lt;9 g/dl; in Hgb ≥9 g/dl, monitor Hgb after 4-8 wk and every 3 mo thereafter</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13467">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy (C)/breastfeeding: use during pregnancy only if the potential benefit justifies the potential risk to the fetus; if pregnancy occurs, enrollment in the pregnancy registry is encouraged by calling 1-877-311-8972; discontinue product or breastfeeding; serious adverse reactions can occur in nursing infants</emphasis>
<bbw>Neoplastic disease (lymphomas/leukemias)</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13481">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13485">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation, pain in joints, decreased joint destruction</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13491">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13496">
								<item>
									<label>•</label>
									<para>Not to have vaccines while taking this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13501">
								<item>
									<label>•</label>
									<para>Not to take any live virus vaccines during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13506">
								<item>
									<label>•</label>
									<para>To report signs of infection, allergic reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13512">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy (C): teach patient to report if pregnancy is planned or suspected; do not breastfeed</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="62" status="active">
			<mono_name>tolcapone (Rx)</mono_name>
			<info>
				<pronunciation>(toll′cah′pone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x135220">Tasmar</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> COMT inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x13532">
				<sec_title>Action:</sec_title>
				<para>Inhibits COMT; used as adjunct to levodopa/carbidopa therapy</para>
			</section>
			<section type="uses" id="sidelem4x13537">
				<sec_title>Uses:</sec_title>
				<para>Parkinson’s disease</para>
			</section>
			<section type="contra" id="sidelem4x13542">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, rhabdomyolysis</para>
				<para>
					<bbw>Hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x13557">
					<section type="none" id="sidelem4x13558">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, cardiac/renal disease, hypertension, asthma, history of rhabdomyolysis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13564">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13572">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13572">
							<item>
								<label>•</label>
								<para> 100-200 mg tid with levodopa/carbidopa therapy; max 600 mg/day, discontinue if no benefit after 3 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13576">
					<section type="none" id="sidelem4x13577">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x13582">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13586">
								<item>
									<label>•</label>
									<para>Only to be used if levodopa/carbidopa does not provide satisfactory results</para>
								</item>
								<item>
									<label>•</label>
									<para>Give without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13597">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13600">
					<section type="none" id="sidelem4x13601">
						<sec_title>CNS:</sec_title>
						<para> Dystonia, dyskinesia, dreaming, <emphasis style="italic">fatigue, headache, confusion,</emphasis> psychosis, hallucination, dizziness, sleep disorders</para>
					</section>
					<section type="none" id="sidelem4x13609">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> chest pain, hypotension</para>
					</section>
					<section type="none" id="sidelem4x13617">
						<sec_title>EENT:</sec_title>
						<para> Cataract, eye inflammation</para>
					</section>
					<section type="none" id="sidelem4x13622">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, abdominal distress,</emphasis> diarrhea, constipation, <emphasis style="bold">fatal hepatic failure,</emphasis> increased LFTs</para>
					</section>
					<section type="none" id="sidelem4x13633">
						<sec_title>GU:</sec_title>
						<para> UTI, urine discoloration, uterine tumor, micturition disorder, hematuria</para>
					</section>
					<section type="none" id="sidelem4x13638">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, leukopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13645">
						<sec_title>INTEG:</sec_title>
						<para> Sweating, alopecia</para>
					</section>
					<section type="none" id="sidelem4x13650">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13657">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, peak 2 hr, protein binding 99%, extensively metabolized, half-life 2-3 hr, excreted in urine (60%)/feces (40%)</para>
			</section>
			<section type="interactions" id="sidelem4x13662">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants<list id="lidelem4x13669">
						<item>
							<label>•</label>
							<para>May influence pharmacokinetics of α-methyldopa, DOBUTamine, apomorphine, isoproterenol</para>
						</item>
						<item>
							<label>•</label>
							<para>Inhibition of normal catecholamine metabolism: MAOIs, MAO-B inhibitor may be used</para>
						</item>
					</list></para>
			</section>
			<section type="considerations" id="sidelem4x13680">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13683">
					<section type="none" id="sidelem4x13684">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hepatic disease:</emphasis> AST, ALT, alk phos, LDH, bilirubin, CBC; monitor ALT, AST q2wk × 1 yr, then q4wk × 6 mo, then q8wk thereafter; if LFTs elevated, product should not be used, if no improvement in 3 wk, discontinue</bbw>
						</para>
						<para>
							<list id="lidelem4x13699">
								<item>
									<label>•</label>
									<para>Involuntary movements of parkinsonism: akinesia, tremors, staggering gait, muscle rigidity, drooling</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P, respiration during initial treatment; hypo/hypertension should be reported</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, avoid use in those with dystonia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13715">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13719">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in akathisia, increased mood</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13725">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13730">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13735">
								<item>
									<label>•</label>
									<para>That urine, sweat may change color</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13740">
								<item>
									<label>•</label>
									<para>That food taken within 1 hr before meals or 2 hr after meals decreases action of product by 20%; may be taken without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13745">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected, pregnancy (C)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13750">
								<item>
									<label>•</label>
									<para>That CNS changes may occur, hallucinations, involuntary movement</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13755">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until reaction is known; dizziness may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13763">
							<para>
								<list id="lidelem4x13763">
									<item>
										<label>•</label>
										<para>That nausea and diarrhea are common
<bbw>
												<emphasis alert="lifethreat">To report signs of hepatic injury:</emphasis> clay-colored stools, jaundice, fatigue, appetite loss, lethargy, fatigue, itching, right upper abdominal pain</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13776">
								<item>
									<label>•</label>
									<para>To report nausea, vomiting, anorexia; that nausea may occur at beginning of treatment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="63" status="active">
			<mono_name>tolnaftate topical</mono_name>
			<section type="none" id="sidelem4x13784">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="64" status="active">
			<mono_name>tolterodine (Rx)</mono_name>
			<info>
				<pronunciation>(toll-tehr′oh-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x137941">Detrol</tradename>
					<tradename id="tnidelem4x137940">Detrol LA</tradename>
				</tradenames>
				<class type="func"> Overactive bladder product</class>
				<class type="chem"> Muscarinic receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x13804">
				<sec_title>Action:</sec_title>
				<para>Relaxes smooth muscles in urinary tract by inhibiting acetylcholine at postganglionic sites</para>
			</section>
			<section type="uses" id="sidelem4x13809">
				<sec_title>Uses:</sec_title>
				<para>Overactive bladder (urinary frequency, urgency), urinary incontinence</para>
			</section>
			<section type="contra" id="sidelem4x13814">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, uncontrolled closed-angle glaucoma, urinary retention, gastric retention</para>
				<section type="none" id="sidelem4x13819">
					<section type="none" id="sidelem4x13820">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal/hepatic disease, controlled closed-angle glaucoma, bladder obstruction, QT prolongation, decreased GI motility</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13825">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13833">
					<label>•</label>
					<sec_title>Adult and geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13833">
							<item>
								<label>•</label>
								<para> 2 mg bid; may decrease to 1 mg bid;  4 mg/day, may decrease to 2 mg/day if needed, max 4 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13840">
					<section type="none" id="sidelem4x13841">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x13849">
							<label>•</label>
							<sec_title>Adult<route> PO 1 mg bid (50% dose) or EXT REL 2 mg/day; CCr ≤30 ml/min, reduce by 50%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13852">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2 mg; ext rel caps 2, 4 mg</para>
					</section>
					<section type="none" id="sidelem4x13857">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13861">
								<item>
									<label>•</label>
									<para>Whole; take with liquids; do not crush, chew, or break ext rel product; without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13867">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13870">
					<section type="none" id="sidelem4x13871">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, paresthesia, fatigue, <emphasis style="italic">dizziness, headache;</emphasis> increasing dementia, memory impairment</para>
					</section>
					<section type="none" id="sidelem4x13879">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypertension, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13886">
						<sec_title>EENT:</sec_title>
						<para> Vision abnormalities, xerophthalmia</para>
					</section>
					<section type="none" id="sidelem4x13891">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> abdominal pain, constipation, dry mouth, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x13899">
						<sec_title>GU:</sec_title>
						<para> Dysuria, urinary retention, frequency, UTI</para>
					</section>
					<section type="none" id="sidelem4x13904">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x13909">
						<sec_title>RESP:</sec_title>
						<para> Bronchitis, cough, pharyngitis, upper respiratory tract infection</para>
					</section>
					<section type="none" id="sidelem4x13914">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13921">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; highly protein bound; extensively metabolized by CYP2D6; a portion of the population may be poor metabolizers; excreted in urine, feces</para>
			</section>
			<section type="interactions" id="sidelem4x13926">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x13934">
					<label>•</label>
					<sec_title>
						<route>Do not use in those with known hypersensitivity-festerodine</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x13938">
						<item>
							<para>
								<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of tolterodine—antiretroviral protease inhibitors, macrolide antiinfectives, azole antifungals</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effect—antimuscarinics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> urinary frequency—diuretics</para>
				<section type="none" id="sidelem4x13955">
					<section type="none" id="sidelem4x13956">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x13960">
								<item>
									<label>•</label>
									<para>Food increases bioavailability of tolterodine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13966">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, bilirubin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13973">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13976">
					<section type="none" id="sidelem4x13977">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x13985">
							<label>•</label>
							<sec_title>Urinary patterns</sec_title>
							<para>
								<list id="lidelem4x13985">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urinary patterns:</emphasis> distention, nocturia, frequency, urgency, incontinence</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13990">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin disorders: angioedema, Stevens-Johnson syndrome; allergic reactions: rash; if this occurs, product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13996">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG, ejection fraction; assess for chest pain, palpitations, dyspnea</emphasis>
<bbw>
											<emphasis alert="lifethreat">Fatal hepatic injury:</emphasis> increased LFTs, bilirubin during first 18 mo of therapy in those with autosomal dominant polycystic kidney disease; assess for fatigue, anorexia, right upper abdominal pain, dark urine, jaundice; if these occur, discontinue product and do not restart if cause is liver injury</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14012">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14016">
								<item>
									<label>•</label>
									<para>Decreasing dysuria, frequency, nocturia, incontinence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14022">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14027">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities; dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14032">
								<item>
									<label>•</label>
									<para>Not to drink liquids before bedtime, to swallow ext rel product whole</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14037">
								<item>
									<label>•</label>
									<para>About the importance of bladder maintenance</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14045">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14048">
								<item>
									<label>•</label>
									<para>To report signs of infection, skin effects, shortness of breath, urinary retention</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="65" status="active">
			<mono_name>tolvaptan (Rx)</mono_name>
			<info>
				<pronunciation>(tole-vap′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x140580">Samsca</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Vasopressin receptor antagonist, V2</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x14068">
				<sec_title>Action:</sec_title>
				<para>Arginine vasopressin (AVP) antagonist with affinity for V2 receptors; level of circulating AVP in circulating blood is critical for the regulation of water and the electrolyte balance, and it is usually elevated with euvolemic/hypervolemic hyponatremia</para>
			</section>
			<section type="uses" id="sidelem4x14073">
				<sec_title>Uses:</sec_title>
				<para>Hypervolemic/euvolemic hyponatremia with heart failure, cirrhosis, SIADH</para>
			</section>
			<section type="contra" id="sidelem4x14078">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hypovolemia, anuria</para>
				<section type="none" id="sidelem4x14083">
					<section type="none" id="sidelem4x14084">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breast-feeding, children, dehydration, geriatric, hyperkalemia, autosomal dominant PKD</para>
						<para>
							<bbw>Alcoholism, malnutrition, hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14099">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14107">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14107">
							<item>
								<label>•</label>
								<para> 15 mg daily; after 24 hr, may increase to 30 mg daily; max 60 mg/day for ≤30 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14111">
					<section type="none" id="sidelem4x14112">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 15, 30 mg</para>
					</section>
					<section type="none" id="sidelem4x14117">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14121">
								<item>
									<label>•</label>
									<para>PO with/without food</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid fluid restriction for first 24 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Initiate in hospital setting</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14137">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14140">
					<section type="none" id="sidelem4x14141">
						<sec_title>CNS:</sec_title>
						<para> Fever, dizziness</para>
					</section>
					<section type="none" id="sidelem4x14146">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Ventricular fibrillation, DIC, stroke, thrombosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14153">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, <emphasis style="italic">constipation,</emphasis> colitis, hepatic injury</para>
					</section>
					<section type="none" id="sidelem4x14164">
						<sec_title>GU:</sec_title>
						<para> Polyuria</para>
					</section>
					<section type="none" id="sidelem4x14169">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14176">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Dehydration, hyperglycemia,</emphasis> hyperkalemia, hypernatremia</para>
					</section>
					<section type="none" id="sidelem4x14184">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14191">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression, pulmonary embolism</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14198">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-4 hr, protein binding 99%, metabolized by CYP3A4, terminal half-life 12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x14203">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> concentrations of tolvaptan—CYP3A4 inhibitors (efavirenz, fosamprenavir, quiNINE); P-gp inhibitors (cycloSPORINE, azithromycin, mefloquine, palperidone, propafenone, quiNIDine, testosterone)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> concentration of tolvaptan—CYP3A4 inducers (carBAMazepine, dexamethasone, etravirine, flutamide, griseofulvin, metyrapsone, modafinil, nafacillin, nevirapine, OXcarbazepine, phenytoin, rifampin, rifabutin, rifapendine, topiramate)</para>
				<section type="none" id="sidelem4x14214">
					<section type="none" id="sidelem4x14215">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decreased:</emphasis> tolvaptan effect: CYP3A4 inducer (St. John’s wort)</para>
					</section>
					<section type="none" id="sidelem4x14223">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x14227">
								<item>
									<label>•</label>
									<para>Grapefruit juice: do not use together</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14233">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14236">
					<section type="none" id="sidelem4x14237">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14241">
								<item>
									<label>•</label>
									<para>Renal, hepatic function
<bbw>Malnutrition, alcoholism, frequent sodium vol status; overly rapid correction of sodium concentration (12 mEq/L per 24 hr), may result in osmotic demyelination syndrome, may occur in alcoholism, severe malnutrition, advanced liver disease, syndrome of inappropriate antidiuretic hormone, correct sodium levels slowly</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>CV status: ventricular fibrillation, hypertension; monitor B/P, pulse</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor electrolytes (sodium, potassium)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14266">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14270">
								<item>
									<label>•</label>
									<para>Therapeutic response: correction of serum sodium levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14276">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14281">
								<item>
									<label>•</label>
									<para>To avoid pregnancy, breastfeeding while taking this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14286">
								<item>
									<label>•</label>
									<para>About administration procedure and expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14294">
							<label>•</label>
							<sec_title>
								<route>To report difficulty swallowing, speaking, seizures, dizziness, drowsiness; embolism may be the cause</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14297">
								<item>
									<label>•</label>
									<para>To drink fluid in response to thirst</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14302">
								<item>
									<label>•</label>
									<para>Not to use grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14307">
								<item>
									<label>•</label>
									<para>To notify prescriber before using other products</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="66" status="active">
			<mono_name>topiramate (Rx)</mono_name>
			<info>
				<pronunciation>(toh-pire′ah-mate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x143174">Qudexy XR</tradename>
					<tradename id="tnidelem4x143173">Topamax</tradename>
					<tradename id="tnidelem4x143172">Topamax Sprinkle</tradename>
					<tradename id="tnidelem4x143171">Topiragen</tradename>
					<tradename id="tnidelem4x143170">Trokendi XR</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant—miscellaneous</class>
				<class type="chem"> Monosaccharide derivative</class>
			</info>
			<section type="actions" id="sidelem4x14327">
				<sec_title>Action:</sec_title>
				<para>May prevent seizure spread as opposed to an elevation of seizure threshold, increases GABA activity</para>
			</section>
			<section type="uses" id="sidelem4x14332">
				<sec_title>Uses:</sec_title>
				<para>Partial seizures in adults and children 2-16 yr old; tonic-clonic seizures; seizures with Lennox-Gastaut syndrome; migraine prophylaxis</para>
				<section type="none" id="sidelem4x14337">
					<section type="none" id="sidelem4x14338">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Infantile spasms, bipolar disorder, alcohol dependence, absence seizures, neuropathic pain, cluster headaches, mania, bulimia nervosa</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14343">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, metabolic acidosis, pregnancy (D)</para>
				<section type="none" id="sidelem4x14348">
					<section type="none" id="sidelem4x14349">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, renal/hepatic disease, acute myopia, secondary closed-angle glaucoma, behavioral disorders, COPD, dialysis, encephalopathy, status asthmaticus, status epilepticus, surgery, paresthesias, maculopathy, nephrolithiasis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14354">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14357">
					<section type="none" id="sidelem4x14358">
						<sec_title>Adjunctive therapy for seizures</sec_title>
						<section type="none" id="sidelem4x14366">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14366">
									<item>
										<label>•</label>
										<para> 25-50 mg/day initially, titrate by 25-50 mg/wk, up to 200-400 mg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14373">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14373">
									<item>
										<label>•</label>
										<para> (Qudexy XR, Trokendi XR) 50 mg daily, increase by 50 mg weekly during wk 2, 3, 4, increase by 100 mg weekly, wk 5, 6, final dose 400 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14380">
							<label>•</label>
							<sec_title>Child 2-9 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14380">
									<item>
										<label>•</label>
										<para> week 1: 25 mg in <emphasis style="smallcaps">pm</emphasis>, then 25 mg bid if tolerated (week 2), then increase by 25-50 mg/day each week as tolerated over 5- to 7-wk titration period, maintenance given in 2 divided doses; &lt;11 kg, minimum 150 mg/day, max 250 mg/day; 12-22 kg, minimum 200 mg/day, max 300 mg/day; 23-31 kg, minimum 200 mg/day, max 350 mg/day; 32-38 kg, minimum 250 mg/day, max 350 mg/day; &gt;38 kg, minimum 250 mg/day, max 400 mg/day; Qudexy XR 25 mg daily at night, may increase to 50 mg wk 2, if tolerated, increase by 25-50 mg each wk over 5- to 7-wk titration period, max dose based on weight</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14390">
							<label>•</label>
							<sec_title>Child ≤11 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14390">
									<item>
										<label>•</label>
										<para> Qudexy XR minimum 150 mg daily, max 250 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14397">
							<label>•</label>
							<sec_title>Child 12-22 kg</sec_title>
							<para>
								<list id="lidelem4x14397">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child 12-22 kg:</emphasis> minimum 200 mg daily, max 300 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14405">
							<label>•</label>
							<sec_title>Child 23-31 kg</sec_title>
							<para>
								<list id="lidelem4x14405">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child 23-31 kg:</emphasis> minimum 200 mg daily, max 350 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14412">
							<label>•</label>
							<sec_title>Child 32-38 kg</sec_title>
							<para>
								<list id="lidelem4x14412">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child 32-38 kg:</emphasis> minimum 250 mg daily, max 350 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14419">
							<label>•</label>
							<sec_title>Child &gt;38 kg</sec_title>
							<para>
								<list id="lidelem4x14419">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child &gt;38 kg:</emphasis> minimum 250 mg daily, max 400 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14423">
						<sec_title>Migraine prophylaxis</sec_title>
						<section type="none" id="sidelem4x14431">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14431">
									<item>
										<label>•</label>
										<para> 25 mg/day initially, increase by 25 mg/day/wk up to 100 mg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14435">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x14443">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;70 ml/min, give 1⁄2 dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14452">
						<sec_title>Atonic/atypical absence/myoclonic seizures (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14460">
							<label>•</label>
							<sec_title>Adult/adolescent &gt;16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14460">
									<item>
										<label>•</label>
										<para> 50 mg/day, titrate slowly by 50 mg/wk to 100-300 mg tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14467">
							<label>•</label>
							<sec_title>Child 2-16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14467">
									<item>
										<label>•</label>
										<para> 0.5-1 mg/kg, max 25 mg, initially daily × 7 days, then increase by 0.5-1 mg/kg/day weekly up to 3-6 mg/kg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14471">
						<sec_title>Refractory infantile spasms (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14479">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14479">
									<item>
										<label>•</label>
										<para> 25 mg/day, may increase by 25 mg q2-3days until spasms controlled, max 24 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14483">
						<sec_title>Alcoholism (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14491">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14491">
									<item>
										<label>•</label>
										<para> 25 mg/day, titrated to max 300 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14495">
						<sec_title>Neuropathic pain (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14503">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14503">
									<item>
										<label>•</label>
										<para> 12.5-25 mg daily or bid × 4 wk, then double dose q4wk to max 100-200 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14507">
						<sec_title>Bipolar disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14515">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14515">
									<item>
										<label>•</label>
										<para> 25 mg/day, then increase by 25-mg increments to 200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14519">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100, 200 mg; sprinkle caps 15, 25 mg; ext rel caps 25, 50, 100, 200 mg; ext rel cap (sprinkles 24 hr) 25, 50, 100, 150, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x14524">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14528">
								<item>
									<label>•</label>
									<para>Swallow tabs whole; do not break, crush, or chew tabs; very bitter</para>
								</item>
								<item>
									<label>•</label>
									<para>May take without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Sprinkle cap can be given whole or opened and sprinkled on soft food; do not chew, drink water after sprinkle</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature away from heat, light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14549">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14552">
					<section type="none" id="sidelem4x14553">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, fatigue</emphasis>, cognitive disorders, insomnia, <emphasis style="italic">anxiety</emphasis>, depression, paresthesia, <emphasis style="italic">memory loss, tremors,</emphasis> motor retardation, <emphasis style="bold">suicidal ideation,</emphasis> poor balance, ataxia</para>
					</section>
					<section type="none" id="sidelem4x14570">
						<sec_title>CV:</sec_title>
						<para> Flushing, chest pain</para>
					</section>
					<section type="none" id="sidelem4x14575">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, <emphasis style="italic">vision abnormality</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14582">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, <emphasis style="italic">anorexia, nausea, dyspepsia</emphasis>, abdominal pain, constipation, dry mouth, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14592">
						<sec_title>GU:</sec_title>
						<para> Breast pain, dysmenorrhea, menstrual disorder</para>
					</section>
					<section type="none" id="sidelem4x14597">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia</para>
					</section>
					<section type="none" id="sidelem4x14602">
						<sec_title>MISC:</sec_title>
						<para> Weight loss, leukopenia, metabolic acidosis, increased body temperature; <emphasis style="bold">unexplained death (epilepsy)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14609">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory tract infection, pharyngitis, sinusitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14614">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, peak 2 hr, terminal half-life 19-25 hr, excreted in urine (55%-97% unchanged), crosses placenta, excreted in breast milk, protein binding (9%-17%), steady-state 4 days</para>
			</section>
			<section type="interactions" id="sidelem4x14619">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> renal stones—carbonic anhydrase inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of amitriptyline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> topiramate levels—metformin, hydrochlorothiazide, lamoTRIgine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of oral contraceptives, estrogen, digoxin, valproic acid, lithium, risperiDONE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> topiramate levels—phenytoin, carBAMazepine, valproic acid, probenecid</para>
			</section>
			<section type="considerations" id="sidelem4x14646">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14649">
					<section type="none" id="sidelem4x14650">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x14658">
							<label>•</label>
							<sec_title>Seizures</sec_title>
							<para>
								<list id="lidelem4x14658">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Seizures:</emphasis> location, type, duration, aura</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14665">
							<label>•</label>
							<sec_title>Bipolar disorder</sec_title>
							<para>
								<list id="lidelem4x14665">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bipolar disorder:</emphasis> mood, behavior</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x14669">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, urine creatinine, electrolytes q3mo; symptoms of renal colic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14674">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin if patient receiving long-term treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14680">
								<item>
									<label>•</label>
									<para>CBC during long-term therapy (anemia); serum bicarbonate (metabolic acidosis)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14685">
								<item>
									<label>•</label>
									<para>Migraines: pain location, duration; alleviating factors</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14691">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14696">
								<item>
									<label>•</label>
									<para>Body weight, evidence of cognitive disorder</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14701">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during early part of treatment; dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14706">
								<item>
									<label>•</label>
									<para>Seizure precautions: padded side rails, move objects that may harm patient</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14711">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14715">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14721">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14726">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name, and phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14731">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness, until response is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14736">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14744">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately of blurred vision, periorbital pain, vision loss may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14747">
								<item>
									<label>•</label>
									<para>To maintain adequate fluid intake</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14752">
								<item>
									<label>•</label>
									<para>About administration procedure and expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14760">
							<label>•</label>
							<sec_title>
								<route>To use nonhormonal contraceptive; that effect of oral contraceptives is decreased, pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14763">
								<item>
									<label>•</label>
									<para>To drink plenty of fluids to prevent kidney stones</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14768">
								<item>
									<label>•</label>
									<para>May need to increase amount of food consumed; weight loss may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14773">
								<item>
									<label>•</label>
									<para>To swallow ext rel product whole</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="67" status="active" ha="yes">
			<mono_name> topotecan (Rx)</mono_name>
			<info>
				<pronunciation>(toh-poh-tee′kan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x147850">Hycamtin</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, natural; topoisomerase inhibitor</class>
				<class type="chem"> Camptothecin analog</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x14795">
				<sec_title>Action:</sec_title>
				<para>Antitumor product with topoisomerase-I–inhibitory activity; topoisomerase I relieves torsional strain in DNA by causing single-strand breaks; also causes double-strand DNA damage</para>
			</section>
			<section type="uses" id="sidelem4x14800">
				<sec_title>Uses:</sec_title>
				<para>Metastatic ovarian cancer after failure of traditional chemotherapy; relapsed small-cell lung cancer; cervical cancer</para>
				<section type="none" id="sidelem4x14805">
					<section type="none" id="sidelem4x14806">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Non–small-cell lung cancer (NSCLC), rhabdomyosarcoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14811">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, severe bone marrow depression</para>
				<para>
					<bbw>Neutropenia</bbw>
				</para>
				<section type="none" id="sidelem4x14826">
					<section type="none" id="sidelem4x14827">
						<sec_title>Precautions:</sec_title>
						<para> Children, renal disease, gelatin hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14832">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14835">
					<section type="none" id="sidelem4x14836">
						<sec_title>Metastatic carcinoma of the ovary after failure of first or subsequent chemotherapy; SCLC-sensitive disease after failure of first-line therapy</sec_title>
						<section type="none" id="sidelem4x14844">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x14844">
									<item>
										<label>•</label>
										<para> 1.5 mg/m<emphasis style="sup">2</emphasis> over 30 min daily × 5 days starting on day 1 of 21-day course × 4 courses; may be reduced to 0.25 mg/m<emphasis style="sup">2</emphasis> for subsequent courses if severe neutropenia occurs; relapsed small-cell lung cancer (SCLC) in those with a prior complete or partial response, ≥45 days from end of first-line treatment;  2.3 mg/m<emphasis style="sup">2</emphasis>/day on days 1-5 of 21-day course</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14861">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x14869">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 20-39 ml/min, 0.75 mg/m2/day × 5 days starting on day 1 of 21-day course</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14875">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder for inj 4 mg; caps 0.25, 1 mg</para>
					</section>
					<section type="none" id="sidelem4x14880">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14884">
								<item>
									<label>•</label>
									<para>Store caps in refrigerator; IV INFUSION unopened at room temperature; protect both from light</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14890">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x14894">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew, or open caps; protect from light</para>
									</item>
									<item>
										<label>•</label>
										<para>Take without regard to food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14905">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x14909">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute each 4-mg vial with 4 ml sterile water for injection; use immediately; no preservative</para>
									</item>
									<item>
										<label>•</label>
										<para>Withdraw the appropriate volume of the reconstituted solution; dilute further; dilute in 0.9% NaCl or D5W before administration</para>
									</item>
									<item>
										<label>•</label>
										<para>The reconstituted solution is yellow or yellow-green</para>
									</item>
									<item>
										<label>•</label>
										<para>Topotecan injection diluted for infusion is stable at room temperature with normal light for 24 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse over 30 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14940">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14943">
					<section type="none" id="sidelem4x14944">
						<sec_title>CNS:</sec_title>
						<para> Arthralgia, <emphasis style="italic">asthenia, headache,</emphasis> myalgia, <emphasis style="italic">pain,</emphasis> weakness</para>
					</section>
					<section type="none" id="sidelem4x14955">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, constipation,</emphasis> diarrhea, obstruction, <emphasis style="italic">nausea,</emphasis> stomatitis, <emphasis style="italic">vomiting;</emphasis> increased ALT, AST; anorexia</para>
					</section>
					<section type="none" id="sidelem4x14969">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, thrombocytopenia, anemia, sepsis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14976">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Total alopecia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14983">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough, <emphasis style="bold">interstitial lung disease</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14990">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly and completely absorbed, excreted in urine and feces as metabolites, half-life 2.8 hr, 7%-35% bound to plasma proteins</para>
			</section>
			<section type="interactions" id="sidelem4x14995">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x14999">
						<item>
							<label>•</label>
							<para>Avoid use with P-glycoprotein, breast cancer resistance protein inhibitors (amiodarone, clarithromycin, diltiazem, erythromycin, indinavir), quiNIDine, testosterone, verapamil, tamoxifen, itraconazole, mefloquine, RU-486, niCARdipine, vaccines, toxoids</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression when used with CISplatin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, thrombolytics, platelet inhibitors</para>
				<section type="none" id="sidelem4x15013">
					<section type="none" id="sidelem4x15014">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x15018">
								<item>
									<label>•</label>
									<para>Avoid use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15024">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15027">
					<section type="none" id="sidelem4x15028">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x15033">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, alk phos, which may be elevated; creatinine, BUN
<bbw>CBC, differential, platelet count weekly; withhold product if WBC is &lt;3500/mm3 or platelet count is &lt;100,000/mm3; notify prescriber of results; product should be discontinued</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15053">
								<item>
									<label>•</label>
									<para>Buccal cavity for dryness, sores or ulcerations, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15061">
							<label>•</label>
							<sec_title>Interstitial lung disease (ILD)<route> fever, cough, dyspnea, hypoxia, may be fatal</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x15064">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent dehydration unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15069">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicator for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15074">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15078">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15084">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15089">
								<item>
									<label>•</label>
									<para>That total alopecia may occur; that hair grows back but is different in color and texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15094">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid or hot or rough texture if stomatitis is present; to drink adequate fluids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15099">
								<item>
									<label>•</label>
									<para>To report stomatitis and any bleeding, white spots, ulcerations in mouth; to examine mouth daily; to report symptoms
<bbw>To report signs of anemia: fatigue, headache, faintness, SOB, irritability</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15116">
							<label>•</label>
							<sec_title>
								<route>To use effective contraception during treatment and for ≤6 mo after, pregnancy (D); to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15119">
								<item>
									<label>•</label>
									<para>To avoid OTC products without approval of prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15124">
								<item>
									<label>•</label>
									<para>To avoid driving or other activities requiring alertness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15129">
								<item>
									<label>•</label>
									<para>To avoid vaccines, toxoids</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="68" status="active" ru="yes">
			<mono_name> toremifene (Rx)</mono_name>
			<info>
				<pronunciation>(tor-em′ih-feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x151410">Fareston</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Antiestrogen hormone</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="uses" id="sidelem4x15151">
				<sec_title>Uses:</sec_title>
				<para>Advanced breast carcinoma not responsive to other therapy in estrogen-receptor–positive patients (usually postmenopausal)</para>
			</section>
			<section type="contra" id="sidelem4x15156">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, history of thromboembolism</para>
				<para>
					<bbw>QT prolongation</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x15171">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15179">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15179">
							<item>
								<label>•</label>
								<para> 60 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15183">
					<section type="none" id="sidelem4x15184">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 60 mg</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="69" status="active">
			<mono_name>torsemide (Rx)</mono_name>
			<info>
				<pronunciation>(tor′suh-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x151940">Demadex</tradename>
				</tradenames>
				<class type="func"> Loop diuretic</class>
				<class type="chem"> Sulfonamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x15204">
				<sec_title>Action:</sec_title>
				<para>Acts on loop of Henle by inhibiting absorption of chloride, sodium, water</para>
			</section>
			<section type="uses" id="sidelem4x15209">
				<sec_title>Uses:</sec_title>
				<para>Treatment of hypertension and edema with CHF, ascites</para>
			</section>
			<section type="contra" id="sidelem4x15214">
				<sec_title>Contraindications:</sec_title>
				<para>Infants, hypersensitivity to sulfonamides, anuria</para>
				<section type="none" id="sidelem4x15219">
					<section type="none" id="sidelem4x15220">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, diabetes mellitus, dehydration, severe renal disease, electrolyte depletion, hypovolemia, syncope, ventricular dysrhythmias</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15225">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15228">
					<section type="none" id="sidelem4x15229">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x15237">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x15237">
									<item>
										<label>•</label>
										<para> 10-20 mg/day, may increase as needed, max 200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15241">
						<sec_title>Edema in chronic renal failure</sec_title>
						<section type="none" id="sidelem4x15249">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x15249">
									<item>
										<label>•</label>
										<para> 20 mg/day, may increase to 200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15253">
						<sec_title>Hepatic cirrhosis in combination with aldosterone antagonist/potassium-sparing diuretic</sec_title>
						<section type="none" id="sidelem4x15261">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x15261">
									<item>
										<label>•</label>
										<para> 5-10 mg/day, may increase as needed, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15265">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x15273">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15273">
									<item>
										<label>•</label>
										<para> 5 mg/day, may increase to 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15277">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20, 100 mg; inj 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x15282">
						<sec_title>Administer:</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x15286">
						<sec_title>PO route</sec_title>
						<para>
							<list id="lidelem4x15290">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep if using product as diuretic</para>
								</item>
								<item>
									<label>•</label>
									<para>With food or milk if nausea occurs; absorption may be decreased slightly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15304">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x15308">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Give either slowly as an IV bolus or as a continuous IV infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Ampules are single-use containers; discard any unused portion after opening</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15324">
							<sec_title>IV bolus</sec_title>
							<para>
								<list id="lidelem4x15328">
									<item>
										<label>•</label>
										<para>No dilution is necessary if given as a slow IV injection; give over 2 min</para>
									</item>
									<item>
										<label>•</label>
										<para>If administered through an IV line, flush the line with 0.9% sodium chloride for injection before and after administration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15339">
							<sec_title>Continuous IV INFUSION</sec_title>
							<para>
								<list id="lidelem4x15343">
									<item>
										<label>•</label>
										<para>If administered through an IV line, flush the line with 0.9% sodium chloride for injection before and after use</para>
									</item>
									<item>
										<label>•</label>
										<para>Stable for 24 hr at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15355">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15358">
					<section type="none" id="sidelem4x15359">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> asthenia, insomnia, nervousness</para>
					</section>
					<section type="none" id="sidelem4x15367">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, chest pain, ECG changes, <emphasis style="bold">circulatory collapse,</emphasis> ventricular tachycardia, edema</para>
					</section>
					<section type="none" id="sidelem4x15375">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Loss of hearing,</emphasis> ear pain, tinnitus, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x15383">
						<sec_title>ELECT:</sec_title>
						<para> <emphasis style="italic">Hypokalemia, hypochloremic alkalosis, hyponatremia,</emphasis> metabolic alkalosis</para>
					</section>
					<section type="none" id="sidelem4x15391">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="italic">Hyperglycemia, hyperuricemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15398">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> diarrhea, dyspepsia, cramps, constipation</para>
					</section>
					<section type="none" id="sidelem4x15406">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Polyuria,</emphasis><emphasis style="bold">renal failure,</emphasis> glycosuria</para>
					</section>
					<section type="none" id="sidelem4x15416">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> photosensitivity, pruritus</para>
					</section>
					<section type="none" id="sidelem4x15424">
						<sec_title>MS:</sec_title>
						<para> Cramps, stiffness</para>
					</section>
					<section type="none" id="sidelem4x15429">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, cough increase</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15434">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x15437">
					<section type="none" id="sidelem4x15438">
						<sec_title>PO:</sec_title>
						<para> Rapidly absorbed; duration 6 hr; breast milk; crosses placenta; half-life 3.5 hr; protein binding 97%-99%, cleared through hepatic metabolism</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x15443">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—lithium, nondepolarizing skeletal muscle relaxants, digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of antihypertensives, oral anticoagulants, nitrates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ototoxicity—aminoglycosides, CISplatin, vancomycin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect of torsemide—indomethacin, carBAMazepine, PHENobarbital, phenytoin, rifampin, NSAIDs</para>
				<section type="none" id="sidelem4x15462">
					<section type="none" id="sidelem4x15463">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x15467">
								<item>
									<label>•</label>
									<para>Severe photosensitivity: St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15473">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine, uric acid, blood glucose, cholesterol</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, magnesium, chloride sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15484">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15487">
					<section type="none" id="sidelem4x15488">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x15493">
								<item>
									<label>•</label>
									<para>Hearing when giving high doses</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15498">
								<item>
									<label>•</label>
									<para>Weight, I&amp;O daily to determine fluid loss; effect of product may be decreased if used daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15503">
								<item>
									<label>•</label>
									<para>B/P lying, standing; postural hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15508">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chlorine; include BUN, blood glucose, CBC, serum creatinine, blood pH, ABGs, uric acid, calcium, magnesium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15513">
								<item>
									<label>•</label>
									<para>Glucose in urine of diabetic patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15521">
							<label>•</label>
							<sec_title>Metabolic alkalosis</sec_title>
							<para>
								<list id="lidelem4x15521">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Metabolic alkalosis:</emphasis> drowsiness, restlessness</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15528">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x15528">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> postural hypotension, malaise, fatigue, tachycardia, leg cramps, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15532">
								<item>
									<label>•</label>
									<para>Rashes, temperature elevation daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15537">
								<item>
									<label>•</label>
									<para>Confusion, especially in geriatric patients; take safety precautions if needed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15542">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15546">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in edema of feet, legs, sacral area daily if medication is being used with CHF</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15552">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15556">
								<item>
									<label>•</label>
									<para>To rise slowly from lying, sitting position</para>
								</item>
								<item>
									<label>•</label>
									<para>To recognize adverse reactions: muscle cramps, weakness, nausea, dizziness, tinnitus</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with food or milk for GI symptoms; to limit alcohol use</para>
								</item>
								<item>
									<label>•</label>
									<para>To take early during the day to prevent nocturia</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunscreen, protective clothing to prevent sunburn</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x15582">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if taken orally; monitor electrolytes; administer dextrose in saline; monitor hydration, CV, renal status</para>
			</section>
		</monograph>
<monograph id="70" status="active">
			<mono_name>traMADol (Rx)</mono_name>
			<info>
				<pronunciation>(tram′a-dole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x155923">ConZip</tradename>
					<tradename id="tnidelem4x155922">Ultram</tradename>
					<tradename id="tnidelem4x155921">Ultram ER</tradename>
					<tradename id="tnidelem4x155920">
						<country code="CAN">Zytram </country>
					</tradename>
				</tradenames>
				<class type="func"> Analgesic—miscellaneous</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x15600">
				<para>
					<confusion>
						<tradename id="tnidelem4x156000">traMADol</tradename>
						<drug type="generic" refid="idelem4x156000">Toradol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x15604">
				<sec_title>Action:</sec_title>
				<para>Binds to μ-opioid receptors, inhibits reuptake of norepinephrine, serotonin</para>
			</section>
			<section type="uses" id="sidelem4x15610">
				<sec_title>Uses:</sec_title>
				<para>Management of moderate to severe pain, chronic pain</para>
				<section type="none" id="sidelem4x15615">
					<section type="none" id="sidelem4x15616">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Restless leg syndrome (RLS), postoperative shivering, arthralgia/myalgia, bone/dental/neuropathic pain, headache, osteoarthritis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15621">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, acute intoxication with any CNS depressant, alcohol, asthma, respiratory depression</para>
				<section type="none" id="sidelem4x15626">
					<section type="none" id="sidelem4x15627">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, seizure disorder, renal/hepatic disease, respiratory depression, head trauma, increased intracranial pressure, acute abdominal condition, drug abuse, depression, suicidal ideation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15632">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15635">
					<section type="none" id="sidelem4x15636">
						<sec_title>Mild to moderate pain</sec_title>
						<section type="none" id="sidelem4x15644">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15644">
									<item>
										<label>•</label>
										<para> 25 mg daily, titrate by 25 mg ≥3 days to 100 mg/day (25 mg qid), then may increase by 50 mg ≥3 days to 200 mg (50 mg qid), then 50-100 mg q4-6hr, max 400 mg/day, use caution in geriatric patients</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15651">
							<label>•</label>
							<sec_title>Geriatric &gt;75 years<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15651">
									<item>
										<label>•</label>
										<para>&lt;300 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15655">
						<sec_title>Moderate to severe chronic pain</sec_title>
						<section type="none" id="sidelem4x15663">
							<label>•</label>
							<sec_title>Adult<route> PO-ER</route></sec_title>
							<para>
								<list id="lidelem4x15663">
									<item>
										<label>•</label>
										<para> (Ultram ER) 100 mg daily, titrate upward q5days in 100-mg increments, max 300 mg/day; (Ryzolt) 100 mg, titrate upward q2-3days in 100-mg increments, max 300 mg/day; products are not interchangeable</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15667">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x15675">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, give q12hr, max 200 mg/day; do not use ext rel tab</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15678">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x15686">
							<label>•</label>
							<sec_title>Adult (Child-Pugh C)<route> PO 50 mg q12hr; do not use ext rel tab</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15689">
						<sec_title>Restless leg syndrome (RLS) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x15697">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15697">
									<item>
										<label>•</label>
										<para> 50-150 mg/day × 15-24 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15701">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50 mg; ext rel tab 100, 200, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x15706">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x15714">
							<label>•</label>
							<sec_title>
								<route>Some ext rel products (Ultram ER) are not interchangeable</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15717">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15722">
								<item>
									<label>•</label>
									<para>With antiemetic for nausea, vomiting</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15727">
								<item>
									<label>•</label>
									<para>When pain is beginning to return; determine dosage interval by patient response</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15732">
								<item>
									<label>•</label>
									<para>With or without food; ER: always give with food, or always give on empty stomach</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15737">
								<item>
									<label>•</label>
									<para>Store in cool environment; protected from sunlight</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15742">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15745">
					<section type="none" id="sidelem4x15746">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, CNS stimulation, somnolence, headache, anxiety, confusion, euphoria, <emphasis style="bold">seizures,</emphasis> hallucinations, sedation, <emphasis style="bold">neuroleptic-malignant-syndrome–like reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15756">
						<sec_title>CV:</sec_title>
						<para> Vasodilation, orthostatic hypotension, tachycardia, hypertension, abnormal ECG</para>
					</section>
					<section type="none" id="sidelem4x15761">
						<sec_title>EENT:</sec_title>
						<para> Visual disturbances</para>
					</section>
					<section type="none" id="sidelem4x15766">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, vomiting, dry mouth, diarrhea, abdominal pain, anorexia, flatulence, <emphasis style="bold">GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15773">
						<sec_title>GU:</sec_title>
						<para> Urinary retention/frequency, menopausal symptoms, dysuria, menstrual disorder</para>
					</section>
					<section type="none" id="sidelem4x15778">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash, urticaria, vesicles, flushing</para>
					</section>
					<section type="none" id="sidelem4x15783">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis,</emphasis> serotonin syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15791">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly and almost completely absorbed, steady-state 2 days, peak 1.5 hr, duration 6 hr, terminal half-life 7.9-8.8 hr, may cross blood-brain barrier, extensively metabolized, 30% excreted in urine as unchanged product, protein binding 20%</para>
			</section>
			<section type="interactions" id="sidelem4x15796">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x15800">
						<item>
							<label>•</label>
							<para>Inhibition of norepinephrine and serotonin reuptake: MAOIs; use together with caution</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, sedatives, hypnotics, opiates</para>
				<para>
					<emphasis alert="nurse">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin-receptor agonists</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> traMADol levels—CYP3A4 inhibitors (aprepitant, antiretroviral protease inhibitors, clarithromycin, danazol, delavirdine, diltiazem, erythromycin, fluconazole, FLUoxetine, fluvoxaMINE, imatinib, ketoconazole, mibefradil, nefazodone, telithromycin, voriconazole)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> traMADol effects—CYP3A4 inducers (barbiturates, bosentan, carBAMazepine, efavirenz, phenytoins, nevirapine, rifabutin, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of traMADol—carBAMazepine</para>
				<section type="none" id="sidelem4x15828">
					<section type="none" id="sidelem4x15829">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x15833">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—chamomile, hops, kava, skullcap, valerian</para>
					</section>
					<section type="none" id="sidelem4x15843">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatinine, hepatic enzymes</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15854">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15857">
					<section type="none" id="sidelem4x15858">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15866">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x15866">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, type, character, give before pain becomes extreme</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15873">
							<label>•</label>
							<sec_title>Respiratory depression</sec_title>
							<para>
								<list id="lidelem4x15873">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory depression:</emphasis> withhold if respirations &lt;12/min</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15877">
								<item>
									<label>•</label>
									<para>I&amp;O ratio: check for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15882">
								<item>
									<label>•</label>
									<para>Need for product; dependency</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15887">
								<item>
									<label>•</label>
									<para>Bowel pattern; for constipation, increase fluids, bulk in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15892">
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15900">
							<label>•</label>
							<sec_title>Hypersensitivity<route> usually after beginning treatment</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x15903">
								<item>
									<label>•</label>
									<para>Increased side effects in renal/hepatic disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15909">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome, neuroleptic malignant syndrome: increased heart rate, shivering, sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15914">
								<item>
									<label>•</label>
									<para>Assistance with ambulation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15919">
								<item>
									<label>•</label>
									<para>Safety measures: side rails, night-light, call bell within easy reach</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15924">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15928">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15934">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15938">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions, serotonin syndrome, seizures</para>
								</item>
								<item>
									<label>•</label>
									<para>That drowsiness, dizziness, and confusion may occur; to avoid hazardous activities</para>
								</item>
								<item>
									<label>•</label>
									<para>To make position changes slowly because orthostatic hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications, herbs, supplements, CNS depressants, and alcohol unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue abruptly, taper</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="71" status="active" ha="yes">
			<mono_name> trametinib</mono_name>
			<info>
				<pronunciation>(tra-me′ti-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x159710">MeKinist</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic response modifiers</class>
				<class type="chem"> Signal transduction inhibitors (STIs), tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x15981">
				<sec_title>Action:</sec_title>
				<para>Inhibits MEK-1, MEK-2 tyrosine kinase created in patients with malignant melanoma</para>
			</section>
			<section type="uses" id="sidelem4x15986">
				<sec_title>Uses:</sec_title>
				<para>Unresectable or metastatic BRAD V600E or BRAF V600K mutated malignant melanoma</para>
			</section>
			<section type="contra" id="sidelem4x15991">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x15996">
					<section type="none" id="sidelem4x15997">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, diarrhea, geriatric patients, hepatic disease, bone marrow suppression, infection, thrombocytopenia, neutropenia, immunosuppression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16002">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16005">
					<section type="none" id="sidelem4x16006">
						<sec_title>Unresectable or metastatic malignant melanoma (BRAF V600E or V600K mutations) as a single agent</sec_title>
						<section type="none" id="sidelem4x16014">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16014">
									<item>
										<label>•</label>
										<para> 2 mg daily; may be used in combination with dacarbazine or PACLitaxel in those with BRAF V600E</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x16019">
					<section type="none" id="sidelem4x16020">
						<sec_title>Unresectable or metastatic malignant melanoma (BRAF V600E or V600K mutations) in combination with dabrafenib</sec_title>
						<section type="none" id="sidelem4x16028">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16028">
									<item>
										<label>•</label>
										<para> 2 mg daily with dabrafenib 150 mg q12hr until disease progression, take both at same time</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x16032">
					<section type="none" id="sidelem4x16033">
						<sec_title>Management of treatment-related toxicity</sec_title>
						<section type="none" id="sidelem4x16036">
							<sec_title>Cutaneous toxicity:</sec_title>
							<section type="none" id="sidelem4x16044">
								<label>•</label>
								<sec_title>Grade 2 rash<route> reduce dose by 0.5 mg (e.g., 2 mg/day to 1.5 mg/day) or discontinue in patients who are receiving trametinib 1 mg/day; in patients with an intolerable grade 2 rash that does not improve within 3 wk of a dosage reduction, withhold trametinib for up to 3 wk; if the rash is improved within 3 wk, resume therapy at a lower dose (reduce the previous dose by 0.5 mg); discontinue in patients who are receiving trametinib 1 mg/day; if the rash does not improve within 3 wk, permanently discontinue</route></sec_title>
							</section>
							<section type="none" id="sidelem4x16052">
								<label>•</label>
								<sec_title>Grade 3 or 4 rash<route> withhold for up to 3 wk; if the rash is improved within 3 wk, resume at a lower dose (reduce the previous dose by 0.5 mg); discontinue in patients who are receiving trametinib 1 mg/day; if the rash does not improve within 3 wk, permanently discontinue therapy</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x16057">
							<sec_title>Cardiac toxicity:</sec_title>
							<section type="none" id="sidelem4x16065">
								<label>•</label>
								<sec_title>Asymptomatic cardiac toxicity and an absolute decrease in LVEF of ≥10% from baseline and is below institutional lower limits of normal (LLN) from pretreatment value<route> withhold for up to 4 wk; if the LVEF is improved within 4 wk, resume at a lower dose (reduce the previous dose by 0.5 mg); discontinue in patients who are receiving 1 mg/day; if the LVEF does not improve to normal within 4 wk, permanently discontinue</route></sec_title>
							</section>
							<section type="none" id="sidelem4x16071">
								<label>•</label>
								<sec_title>Symptomatic CHF or an absolute decrease in LVEF of &gt;20% from baseline and is below institutional LLN<route> permanently discontinue</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x16074">
							<sec_title>Ocular toxicity:</sec_title>
							<section type="none" id="sidelem4x16082">
								<label>•</label>
								<sec_title>Grade 2 or 3 retinal pigment epithelial detachment (RPED)<route> withhold for up to 3 wk; if the RPED improves to grade 1 or less within 3 wk, resume at a lower dose (reduce the previous dose by 0.5 mg); discontinue therapy in patients who are receiving 1 mg/day; if the RPED does not improve to at least grade 1 within 3 wk, permanently discontinue</route></sec_title>
							</section>
							<section type="none" id="sidelem4x16090">
								<label>•</label>
								<sec_title>Retinal vein occlusion<route> permanently discontinue therapy</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x16093">
							<sec_title>Pulmonary toxicity</sec_title>
							<section type="none" id="sidelem4x16101">
								<label>•</label>
								<sec_title>Interstitial lung disease/pneumonitis<route> permanently discontinue</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x16104">
							<sec_title>Other toxicity:</sec_title>
							<section type="none" id="sidelem4x16112">
								<label>•</label>
								<sec_title>Grade 3 toxicity<route> withhold for up to 3 wk</route></sec_title>
							</section>
							<section type="none" id="sidelem4x16120">
								<label>•</label>
								<sec_title>Grade 4 toxicity<route> permanently discontinue</route></sec_title>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x16125">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 2 mg</para>
					</section>
					<section type="none" id="sidelem4x16130">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16134">
								<item>
									<label>•</label>
									<para>Give 1 hr before or 2 hr after a meal</para>
								</item>
								<item>
									<label>•</label>
									<para>If dose is missed, take within 12 hr of missed dose; if &gt;12 hr have passed, skip dose</para>
								</item>
								<item>
									<label>•</label>
									<para>Follow cytotoxic handling procedures</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16150">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16153">
					<section type="none" id="sidelem4x16154">
						<sec_title>CNS:</sec_title>
						<para> Dizziness</para>
					</section>
					<section type="none" id="sidelem4x16159">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure,</emphasis> hypertension, cardiomyopathy</para>
					</section>
					<section type="none" id="sidelem4x16167">
						<sec_title>EENT:</sec_title>
						<para> Ocular hemorrhage, retinal detachment, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x16172">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, vomiting, abdominal pain, stomatitis</para>
					</section>
					<section type="none" id="sidelem4x16177">
						<sec_title>GU:</sec_title>
						<para> Hematuria</para>
					</section>
					<section type="none" id="sidelem4x16182">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, acne, folliculitis, erythema</para>
					</section>
					<section type="none" id="sidelem4x16187">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16194">
						<sec_title>OTHER:</sec_title>
						<para> Elevated LFTs, <emphasis style="bold">hand-foot syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16201">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, <emphasis style="bold">pleural effusion,</emphasis> pneumonitis, edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16209">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 97.4%, peak 1.5 hr, excreted in feces</para>
			</section>
			<section type="interactions" id="sidelem4x16214">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x16218">
						<item>
							<label>•</label>
							<para>None known</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x16224">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16227">
					<section type="none" id="sidelem4x16228">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16232">
								<item>
									<label>•</label>
									<para>LFTs every mo ×3 mo, then as clinically indicated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16238">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16242">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in progression of disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16248">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16253">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately, bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16258">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16266">
							<label>•</label>
							<sec_title>
								<route>To use effective contraception during treatment and up to 30 days after discontinuing treatment</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="72" status="active">
			<mono_name>trandolapril (Rx)</mono_name>
			<info>
				<pronunciation>(tran-doe′la-prill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x162740">Mavik</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotension-converting enzyme inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x16284">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE; prevents conversion of angiotensin I to angiotensin II, dilates arterial and venous vessels, lowers B/P</para>
			</section>
			<section type="uses" id="sidelem4x16289">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, heart failure, left ventricular dysfunction post MI</para>
			</section>
			<section type="contra" id="sidelem4x16294">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity, history of angioedema</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x16310">
					<section type="none" id="sidelem4x16311">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, hyperkalemia, hepatic disease, bilateral renal stenosis, after kidney transplant, aorta/mitral valve stenosis, cirrhosis, severe renal disease, untreated CHF, autoimmune disease, cough, pregnancy (C) 1st trimester, African descent</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16316">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16319">
					<section type="none" id="sidelem4x16320">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x16328">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16328">
									<item>
										<label>•</label>
										<para> 1 mg/day; 2 mg/day in African Americans; make dosage adjustment ≥1 wk; max 8 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16332">
						<sec_title>Heart failure, left ventricular dysfunction post MI</sec_title>
						<section type="none" id="sidelem4x16340">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16340">
									<item>
										<label>•</label>
										<para> 1 mg/day, titrate upward to 4 mg/day if tolerated, 2-4 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16344">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x16352">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min or hepatic disease, 0.5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16355">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2, 4 mg</para>
					</section>
					<section type="none" id="sidelem4x16360">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16364">
								<item>
									<label>•</label>
									<para>Discontinue diuretic 2-3 days before starting this product; if not possible, decrease initial dose to 0.5 mg</para>
								</item>
								<item>
									<label>•</label>
									<para>Make dosage changes ≥1 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>Give without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Space antacids by 2 hr after dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16385">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16388">
					<section type="none" id="sidelem4x16389">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, syncope,</emphasis> paresthesias, headache, fatigue, drowsiness, depression, sleep disturbances, anxiety, syncope</para>
					</section>
					<section type="none" id="sidelem4x16397">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis><emphasis style="bold">MI,</emphasis> palpitations, angina, TIAs, <emphasis style="bold">stroke,</emphasis><emphasis style="italic">bradycardia,</emphasis> dysrhythmias</para>
					</section>
					<section type="none" id="sidelem4x16412">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, cramps, diarrhea, constipation, <emphasis style="bold">pancreatitis,</emphasis><emphasis style="italic">dyspepsia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16421">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Proteinuria, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16428">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, neutropenia, leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16435">
						<sec_title>INTEG:</sec_title>
						<para> Rash, purpura, pruritus, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16442">
						<sec_title>MISC:</sec_title>
						<para> Hyperkalemia, hyponatremia, impotence, <emphasis style="italic">myalgia,</emphasis><emphasis style="bold">angioedema,</emphasis> muscle cramps, <emphasis style="italic">asthenia,</emphasis> hypocalcemia, gout</para>
					</section>
					<section type="none" id="sidelem4x16455">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="italic">cough</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16462">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 4-10 hr, duration 24 hr, half-life 6-10 hr, metabolized by liver (active metabolite trandolaprilat), excreted in urine (33%), feces (66%), protein binding 65%-94%</para>
			</section>
			<section type="interactions" id="sidelem4x16467">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—phenothiazines, diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypotension—diuretics, other antihypertensives, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> potassium levels—salt substitutes, potassium-sparing diuretics, potassium supplements, ACE inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of ergots, neuromuscular blocking agents, antihypertensives, hypoglycemics, barbiturates, reserpine, levodopa, lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of trandolapril—antacids, NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x16491">
					<section type="none" id="sidelem4x16492">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> potassium, LFTs, BUN, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16503">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16506">
					<section type="none" id="sidelem4x16507">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Pregnancy:</emphasis> Identify if pregnancy is planned or suspected, pregnancy (D)</bbw>
						</para>
						<section type="none" id="sidelem4x16527">
							<label>•</label>
							<sec_title>Hepatotoxicity (rare)<route> increased LFTs, jaundice, fulfillment hepatic necrosis; if jaundice occurs, discontinue product</route></sec_title>
						</section>
						<section type="none" id="sidelem4x16533">
							<label>•</label>
							<sec_title>
								<route>Angioedema of the face, edema of the extremities, mucous membranes; may need to discontinue</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x16539">
							<label>•</label>
							<sec_title>Hyperkalemia</sec_title>
							<para>
								<list id="lidelem4x16539">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperkalemia:</emphasis> monitor electrolytes, check potassium</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x16543">
								<item>
									<label>•</label>
									<para>B/P, pulse q4hr; note rate, rhythm, quality</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16548">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16553">
								<item>
									<label>•</label>
									<para>Edema in feet, legs daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16561">
							<label>•</label>
							<sec_title>Symptoms of CHF</sec_title>
							<para>
								<list id="lidelem4x16561">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Symptoms of CHF:</emphasis> edema, dyspnea, wet crackles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16565">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16569">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16575">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16579">
								<item>
									<label>•</label>
									<para>Not to use OTC (cough, cold, or allergy) products unless directed by prescriber, to separate antacids by 2 hr; to avoid salt substitutes</para>
								</item>
								<item>
									<label>•</label>
									<para>To comply with dosage schedule even if feeling better</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of mouth sores, sore throat, fever, swelling of hands/feet, irregular heartbeat, chest pain, signs of angioedema</para>
								</item>
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber if these occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting; lightheadedness may occur during 1st few days of therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause skin rash or impaired perspiration</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly, taper</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension
<bbw>To notify prescriber if pregnancy is planned or suspected; pregnancy (D)</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="73" status="active" ha="yes">
			<mono_name> trastuzumab (Rx)</mono_name>
			<info>
				<pronunciation>(tras-tuz′uh-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x166360">Herceptin</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Humanized monoclonal antibody</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x16646">
				<sec_title>Action:</sec_title>
				<para>DNA-derived monoclonal antibody selectively binds to extracellular portion of human epidermal growth factor receptor 2; it inhibits the proliferation of cancer cells</para>
			</section>
			<section type="uses" id="sidelem4x16651">
				<sec_title>Uses:</sec_title>
				<para>Breast cancer; metastatic with overexpression of HER2, early breast cancer (adjuvant, neoadjuvant), gastric cancer; previously untreated HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma with CISplatin, 5-fluorouracil, or capecitabine</para>
			</section>
			<section type="contra" id="sidelem4x16656">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>); hypersensitivity to this product, Chinese hamster ovary cell protein</para>
				<section type="none" id="sidelem4x16661">
					<section type="none" id="sidelem4x16662">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, pulmonary disease, anemia, leukopenia</para>
						<para>
							<bbw>Cardiac disease, respiratory distress syndrome, respiratory insufficiency, infusion-related reactions, cardiomyopathy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16678">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16681">
					<section type="none" id="sidelem4x16682">
						<sec_title>Breast cancer</sec_title>
						<para>
							<list id="lidelem4x16687">
								<item>
									<label>•</label>
									<para>Several regimens may be used</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16695">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16695">
									<item>
										<label>•</label>
										<para> 4 mg/kg given over 90 min, then maintenance 2 mg/kg given over 30 min; do not give as IV push or bol; may be given in combination with other antineoplastics</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16699">
						<sec_title>Gastric cancer</sec_title>
						<section type="none" id="sidelem4x16707">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16707">
									<item>
										<label>•</label>
										<para> 8 mg/kg over 90 min on day 1, then 6 mg/kg over 30-90 min q21days from day 22, give with CISplatin 80 mg/m<emphasis style="sup">2</emphasis> on day 1 plus 5-fluorouracil 800 mg/m<emphasis style="sup">2</emphasis> on days 1-5 or capecitabine 1000 mg/m<emphasis style="sup">2</emphasis> bid on days 1-14, repeat cycle q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16722">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder 440 mg</para>
					</section>
					<section type="none" id="sidelem4x16727">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16731">
								<item>
									<label>•</label>
									<para>Acetaminophen as ordered to alleviate fever and headache</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16737">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x16741">
									<item>
										<label>•</label>
										<para>After reconstituting vial with 20 ml bacteriostatic water for inj, 1.1% benzyl alcohol preserved (supplied) to yield 21 mg/ml; mark date on vial 28 days from reconstitution date; if patient is allergic to benzyl alcohol, reconstitute with sterile water for inj; use immediately; infuse over 90 min; q3wk give 8 mg/kg loading dose over 90 min; subsequent 6 mg/kg dose may be given over 30-60 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not mix or dilute with other products or dextrose sol</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16752">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16755">
					<section type="none" id="sidelem4x16756">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, numbness, paresthesias,</emphasis> depression, <emphasis style="italic">insomnia,</emphasis> neuropathy, peripheral neuritis</para>
					</section>
					<section type="none" id="sidelem4x16767">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Tachycardia, CHF</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16774">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, <emphasis style="italic">anorexia, diarrhea,</emphasis> abdominal pain, <emphasis style="bold">hepatotoxicity,</emphasis> dysgeusia</para>
					</section>
					<section type="none" id="sidelem4x16785">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="italic">Anemia,</emphasis><emphasis style="bold">leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16794">
						<sec_title>INTEG:</sec_title>
						<para> Rash, acne, herpes simplex</para>
					</section>
					<section type="none" id="sidelem4x16799">
						<sec_title>META:</sec_title>
						<para> Edema, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x16804">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Flulike symptoms; fever, headache, chills</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16811">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, <emphasis style="italic">bone pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16818">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, dyspnea, pharyngitis, rhinitis,</emphasis> sinusitis, <emphasis style="bold">pneumonia, pulmonary edema/fibrosis,</emphasis> acute respiratory distress syndrome (ARDS)</para>
					</section>
					<section type="none" id="sidelem4x16829">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16836">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1-32 days</para>
			</section>
			<section type="interactions" id="sidelem4x16841">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cardiomyopathy—anthracyclines, cyclophosphamide; avoid use</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> immune response—vaccines, toxoids</para>
			</section>
			<section type="considerations" id="sidelem4x16856">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16859">
					<section type="none" id="sidelem4x16860">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16865">
								<item>
									<label>•</label>
									<para>CBC, HER2 overexpression
<bbw>CHF, other cardiac symptoms: dyspnea, coughing; gallop; obtain full cardiac workup including ECG, echo, multigated acquisition scan</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16879">
								<item>
									<label>•</label>
									<para>Symptoms of infection; may be masked by product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16884">
								<item>
									<label>•</label>
									<para>CNS reaction: LOC, mental status, dizziness, confusion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16890">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitive reactions, anaphylaxis</emphasis>
<bbw>
											<emphasis alert="lifethreat">Infusion reactions</emphasis> that may be fatal: fever, chills, nausea, vomiting, pain, headache, dizziness, hypotension; discontinue product</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16909">
							<label>•</label>
							<sec_title>Pulmonary toxicity<route> dyspnea, interstitial pneumonitis, pulmonary hypertension, ARDs; can occur after infusion reaction, those with lung disease may have more severe toxicity</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16912">
						<sec_title>Perform/provide:</sec_title>
						<para>
							<list id="lidelem4x16916">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16922">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16926">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size of tumors</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16933">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16938">
								<item>
									<label>•</label>
									<para>To take acetaminophen for fever</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16943">
								<item>
									<label>•</label>
									<para>To avoid hazardous tasks because confusion, dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16948">
								<item>
									<label>•</label>
									<para>To report signs of infection: sore throat, fever, diarrhea, vomiting</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16953">
								<item>
									<label>•</label>
									<para>That emotional lability is common; to notify prescriber if severe or incapacitating</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16961">
							<label>•</label>
							<sec_title>
								<route>To use contraception while taking this product; pregnancy (D); to avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="74" status="active">
			<mono_name>travoprost ophthalmic</mono_name>
			<section type="none" id="sidelem4x16976">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="75" status="active">
			<mono_name>traZODone (Rx)</mono_name>
			<info>
				<pronunciation>(tray′zoe-done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x169850">Oleptro</tradename>
				</tradenames>
				<class type="func"> Antidepressant—miscellaneous</class>
				<class type="chem"> Triazolopyridine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x16995">
				<para>
					<confusion>
						<tradename id="tnidelem4x169950">traZODone</tradename>
						<drug type="generic" refid="idelem4x169950">traMADol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x16999">
				<sec_title>Action:</sec_title>
				<para>Selectively inhibits serotonin uptake by brain; potentiates behavorial changes</para>
			</section>
			<section type="uses" id="sidelem4x17004">
				<sec_title>Uses:</sec_title>
				<para>Depression</para>
				<section type="none" id="sidelem4x17009">
					<section type="none" id="sidelem4x17010">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Alcoholism, anxiety, panic disorder, insomnia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17015">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to tricyclics</para>
				<section type="none" id="sidelem4x17020">
					<section type="none" id="sidelem4x17021">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), suicidal patients, severe depression, increased intraocular pressure, closed-angle glaucoma, urinary retention, cardiac/hepatic disease, hyperthyroidism, electroshock therapy, elective surgery, bleeding, abrupt discontinuation, bipolar disorder, breastfeeding, dehydration, hyponatremic, hypovolemia, recovery phase of MI, seizure disorders, prostatic hypertrophy, family history of long QT</para>
						<para>
							<bbw>Suicidal ideation in children/adolescents</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17036">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17039">
					<section type="none" id="sidelem4x17040">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x17048">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17048">
									<item>
										<label>•</label>
										<para> 150 mg/day in divided doses, may increase by 50 mg/day q3-4days, max 400 mg/day (outpatient), 600 mg/day (inpatients);  150 mg in <emphasis style="smallcaps">pm</emphasis>, may increase gradually by 75 mg/day q3days, max 375 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17061">
							<label>•</label>
							<sec_title>Child 6-18 yr (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17061">
									<item>
										<label>•</label>
										<para> 1.5-2 mg/kg/day in divided doses, may increase q3-4days up to 6 mg/kg/day or 400 mg/day, whichever is less</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17068">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17068">
									<item>
										<label>•</label>
										<para> 25-50 mg at bedtime, increase by 25-50 mg q3-7days to desired dose, usually 75-150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17072">
						<sec_title>Alcoholism (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17080">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17080">
									<item>
										<label>•</label>
										<para> 50-100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17084">
						<sec_title>Panic disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17092">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17092">
									<item>
										<label>•</label>
										<para> 150 mg in divided doses, may increase by 50 mg/day q3-4days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17096">
						<sec_title>Insomnia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17104">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17104">
									<item>
										<label>•</label>
										<para> 50 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17108">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 100, 150, 300 mg; ext rel tabs 150, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x17113">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17117">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet if constipation occurs, especially in geriatric patients</para>
								</item>
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Dosage at bedtime for oversedation during day; may take entire dose at bedtime; geriatric patients may not tolerate daily dosing</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use of CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not crush, break, chew ext rel product</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17148">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17151">
					<section type="none" id="sidelem4x17152">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, weakness, insomnia, nightmares, EPS (geriatric patients), increase in psychiatric symptoms, <emphasis style="bold">suicide in children/adolescents</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17164">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension, ECG changes, tachycardia,</emphasis><emphasis style="bold">hypertension,</emphasis> palpitations</para>
					</section>
					<section type="none" id="sidelem4x17174">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis</para>
					</section>
					<section type="none" id="sidelem4x17182">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, dry mouth,</emphasis> nausea, vomiting, <emphasis style="bold">paralytic ileus,</emphasis> increased appetite, cramps, epigastric distress, jaundice, <emphasis style="bold">hepatitis,</emphasis> stomatitis, constipation</para>
					</section>
					<section type="none" id="sidelem4x17196">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary retention,</emphasis><emphasis style="bold">acute renal failure,</emphasis> priapism</para>
					</section>
					<section type="none" id="sidelem4x17206">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17213">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, sweating, pruritus, photosensitivity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17218">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1 hr without food, 2 hr with food; metabolized by liver (CYP3A4); excreted by kidneys, in feces; half-life 4.4-7.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x17223">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Hyperpyretic crisis, seizures, hypertensive episode: MAOIs; do not use within 14 days of traZODone</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity, serotonin syndrome—FLUoxetine, nefazodone, other SSRIs, SNRIs, linezolid; methylene blue (IV)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of direct-acting sympathomimetics (EPINEPHrine), alcohol, barbiturates, benzodiazepines, CNS depressants, digoxin, phenytoin, carBAMazepine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of traZODone—CYP3A4, 2D6 inhibitors (phenothiazines, protease inhibitors, azole antifungals)</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> effects of warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of guanethidine, cloNIDine, indirect-acting sympathomimetics (ePHEDrine)</para>
				<section type="none" id="sidelem4x17250">
					<section type="none" id="sidelem4x17251">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Increase: serotonin syndrome—SAM-e, St. John’s wort</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—hops, kava, lavender, valerian</para>
					</section>
					<section type="none" id="sidelem4x17261">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17272">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17275">
					<section type="none" id="sidelem4x17276">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x17281">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take vital signs q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17286">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, leukocytes, differential</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17291">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17296">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may increase with product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17301">
								<item>
									<label>•</label>
									<para>ECG for flattening of T wave, bundle branch block, AV block, dysrhythmias in cardiac patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17306">
								<item>
									<label>•</label>
									<para>EPS, primarily in geriatric patients: rigidity, dystonia, akathisia
<bbw>Mental status changes: mood, sensorium, affect, suicidal tendencies, increase in psychiatric symptoms, depression, panic; observe for suicidal behaviors in children/adolescents, not approved for children</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17320">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation; constipation most likely in children</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17328">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x17328">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness; not usual unless product discontinued abruptly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17332">
								<item>
									<label>•</label>
									<para>Alcohol consumption; hold dose until morning</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17338">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome, neuroleptic malignant syndrome: increased heart rate, shivering, sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17343">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy for drowsiness, dizziness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17348">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17352">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17358">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17363">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take 2-3 wk; to take product before bedtime; not to crush, chew ext rel product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17368">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17373">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17378">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use; may cause nausea, headache, malaise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17383">
								<item>
									<label>•</label>
									<para>To report urinary retention, priapism &gt;4 hr immediately</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17388">
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat because photosensitivity occurs
<bbw>That suicidal thoughts/behaviors may occur (adolescents/children)</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17405">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (C), avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17408">
								<item>
									<label>•</label>
									<para>To rise slowly to prevent dizziness</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x17413">
				<sec_title>Treatment of overdose:</sec_title>
				<para>ECG monitoring; lavage, activated charcoal; administer anticonvulsant, atropine for bradycardia</para>
			</section>
		</monograph>
<monograph id="76" status="active">
			<mono_name>treprostinil (Rx)</mono_name>
			<info>
				<pronunciation>(treh-prah′stin-ill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x174231">Remodulin</tradename>
					<tradename id="tnidelem4x174230">Tyvaso</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, vasodilators</class>
				<class type="chem"> Tricyclic benzidine prostacyclin analog</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x17433">
				<sec_title>Action:</sec_title>
				<para>Direct vasodilation of pulmonary, systemic arterial vascular beds; inhibition of platelet aggregation</para>
			</section>
			<section type="uses" id="sidelem4x17438">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary arterial hypertension (PAH) NYHA class II through IV</para>
				<section type="none" id="sidelem4x17443">
					<section type="none" id="sidelem4x17444">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Pulmonary arterial hypertension in children/adolescents, pediatric patients transitioning from epoprostenol to treprostinil, claudication</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17449">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, other prostacyclin analogs</para>
				<section type="none" id="sidelem4x17454">
					<section type="none" id="sidelem4x17455">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, past renal/hepatic disease, thromboembolic disease, abrupt discontinuation, IV administration</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17460">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17463">
					<section type="none" id="sidelem4x17464">
						<sec_title>Pulmonary arterial hypertension (WHO Group 1)</sec_title>
						<section type="none" id="sidelem4x17472">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x17472">
									<item>
										<label>•</label>
										<para> 1.25 ng/kg/min by  may reduce to 0.625 ng/kg/min if not tolerated; may increase by 1.25 ng/kg/min weekly for first 4 wk, then 2.5 ng/kg/min/wk for remainder of infusion;  3 breaths via Tyvaso inh system qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17482">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x17490">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT INFUSION 0.625 ng/kg ideal body weight/min; increase cautiously</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17493">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1, 2.5, 5, 10 mg/ml; neb sol 1.74 mg/2.9 ml</para>
					</section>
					<section type="none" id="sidelem4x17498">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17502">
								<item>
									<label>•</label>
									<para>Sudden decreased doses, abrupt withdrawal may worsen pulmonary arterial hypertension symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17508">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x17512">
									<item>
										<label>•</label>
										<para>By continuous infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>No dilution required</para>
									</item>
									<item>
										<label>•</label>
										<para>Subcutaneous infusion rate = [dose (mg/kg/min) × weight (kg) × 0.00006]/treprostinil vial strength (mg/ml)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17528">
							<sec_title>Oral INH route</sec_title>
							<para>
								<list id="lidelem4x17532">
									<item>
										<label>•</label>
										<para>Avoid skin, eyes; do not take orally; use Tyvaso Inhalation System only</para>
									</item>
									<item>
										<label>•</label>
										<para>Patient should have backup Optineb-ir device to avoid interruptions</para>
									</item>
									<item>
										<label>•</label>
										<para>Follow instructions for use, cleaning</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not mix with other medications in Optineb-ir device</para>
									</item>
									<item>
										<label>•</label>
										<para>Twist off cap; squeeze total contents into medicine cup; vol is sufficient for 4 treatments</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17558">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x17562">
									<item>
										<label>•</label>
										<para>By surgically placed CV catheter using ambulatory infusion pump</para>
									</item>
									<item>
										<label>•</label>
										<para>IV pump, product, patient education can be obtained from Priority Healthcare in United States</para>
									</item>
									<item>
										<label>•</label>
										<para>Must be diluted with sterile water for inj or 0.9% NaCl</para>
									</item>
									<item>
										<label>•</label>
										<para>Concentration should be calculated using this formula: diluted concentration = [dose (ng/kg/min) × weight (kg) × 0.00006] / infusion rate (ml/hr)]</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17584">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17587">
					<section type="none" id="sidelem4x17588">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, syncope</para>
					</section>
					<section type="none" id="sidelem4x17593">
						<sec_title>CV:</sec_title>
						<para> Vasodilation, <emphasis style="italic">hypotension, edema,</emphasis><emphasis style="bold">right ventricular heart failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17602">
						<sec_title>GI:</sec_title>
						<para> Nausea, <emphasis style="italic">diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17609">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus</para>
					</section>
					<section type="none" id="sidelem4x17617">
						<sec_title>OTHER:</sec_title>
						<para> Jaw pain, cough, throat irritation</para>
					</section>
					<section type="none" id="sidelem4x17622">
						<sec_title>SYST:</sec_title>
						<para> Infusion-site reactions, pain; increased risk for infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17627">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted in urine, feces; terminal half-life 2-4 hr; 90% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x17632">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x17636">
						<item>
							<label>•</label>
							<para>Excessive hypotension: diuretics, antihypertensives, vasodilators, MAOIs, β-blockers, calcium channel blockers</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding tendencies—anticoagulants, aspirin, NSAIDs, thrombin inhibitors, SSRIs</para>
			</section>
			<section type="considerations" id="sidelem4x17646">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17649">
					<section type="none" id="sidelem4x17650">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x17658">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x17658">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> monitor B/P, baseline and periodically</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17662">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, creatinine with long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17668">
								<item>
									<para>
										<emphasis alert="nurse">Blood studies: CBC; CBC q2wk × 3 mo, Hct, Hgb, PT with long-term therapy, ABGs</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17674">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding time at baseline, throughout treatment; levels may be 2-5× normal limit</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17679">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17683">
								<item>
									<label>•</label>
									<para>Avoid abrupt discontinuation</para>
								</item>
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pulmonary arterial hypertension (PAH)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17694">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17698">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment; that treatment may last for years</para>
								</item>
								<item>
									<label>•</label>
									<para>To report side effects such as diarrhea, skin rashes</para>
								</item>
								<item>
									<label>•</label>
									<para>That therapy will be needed for prolonged periods of time, sometimes years</para>
								</item>
								<item>
									<label>•</label>
									<para>To prevent infection, aseptic technique must be used for preparation, administration of treprostinil</para>
								</item>
								<item>
									<label>•</label>
									<para>That there are many product, herbal interactions</para>
								</item>
								<item>
									<label>•</label>
									<para>About signs, symptoms of bleeding; blood in urine, stools</para>
								</item>
								<item>
									<label>•</label>
									<para>How to use inhaled solution; how to care for equipment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="77" status="active">
			<mono_name>tretinoin (vit A acid, retinoic acid) (Rx)</mono_name>
			<info>
				<pronunciation>(tret′i-noyn)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x177394">Avita</tradename>
					<tradename id="tnidelem4x177393">Renova</tradename>
					<tradename id="tnidelem4x177392">Retin-A</tradename>
					<tradename id="tnidelem4x177391">Retin-A Micro</tradename>
					<tradename id="tnidelem4x177390">
						<country code="CAN">Stieva-A </country>
					</tradename>
				</tradenames>
				<class type="func"> Vit A acid, acne product; antineoplastic (miscellaneous)</class>
				<class type="chem"> Tretinoin derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x17751">
				<sec_title>Action:</sec_title>
				<para>(Topical) Decreases cohesiveness of follicular epithelium, decreases microcomedone formation; (PO) induces maturation of acute promyelocytic leukemia, exact action is unknown</para>
			</section>
			<section type="uses" id="sidelem4x17756">
				<sec_title>Uses:</sec_title>
				<para>(Topical) Acne vulgaris (grades 1-3); (PO) acute promyelocytic leukemia, facial wrinkles, photoaging</para>
				<section type="none" id="sidelem4x17761">
					<section type="none" id="sidelem4x17762">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acne rosacea, actinic keratosis, ichthyosis, Kaposi’s sarcoma, keloids, keratosis follicularis, melasma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17767">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to retinoids or sensitivity to parabens</para>
				<para>
					<bbw>Pregnancy (D) (PO)</bbw>
				</para>
				<section type="none" id="sidelem4x17782">
					<section type="none" id="sidelem4x17783">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (topical), breastfeeding, eczema, sunburn, sun exposure</para>
						<para>
							<bbw>Rapid-evolving leukocytosis, respiratory compromise, acute promyelocytic leukemia differentiation syndrome, requires a specialized care setting, experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17798">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17806">
					<label>•</label>
					<sec_title>Adult and child<route> TOP</route></sec_title>
					<para>
						<list id="lidelem4x17806">
							<item>
								<label>•</label>
								<para> cleanse area, apply 0.025%-0.1% cream or 0.05% liquid gel at bedtime, cover lightly</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x17811">
					<section type="none" id="sidelem4x17812">
						<sec_title>Promyelocytic leukemia</sec_title>
						<section type="none" id="sidelem4x17820">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17820">
									<item>
										<label>•</label>
										<para> 45 mg/m<emphasis style="sup">2</emphasis>/day given as 2 evenly divided doses until remission, discontinue treatment 30 days after remission or 90 days of treatment, whichever is first</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17827">
						<sec_title>Available forms:</sec_title>
						<para> Cream 0.01%, 0.02%, 0.025%, 0.05%, 0.1%; gel 0.01%, 0.025%, 0.04%, 0.05%, 0.1%; liquid 0.05%; caps 10 mg</para>
					</section>
					<section type="none" id="sidelem4x17832">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x17835">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x17839">
									<item>
										<label>•</label>
										<para>Once daily before bedtime; cover area lightly using gauze; use gloves to apply</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>Handwashing after application</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17855">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17858">
					<section type="none" id="sidelem4x17859">
						<sec_title>PO</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x17863">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fever, sweating,</emphasis> fatigue</para>
					</section>
					<section type="none" id="sidelem4x17871">
						<sec_title>CV:</sec_title>
						<para> Cardiac dysrhythmias, pericardial effusion</para>
					</section>
					<section type="none" id="sidelem4x17876">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis><emphasis style="bold">hemorrhage,</emphasis><emphasis style="italic">abdominal pain, diarrhea, constipation, dyspepsia, distention, hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17887">
						<sec_title>Topical</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x17891">
						<sec_title>INTEG:</sec_title>
						<para> Rash, stinging, warmth, redness, erythema, blistering, crusting, peeling, contact dermatitis, hypo/hyperpigmentation, dry skin, pruritus, scaly skin, retinoic acid syndrome (RAS)</para>
					</section>
					<section type="none" id="sidelem4x17896">
						<sec_title>META:</sec_title>
						<para> Hypercholesterolemia, hypertriglyceridemia</para>
					</section>
					<section type="none" id="sidelem4x17901">
						<sec_title>RESP:</sec_title>
						<para> Pneumonia, upper respiratory tract disease</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17906">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x17909">
					<section type="none" id="sidelem4x17910">
						<sec_title>PO:</sec_title>
						<para> Terminal half-life 0.5-2 hr</para>
					</section>
					<section type="none" id="sidelem4x17915">
						<sec_title>TOPICAL:</sec_title>
						<para> Poor systemic absorption</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x17920">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x17924">
						<item>
							<label>•</label>
							<para>Use with caution: medicated, abrasive soaps; cleansers that have a drying effect; products with high concentration of alcohol astringents (topical)</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> peeling—medication containing agents such as sulfur, benzoyl peroxide, resorcinol, salicylic acid (topical)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of tretinoin—ketoconazole (PO)</para>
				<para>
					<emphasis alert="nurse">Increase: ICP, risk of pseudotumor cerebri—tetracyclines; do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> photosensitivity—retinoids, quinolones, phenothiazines, sulfonamides, sulfonylureas, thiazide diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> thrombotic complications—aninocaproic acid, aprotinin, tranexamic acid</para>
				<section type="none" id="sidelem4x17951">
					<section type="none" id="sidelem4x17952">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17959">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17962">
					<section type="none" id="sidelem4x17963">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x17966">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x17970">
									<item>
										<label>•</label>
										<para>Area of body involved, what helps or aggravates condition; cysts, dryness, itching; lesions may worsen at beginning of treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17976">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x17980">
									<item>
										<label>•</label>
										<para>Hepatic function, coagulation, hematologic parameters; also cholesterol, triglycerides</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17986">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17990">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size, number of lesions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17996">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x17999">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x18003">
									<item>
										<label>•</label>
										<para>To avoid application on normal skin; to avoid getting cream in eyes, nose, other mucous membranes; not to use product on areas with cuts, scrapes</para>
									</item>
									<item>
										<label>•</label>
										<para>To use cream/gel by applying a thin layer to affected skin; to rub gently; to use liquid; to apply with fingertip or cotton swab</para>
									</item>
									<item>
										<label>•</label>
										<para>To avoid sunlight, sunlamps; to use protective clothing, sunscreen</para>
									</item>
									<item>
										<label>•</label>
										<para>That treatment may cause warmth, stinging; that dryness, peeling will occur</para>
									</item>
									<item>
										<label>•</label>
										<para>That cosmetics may be used over product; not to use shaving lotions</para>
									</item>
									<item>
										<label>•</label>
										<para>That rash may occur during first 1-3 wk of therapy</para>
									</item>
									<item>
										<label>•</label>
										<para>That product does not cure condition, only relieves symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>That therapeutic results may be seen in 2-3 wk but may not be optimal until after 6 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18045">
							<sec_title>PO route</sec_title>
							<para>
								<bbw>To notify prescriber if pregnancy is planned or suspected; pregnancy (D) PO</bbw>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="78" status="active">
			<mono_name>tretinoin topical</mono_name>
			<section type="none" id="sidelem4x18061">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="79" status="active">
			<mono_name>triamcinolone (ophthalmic)</mono_name>
			<section type="none" id="sidelem4x18068">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="80" status="active">
			<mono_name>triamcinolone (Rx)</mono_name>
			<info>
				<pronunciation>(trye-am-sin′oh-lone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x180774">Aristospan</tradename>
					<tradename id="tnidelem4x180773">Kenalog-10</tradename>
					<tradename id="tnidelem4x180772">Kenalog-40</tradename>
					<tradename id="tnidelem4x180771">Tac-3</tradename>
					<tradename id="tnidelem4x180770">Triesence</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, synthetic</class>
				<class type="chem"> Glucocorticoid, intermediate acting</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x18087">
				<sec_title>Action:</sec_title>
				<para>Decreases inflammation by suppression of migration of polymorphonuclear leukocytes, fibroblasts; reversal of increased capillary permeability and lysosomal stabilization</para>
			</section>
			<section type="uses" id="sidelem4x18092">
				<sec_title>Uses:</sec_title>
				<para>Severe inflammation, immunosuppression, neoplasms, asthma (steroid dependent); collagen, respiratory, dermatologic/rheumatic disorders</para>
			</section>
			<section type="contra" id="sidelem4x18097">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, neonatal prematurity; epidural/intrathecal administration (Triamcinolone acetonide injections [Kenalog]), systemic fungal infections</para>
				<section type="none" id="sidelem4x18102">
					<section type="none" id="sidelem4x18103">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, diabetes mellitus, glaucoma, osteoporosis, seizure disorders, ulcerative colitis, CHF, myasthenia gravis, renal disease, esophagitis, peptic ulcer, acne, cataracts, coagulopathy, head trauma, children &lt;2 yr, psychosis, idiopathic thrombocytopenia, acute glomerulonephritis, amebiasis, fungal infections, nonasthmatic bronchial disease, AIDS, TB, adrenal insufficiency, acute bronchospasm, acne rosacea, Cushing syndrome, acute MI, thromboembolism</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18108">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18116">
					<label>•</label>
					<sec_title>Adult<route> IM</route></sec_title>
					<para>
						<list id="lidelem4x18116">
							<item>
								<label>•</label>
								<para> (acetonide) 40 mg/wk; (acetonide) 5-48 mg into neoplasms; (acetonide) 2-40 mg into joint or soft tissue; (hexacetonide) 0.5 mg/in<emphasis style="sup">2</emphasis> of affected intralesional skin; (hexacetonide) 2-20 mg into joint or soft tissue</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18123">
					<section type="none" id="sidelem4x18124">
						<sec_title>Severe/incapacitating allergic conditions such as asthma</sec_title>
						<section type="none" id="sidelem4x18132">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x18132">
									<item>
										<label>•</label>
										<para> (Trivaris) 60 mg, titrate, usual range 40-80 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18139">
							<label>•</label>
							<sec_title>Child<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x18139">
									<item>
										<label>•</label>
										<para> (Trivaris) 0.11-1.6 mg/kg/day (3.2-48 mg/m<emphasis style="sup">2</emphasis>/day) in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18146">
						<sec_title>Available forms:</sec_title>
						<para> Inj 3, 10, 40 mg/ml acetonide; inj 20, 5 mg/ml hexacetonide</para>
					</section>
					<section type="none" id="sidelem4x18151">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x18154">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x18158">
									<item>
										<label>•</label>
										<para>After shaking susp (parenteral)</para>
									</item>
									<item>
										<label>•</label>
										<para>Titrated dose; use lowest effective dose</para>
									</item>
									<item>
										<label>•</label>
										<para>IM inj deep in large muscle mass; rotate sites; avoid deltoid; use 21-G needle</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid SUBCUT administration, may damage tissue</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18179">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18182">
					<section type="none" id="sidelem4x18183">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Depression,</emphasis> headache, mood changes</para>
					</section>
					<section type="none" id="sidelem4x18191">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypertension,</emphasis><emphasis style="bold">circulatory collapse, embolism,</emphasis> tachycardia, edema</para>
					</section>
					<section type="none" id="sidelem4x18201">
						<sec_title>EENT:</sec_title>
						<para> Fungal infections, increased intraocular pressure, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x18206">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, abdominal distention,</emphasis><emphasis style="bold">GI hemorrhage,</emphasis><emphasis style="italic">increased appetite,</emphasis><emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18219">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18226">
						<sec_title>INTEG:</sec_title>
						<para> Acne, poor wound healing, ecchymosis, petechiae</para>
					</section>
					<section type="none" id="sidelem4x18231">
						<sec_title>MS:</sec_title>
						<para> Fractures, osteoporosis, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18236">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x18239">
					<section type="none" id="sidelem4x18240">
						<sec_title>PO/IM:</sec_title>
						<para> Peak 1-2 hr, half-life 2-5 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x18246">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects—alcohol, salicylates, indomethacin, amphotericin B, digoxin, cycloSPORINE, diuretics, quinolones</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of triamcinolone—salicylates, estrogens, indomethacin, oral contraceptives, ketoconazole, macrolide antiinfectives, carBAMazepine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of triamcinolone—cholestyramine, colestipol, barbiturates, rifampin, ePHEDrine, phenytoin, theophylline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of anticoagulants, anticonvulsants, antidiabetics, ambenonium, neostigmine, isoniazid, toxoids, vaccines, anticholinesterases, salicylates, somatrem</para>
				<section type="none" id="sidelem4x18265">
					<section type="none" id="sidelem4x18266">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x18270">
								<item>
									<label>•</label>
									<para>Hypokalemia: aloe, cascara, senna</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18276">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, sodium, blood glucose, uric acid, calcium, urine glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, potassium, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">3</emphasis>, thyroid <emphasis style="sup">131</emphasis>I uptake test, urine 17-OHCS, 17-KS, PBI</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18300">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18303">
					<section type="none" id="sidelem4x18304">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18309">
								<item>
									<label>•</label>
									<para>Potassium, blood glucose, urine glucose while patient receiving long-term therapy; hypokalemia and hyperglycemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18314">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber if weekly gain of &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18319">
								<item>
									<label>•</label>
									<para>B/P, pulse; notify prescriber if chest pain occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18324">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18329">
								<item>
									<label>•</label>
									<para>Plasma cortisol levels during long-term therapy (normal level: 138-635 nmol/L SI units when drawn at 8 <emphasis style="smallcaps">am</emphasis>)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18340">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x18340">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> increased temperature, WBC even after withdrawal of medication; product masks infection</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x18344">
								<item>
									<label>•</label>
									<para>Potassium depletion: paresthesias, fatigue, nausea, vomiting, depression, polyuria, dysrhythmias, weakness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18349">
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18354">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, aggression</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18359">
								<item>
									<label>•</label>
									<para>Assistance with ambulation for patient with bone-tissue disease to prevent fractures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18364">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18368">
								<item>
									<label>•</label>
									<para>Therapeutic response: ease of respirations, decreased inflammation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18374">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18379">
								<item>
									<label>•</label>
									<para>That emergency ID as corticosteroid user should be carried; not to discontinue abruptly, taper dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18384">
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases; that dosage adjustment may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18389">
								<item>
									<label>•</label>
									<para>To avoid OTC products: salicylates, alcohol in cough products, cold preparations unless directed by prescriber; to avoid live vaccines</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18394">
								<item>
									<label>•</label>
									<para>About cushingoid symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18402">
							<label>•</label>
							<sec_title>About the symptoms of adrenal insufficiency<route> nausea, anorexia, fatigue, dizziness, dyspnea, weakness, joint pain</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="81" status="active">
			<mono_name>triamcinolone nasal agent</mono_name>
			<section type="none" id="sidelem4x18408">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="82" status="active">
			<mono_name>triamcinolone (topical)</mono_name>
			<info>
				<pronunciation>(try-am-sin′oh-lone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x184171">Kenalog</tradename>
					<tradename id="tnidelem4x184170">Triderm</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, topical</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x18423">
				<sec_title>Action:</sec_title>
				<para>Crosses cell membrane to attach to receptors to decrease inflammation, itching; inhibits multiple inflammatory cytokines</para>
			</section>
			<section type="uses" id="sidelem4x18428">
				<sec_title>Uses:</sec_title>
				<para>Inflammation/itching in corticosteroid-responsive dermatoses on the skin or inflammation in the mouth</para>
			</section>
			<section type="contra" id="sidelem4x18433">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, use on face, ear canal, infections</para>
				<section type="none" id="sidelem4x18438">
					<section type="none" id="sidelem4x18439">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18444">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<list id="lidelem4x18448">
						<item>
							<label>•</label>
							<para>Apply to the affected areas bid-qid</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x18454">
					<section type="none" id="sidelem4x18455">
						<sec_title>Available forms:</sec_title>
						<para> Aerosol 0.2 mg; paste (dental) 0.1%; lotion, cream, ointment 0.025%; ointment 0.05%; lotion, cream, ointment 0.1%; ointment, cream 0.5%</para>
					</section>
					<section type="none" id="sidelem4x18460">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x18463">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x18468">
									<item>
										<label>•</label>
										<para>May be used with occlusive dressings</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18476">
								<label>•</label>
								<sec_title>Cream/Ointment/Lotion</sec_title>
								<para>
									<list id="lidelem4x18476">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/Ointment/Lotion:</emphasis> apply sparingly in a thin film and rub gently into the cleansed, slightly moist affected area; may use gloves to apply cream/ointment/lotion</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18483">
								<label>•</label>
								<sec_title>Paste</sec_title>
								<para>
									<list id="lidelem4x18483">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Paste:</emphasis> apply without rubbing, press into lesion until film develops</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18490">
								<label>•</label>
								<sec_title>Spray</sec_title>
								<para>
									<list id="lidelem4x18490">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Spray:</emphasis> spray a small amount of preparation onto the lesion</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18494">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18497">
					<section type="none" id="sidelem4x18498">
						<sec_title>ENDO:</sec_title>
						<para> HPA axis suppression, Cushing syndrome</para>
					</section>
					<section type="none" id="sidelem4x18503">
						<sec_title>INTEG:</sec_title>
						<para> Burning, folliculitis, pruritus, dermatitis, hypopigmentation</para>
					</section>
					<section type="none" id="sidelem4x18508">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia; glycosuria</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18513">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption varies</para>
			</section>
			<section type="interactions" id="sidelem4x18518">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> blood glucose</para>
			</section>
			<section type="considerations" id="sidelem4x18525">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18528">
					<section type="none" id="sidelem4x18529">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18533">
								<item>
									<label>•</label>
									<para>Skin reactions: burning, pruritus, folliculitis, mouth lesions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18539">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18543">
								<item>
									<label>•</label>
									<para>Decreasing itching, inflammation on the skin, decreasing mouth lesions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18549">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18553">
								<item>
									<label>•</label>
									<para>How to use each product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="83" status="active">
			<mono_name>triamcinolone (topical-oral) (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(trye-am-sin′oh-lone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x185671">Kenalog in Orabase</tradename>
					<tradename id="tnidelem4x185670">Oralone Dental</tradename>
				</tradenames>
				<class type="func"> Topical anesthetic</class>
				<class type="chem"> Synthetic fluorinated adrenal corticosteroid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x18577">
				<sec_title>Action:</sec_title>
				<para>Binds with steroid receptors, decreases inflammation</para>
			</section>
			<section type="uses" id="sidelem4x18582">
				<sec_title>Uses:</sec_title>
				<para>Oral pain</para>
			</section>
			<section type="contra" id="sidelem4x18587">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, application to large areas; presence of fungal, viral, or bacterial infections of mouth or throat</para>
				<section type="none" id="sidelem4x18592">
					<section type="none" id="sidelem4x18593">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children &lt;6 yr, sepsis, denuded skin, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18598">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18606">
					<label>•</label>
					<sec_title>Adult<route> TOP</route></sec_title>
					<para>
						<list id="lidelem4x18606">
							<item>
								<label>•</label>
								<para> Press <emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis> inch into affected area until film appears, repeat bid-tid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18616">
					<section type="none" id="sidelem4x18617">
						<sec_title>Available forms:</sec_title>
						<para> Paste 0.1%</para>
					</section>
					<section type="none" id="sidelem4x18622">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18626">
								<item>
									<label>•</label>
									<para>After cleansing oral cavity after meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18632">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18635">
					<section type="none" id="sidelem4x18636">
						<sec_title>INTEG:</sec_title>
						<para> Rash, irritation, sensitization</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18641">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18644">
					<section type="none" id="sidelem4x18645">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18649">
								<item>
									<label>•</label>
									<para>Allergy: rash, irritation, reddening, swelling</para>
								</item>
								<item>
									<label>•</label>
									<para>Infection: if affected area is infected, do not apply</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18660">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18664">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain in affected area</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18670">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18674">
								<item>
									<label>•</label>
									<para>To report rash, irritation, redness, swelling</para>
								</item>
								<item>
									<label>•</label>
									<para>How to apply paste</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="84" status="active" ha="yes">
			<mono_name> triazolam (Rx)</mono_name>
			<info>
				<pronunciation>(trye-ay′zoe-lam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x186931">
						<country code="CAN">Apo-Triazo </country>
					</tradename>
					<tradename id="tnidelem4x186930">Halcion</tradename>
				</tradenames>
				<class type="func"> Sedative-hypnotic, antianxiety</class>
				<class type="chem"> Benzodiazepine, short acting</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule> (USA), Targeted (CDSA IV) (Canada)</class>
			</info>
			<section type="confusion" id="sidelem4x18708">
				<para>
					<confusion>
						<tradename id="tnidelem4x187080">Halcion</tradename>
						<drug type="generic" refid="idelem4x187080">Haldol/halcinonide</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x18712">
				<sec_title>Action:</sec_title>
				<para>Produces CNS depression at limbic, thalamic, hypothalamic levels of CNS; may be mediated by neurotransmitter γ-aminobutyric acid (GABA); results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, anxiolytic action</para>
			</section>
			<section type="uses" id="sidelem4x18717">
				<sec_title>Uses:</sec_title>
				<para>Insomnia, sedative/hypnotic</para>
			</section>
			<section type="contra" id="sidelem4x18722">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity to benzodiazepines</para>
				<section type="none" id="sidelem4x18727">
					<section type="none" id="sidelem4x18728">
						<sec_title>Precautions:</sec_title>
						<para> Children &lt;15 yr, geriatric patients, anemia, renal/hepatic disease, suicidal individuals, drug abuse, psychosis, acute closed-angle glaucoma, seizure disorders, angioedema, respiratory disease, depression, sleep-related behaviors (sleep walking), intermittent porphyria, myasthenia gravis, Parkinson’s disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18733">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18741">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x18741">
							<item>
								<label>•</label>
								<para> 0.125-0.5 mg at bedtime, max 0.5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18748">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x18748">
							<item>
								<label>•</label>
								<para> 0.0625-0.125 mg at bedtime, max 0.25 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18752">
					<section type="none" id="sidelem4x18753">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.125, 0.25 mg</para>
					</section>
					<section type="none" id="sidelem4x18758">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18762">
								<item>
									<label>•</label>
									<para>After trying conservative measures for insomnia</para>
								</item>
								<item>
									<label>•</label>
									<para>
										<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr before bedtime for sleeplessness</para>
								</item>
								<item>
									<label>•</label>
									<para>On empty stomach for fast onset; may be taken with food if GI symptoms occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use with CNS depressants; serious CNS depression may result</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18788">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18791">
					<section type="none" id="sidelem4x18792">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, lethargy, drowsiness, daytime sedation,</emphasis> dizziness, confusion, lightheadedness, anxiety, irritability, amnesia, poor coordination, <emphasis style="bold">complex sleep-related reactions: sleep driving, sleep eating</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18802">
						<sec_title>CV:</sec_title>
						<para> Chest pain, pulse changes, ECG changes</para>
					</section>
					<section type="none" id="sidelem4x18807">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, heartburn, abdominal pain, constipation, <emphasis style="bold">hepatic injury</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18814">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Severe allergic reactions</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18821">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 15-30 min, duration 6-8 hr, metabolized by liver, excreted by kidneys (inactive metabolites), crosses placenta, excreted in breast milk, half-life 1.5-5.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x18826">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x18830">
						<item>
							<label>•</label>
							<para>Smoking may decrease hypnotic effect</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> triazolam levels—CYP3A4 inhibitors, protease inhibitors</para>
				<para>
					<emphasis alert="nurse">Increase: effects of cimetidine, disulfiram, erythromycin, clarithromycin, probenecid, isoniazid, oral contraceptives; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of both products—alcohol, CNS depressants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of antacids, theophylline, rifampin, smoking</para>
				<section type="none" id="sidelem4x18853">
					<section type="none" id="sidelem4x18854">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—chamomile, hops, kava, lavender, valerian</para>
					</section>
					<section type="none" id="sidelem4x18861">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x18865">
								<item>
									<label>•</label>
									<para>Grapefruit may increase action, avoid concurrent use</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18871">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, serum bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> RAI uptake</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary 17-OHCS</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18886">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18889">
					<section type="none" id="sidelem4x18890">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18894">
								<item>
									<label>•</label>
									<para>Blood studies: Hct, Hgb, RBC if blood dyscrasias suspected (rare)</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin if hepatic damage has occurred</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, memory (long, short term), insomnia, withdrawal symptoms, excessive sedation, impaired coordination</para>
								</item>
								<item>
									<label>•</label>
									<para>Blood dyscrasias: fever, sore throat, bruising, rash, jaundice, epistaxis (rare)</para>
								</item>
								<item>
									<label>•</label>
									<para>Type of sleep problem: falling asleep, staying asleep</para>
								</item>
								<item>
									<label>•</label>
									<para>Assistance with ambulation after receiving dose</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18926">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18930">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to sleep at night, decreased amount of early morning awakening if taking product for insomnia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18936">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x18944">
							<label>•</label>
							<sec_title>
								<route>To use reliable contraception; pregnancy (X)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18947">
								<item>
									<label>•</label>
									<para>That dependence is possible after long-term use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18952">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities requiring alertness until product is stabilized</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18957">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18962">
								<item>
									<label>•</label>
									<para>That effects may take 2 nights for benefits to be noticed; that product is for short-term use only; to use for 7-10 continuous nights</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18967">
								<item>
									<label>•</label>
									<para>About alternative measures to improve sleep: reading, exercise several hours before bedtime, warm bath, warm milk, TV, self-hypnosis, deep breathing</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18975">
							<label>•</label>
							<sec_title>
								<route>That complex sleep-related behaviors (sleep eating/driving) may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18978">
								<item>
									<label>•</label>
									<para>That hangover common in geriatric patients but less common than with barbiturates; that rebound insomnia may occur for 1-2 nights after discontinuing product; to discontinue by decreasing dose by 50% q2 nights until 0.125 mg for 2 nights, then stop</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x18983">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, activated charcoal; monitor electrolytes, VS</para>
			</section>
		</monograph>
<monograph id="85" status="active">
			<mono_name>trifluridine ophthalmic</mono_name>
			<section type="none" id="sidelem4x18991">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="86" status="active">
			<mono_name>trimethobenzamide (Rx)</mono_name>
			<info>
				<pronunciation>(trye-meth-oh-ben′za-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x190000">Tigan</tradename>
				</tradenames>
				<class type="func"> Antiemetic, anticholinergic</class>
				<class type="chem"> Ethanolamine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x19010">
				<sec_title>Action:</sec_title>
				<para>Acts centrally by blocking chemoreceptor trigger zone, which in turn acts on vomiting center</para>
			</section>
			<section type="uses" id="sidelem4x19015">
				<sec_title>Uses:</sec_title>
				<para>Nausea, vomiting</para>
			</section>
			<section type="contra" id="sidelem4x19020">
				<sec_title>Contraindications:</sec_title>
				<para>Children (parenterally), hypersensitivity to opioids, shock</para>
				<section type="none" id="sidelem4x19025">
					<section type="none" id="sidelem4x19026">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, cardiac dysrhythmias, acute febrile illness, encephalitis, gastroenteritis, dehydration, electrolyte imbalances, Reye’s syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19031">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19034">
					<section type="none" id="sidelem4x19035">
						<sec_title>Nausea/vomiting</sec_title>
						<section type="none" id="sidelem4x19043">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x19043">
									<item>
										<label>•</label>
										<para> 200 mg 3-4×/day;  300 mg 3-4×/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19050">
						<sec_title>Postoperative</sec_title>
						<section type="none" id="sidelem4x19058">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x19058">
									<item>
										<label>•</label>
										<para> 200 mg followed by 2nd dose 1 hr later</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19062">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x19070">
							<label>•</label>
							<sec_title>Adult<route> IM CCr 15-30 ml/min, give 50% of dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x19073">
						<sec_title>Available forms:</sec_title>
						<para> Caps 300 mg; inj 100 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x19078">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x19081">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19085">
									<item>
										<label>•</label>
										<para>Capsules may be swallowed whole, chewed, allowed to dissolve</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19091">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x19095">
									<item>
										<label>•</label>
										<para>Inj in large muscle mass; aspirate to avoid IV administration; inj not to be used in children or infants</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Butorphanol, glycopyrrolate, HYDROmorphone, midazolam, nalbuphine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19105">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19108">
					<section type="none" id="sidelem4x19109">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness,</emphasis> headache, dizziness, confusion, disorientation, <emphasis style="bold">coma, seizures,</emphasis> depression, <emphasis style="italic">vertigo,</emphasis> EPS</para>
					</section>
					<section type="none" id="sidelem4x19124">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, palpitation, <emphasis style="bold">cardiac dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19131">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, blurred vision, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x19136">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, vomiting, difficulty swallowing</para>
					</section>
					<section type="none" id="sidelem4x19141">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, fever, chills, flushing, hyperpyrexia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19146">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted by kidneys</para>
				<section type="none" id="sidelem4x19151">
					<section type="none" id="sidelem4x19152">
						<sec_title>PO:</sec_title>
						<para> Onset 20-40 min, duration 3-4 hr</para>
					</section>
					<section type="none" id="sidelem4x19157">
						<sec_title>IM:</sec_title>
						<para> Onset 15-35 min, duration 2-3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x19162">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect—CNS depressants, alcohol</para>
			</section>
			<section type="considerations" id="sidelem4x19169">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19172">
					<section type="none" id="sidelem4x19173">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x19178">
								<item>
									<label>•</label>
									<para>Nausea, vomiting before, after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19183">
								<item>
									<label>•</label>
									<para>VS, B/P; check patients with cardiac disease more often</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19191">
							<label>•</label>
							<sec_title>Signs of toxicity of other products or masking of symptoms of disease<route> brain tumor, intestinal obstruction</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x19194">
								<item>
									<label>•</label>
									<para>Observe for drowsiness, dizziness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19199">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19203">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased nausea, vomiting</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19209">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19213">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities, activities requiring alertness because dizziness may occur; to request assistance with ambulation</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>To keep out of children’s reach</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="87" status="active">
			<mono_name>trospium (Rx)</mono_name>
			<info>
				<pronunciation>(trose′pee-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x192341">Sanctura</tradename>
					<tradename id="tnidelem4x192340">Sanctura XR</tradename>
				</tradenames>
				<class type="func"> Anticholinergic, urinary antispasmodic</class>
				<class type="chem"> Muscarinic receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x19244">
				<sec_title>Action:</sec_title>
				<para>Relaxes smooth muscles in bladder by inhibiting acetylcholine effect on muscarinic receptors</para>
			</section>
			<section type="uses" id="sidelem4x19249">
				<sec_title>Uses:</sec_title>
				<para>Overactive bladder (urinary frequency, urgency)</para>
			</section>
			<section type="contra" id="sidelem4x19254">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, uncontrolled closed-angle glaucoma, urinary retention, gastric retention, myasthenia gravis</para>
				<section type="none" id="sidelem4x19259">
					<section type="none" id="sidelem4x19260">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, renal/hepatic disease, controlled closed-angle glaucoma, ulcerative colitis, intestinal atony, bladder outflow obstruction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19265">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19273">
					<label>•</label>
					<sec_title>Adult &lt;75 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19273">
							<item>
								<label>•</label>
								<para> 20 mg bid 1 hr before meals or on empty stomach;  60 mg in <emphasis style="smallcaps">am</emphasis></para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19285">
					<label>•</label>
					<sec_title>Geriatric ≥75 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19285">
							<item>
								<label>•</label>
								<para> titrate down to 20 mg/day based on response and tolerance</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19289">
					<section type="none" id="sidelem4x19290">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x19298">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, 20 mg/day at bedtime, ext rel product not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x19301">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20 mg; caps ext rel 60 mg</para>
					</section>
					<section type="none" id="sidelem4x19306">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x19310">
								<item>
									<label>•</label>
									<para>1 hr before meals or on empty stomach (reg rel); in <emphasis style="smallcaps">am</emphasis> (ext rel) ≥1 hr before meal</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19319">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19322">
					<section type="none" id="sidelem4x19323">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x19328">
						<sec_title>CV:</sec_title>
						<para> Tachycardia</para>
					</section>
					<section type="none" id="sidelem4x19333">
						<sec_title>EENT:</sec_title>
						<para> Dry eyes, vision abnormalities</para>
					</section>
					<section type="none" id="sidelem4x19339">
						<sec_title>GI:</sec_title>
						<para> Flatulence, abdominal pain, <emphasis style="italic">constipation, dry mouth,</emphasis> dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x19347">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, UTI</para>
					</section>
					<section type="none" id="sidelem4x19352">
						<sec_title>INTEG:</sec_title>
						<para> Dry skin, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19359">
						<sec_title>MISC:</sec_title>
						<para> Heat stroke, fever</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19364">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed (10%); peak 5-6 hr; protein bound (50%-85%); extensively metabolized; excreted in urine, feces; excreted in urine by active tubular secretion; half-life 20 hr</para>
			</section>
			<section type="interactions" id="sidelem4x19369">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> drowsiness—CNS depressants, alcohol</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> trospium effect—products excreted by active renal secretion (aMILoride, digoxin, morphine), metformin, quiNIDine, procainamide, ranitidine, tenofovir, triamterene, vancomycin</para>
				<section type="none" id="sidelem4x19380">
					<section type="none" id="sidelem4x19381">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—high-fat meal</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19388">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19391">
					<section type="none" id="sidelem4x19392">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x19400">
							<label>•</label>
							<sec_title>Urinary patterns</sec_title>
							<para>
								<list id="lidelem4x19400">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urinary patterns:</emphasis> distention, nocturia, frequency, urgency, incontinence, voiding patterns</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19404">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19408">
								<item>
									<label>•</label>
									<para>Therapeutic response: correction of urinary status: absence of dysuria, frequency, nocturia, incontinence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19414">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19418">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities because dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That alcohol may increase drowsiness</para>
								</item>
								<item>
									<label>•</label>
									<para>About anticholinergic effects that may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That overheating may occur with strenuous exercise</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid all other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>